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1. Introduction 
1.1 Chromatin organization and epigenetics 
1.1.1 DNA and chromatin structure 
In the mid-twentieth century deoxyribonucleic acid (DNA) was identified to be the source of 
all genetic instructions. Together with Watson and Crick’s concept of the DNA double helix 
structure (Watson and Crick, 1953), this revolutionized and reshaped the science of biology 
and gave birth to the new area of Molecular Biology. This understanding also opened up a 
whole new level of complex questions such as how cells bearing the same genetic build-up 
can differentiate into very distinctive and functionally varied cell types as found in all 
pluricellular living organisms. 
1.1.2 Information flow in the cell 
The central dogma of molecular biology originates from Crick (Crick, 1970; Crick, 1958) 
who stated that the transfer of information flows from DNA sequence to messenger 
ribonucleic acid sequence (mRNA) to amino acids sequence. This one way direction of 
information flow occurs in most living cells, with the exception of some viruses, where both 
directions are possible. The information is maintained by duplication of the genomic DNA 
(gDNA) during cell division by a process called replication. 
1.1.3 The nucleosome 
The human genome consists of long linear DNA pieces called chromosomes, stabilized by 
telomeres at their ends. Altogether the human genome consist of about 3 billion nucleotides 
(Pollard et al., 2008). Chromosomes consist of two so-called “sister” chromatids that are 
joined at the centromere, a protein junction complex. Diploid human cells have 23 pairs of 
chromosomes, 22 pairs of autosomes and one pair of allosomes, which adds up to 46 
chromosomes. The DNA of a human cell is about 2 m long. To fit into the cell nucleus it has 
to be tightly packed by being wrapped around octamer basic protein complexes called 
histones (H2A, H2B, H3 and H4) to form disk-shaped nucleosomes. There are 147 DNA base 
pairs wrapped around one octamer (Khorasanizadeh, 2004; Kouzarides, 2007). The amino 
terminal ends of the histones (N-terminal tails) of about 30 amino acids and possess important 
Introduction 
 
8
regulatory functions. In addition, one molecule of histone 1 (H1) binds at the entry and exit of 
the DNA at the nucleosome (Figure 1). The nucleosome structure strongly influences whether 
DNA can be accessed by the replication or transcription machinery. 
 
Figure 1: Schematic representation of nucleosome packing: The histone octamer is shown in blue and histone 1 
shown in orange. Illustration of chromatin packaging: from an “open” to a condensed structure. Left panel 
adapted from (Khorasanizadeh, 2004) and right panel adapted from (Arrowsmith et al., 2012). 
1.1.4 Heterochromatin and euchromatin 
Genomic DNA interacts with histone proteins to form large macromolecule complexes 
collectively called chromatin. The local state of chromatin is described as either 
heterochromatin, which is predominantly methylated and has low levels of acetylation at the 
histones. In this state chromatin is more compact and expression of genes is reduced. The 
euchromatin state on the other side, which represents the vast majority of the genome, can 
have highly acetylated and actively transcribed regions as well as inactive regions with low 
levels of acetylation, methylation and phosphorylation (Jenuwein and Allis, 2001).  
1.1.5 Epigenetic gene regulation and the histone code 
While bacteria regulate gene transcription at regions upstream of the transcription start site the 
promoter site using cis-regulatory elements, eukaryotes possess an additional level of gene 
transcriptional regulation called the “histone code” (Strahl and Allis, 2000). Although this 
term is widely used, there is not a strict code of underlying histone modification that defines 
DNA function. Nevertheless the concept of a “histone code” underlines the importance of 
epigenetic processes such as histone post-translational modifications (PTMs) that can be 
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written or erased by specialized enzymes and read by dedicated domains, which ultimately 
influences all DNA-centered processes. The PTMs of histone tails possess important 
functions such as regulation of chromatin environmental state and of replication, gene 
transcription and DNA repair. Histone PTMs include acetylation (Allfrey et al., 1964; 
Parthun, 2007; Sterner and Berger, 2000) and methylation (Shilatifard, 2006; Zhang and 
Reinberg, 2001) but also ubiquitinylation (Shilatifard, 2006), phosphorylation (Nowak and 
Corces, 2004) and poly-adenosine diphosphate-ribosylation (Khorasanizadeh, 2004). Several 
other histone PTMs have additionally been described. It is now widely accepted that 
epigenetic regulation by reader, writer and eraser enzymes is of high functional importance 
for cell fate and function (Figure 2). 
 
Figure 2: Histone modifications: Different PTMs at various positions of the histone tails and core are shown and 
marked. Histone H4 is shown in yellow, H3 in green, H2A in red and H2B in gold. Blue circles indicate 
methylation sites, purple hexagons acetylation sites, purple squares phosphorylation and purple stars 
ubiquitinylation sites. Adapted from (Khorasanizadeh, 2004). 
1.1.5.1 DNA methylation 
Another epigenetic modification is DNA methylation. It was first postulated in 1975 as an 
inheritable epigenetic mark for gene silencing (Holliday and Pugh, 1975; Riggs, 1975). 
Methylation of the DNA takes place at the 5’ carbon atom of cytosine (5mC) predominantly in 
the context of cytosine followed by a guanidine residue (CpG). CpG-rich regions of about 1 
kilo base pairs (kb) length are found in the majority of transcription start site (TSS) of genes. 
DNA methyltransferases (e.g. DNMT1, DNMT3A and DNMT3B) have been identified to be 
responsible for the set-up and maintenance of DNA methylation patterns. DNA demethylation 
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can be a rather indirect process involving removal of the complete methylated base during cell 
division or DNA repair mechanisms. Enzymes like the methylcytosine dioxygenases ten-
eleven translocation (TET) have been found to drive this process (Rawluszko-Wieczorek et 
al., 2015). 
1.1.5.2 Histone variants  
During the synthesis phase (S phase) of the cell cycle, chromatin assembles from canonical 
histones (H2A, H2B, H3 and H4) (Kamakaka and Biggins, 2005). While there are multiple 
copies of genes coding for the canonical histones, there are also some histone variants 
(paralogs) that can influence some properties of the nucleosome, when integrated. Histone 
variant expression is not restricted to S phase and also plays a major role in cell differentiation 
(Bosch and Suau, 1995; Pina and Suau, 1987; Winston, 2001). There are a number of H1 (e.g. 
H10 and H5) (Parseghian and Hamkalo, 2001; Roche et al., 1985) and H2A (e.g. H2A.Z and 
H2A.X) (Ausio and Abbott, 2002; Redon et al., 2002) variants, while there are no or very 
little known variants of H2B and H4. There are two major H3 variants (H3.3 and centromeric 
H3 (CenH3)). Histone variants also play an important role in the cellular DNA damage 
response (DDR). For instance H2A.X phosphorylation by DDR kinases takes place at DNA 
double-strand break (DSB) sites (Rogakou et al., 1998) and functions as a marker leading to 
DSB repair initiation. 
1.1.5.3 Histone acetylation 
Histones can be acetylated at the ε-nitrogen of lysine (K) residue by enzymes named type-A 
and type-B histone acetyltransferases (HATs), which use acetyl coenzyme A (acetyl-CoA) as 
cofactor. Acetylation of histones takes place at histone tails (e.g. H3K27Ac, H4K5Ac, 
H4K8Ac, H4K12ac and H4K16ac) as well as at histone core elements under cellular stress 
like DNA damage. (e.g. H3K56ac) (Tjeertes et al., 2009). Acetylation changes the charge of 
the ε-nitrogen leading to reduced interaction with the negative phosphate backbone of the 
DNA (Figure 3). 
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Figure 3: Schematic illustration of lysine DNA interaction: Acetylation of lysine by histone acetyl transferases 
(HATs) and deacetylation by histone deacetylases (HDACs) can change the charge of the ε-nitrogen of the amino 
acid residue, leading to changes of the interaction between histone tails and the negatively charged phosphate 
backbone of DNA. Addition of a methyl group at the ε-nitrogen of lysine by histone lysine methyl transferases 
on the other hand does not change the charge of lysine. Adapted from (Tessarz and Kouzarides, 2014). 
Type-A HATs are a diverse family of enzymes with sequence and conformational structure 
homology found in the nucleus (Marmorstein, 2001; Sterner and Berger, 2000). Type-B HATs 
are predominantly located in the cytosol and all share sequence homology (Parthun, 2007). 
The type-A HATs form 3 families, GNAT, MYST and CBP/p300, and are usually associated 
with large multi-protein complexes (Yang and Seto, 2007), defining their functional role 
(Bannister and Kouzarides, 2011). CBP/p300 acetylates H3K27, marking transcriptionally 
regulatory regions (enhancer). Type-B HATs only acetylate newly synthesized non-
nucleosomal histones. The acetylation of histones H3 and H4 is removed during histone 
maturation and integration into nucleosomes (Parthun, 2007).  
The enzymatic counterparts to HATs are the histone deacetylases (HDACs). They are 
subdivided into four family classes. Class I, II and IV share structural homology and use zinc 
metal ions to remove the acetyl group from lysine (Hodawadekar and Marmorstein, 2007), 
while Class III, the sirtuin family, uses nicotinamide adenine dinucleotide (NAD+) as a 
cofactor (Frye, 2000; Imai et al., 2000). Histone deacetylation is a rather unselective process 
and little preference for individual histone lysine residues has been evidenced (22). As 
removal of acetylation is correlated with more compact DNA and repression of transcription, 
HDACs are often found in repressive complexes (Bernstein and Schreiber, 2002; Jenuwein 
and Allis, 2001; Kouzarides, 2007). 
Introduction 
 
12 
1.1.5.4 Histone phosphorylation 
Phosphorylation of histones can take place at the hydroxyl-residues of serine, threonine or 
tyrosine, and are dependent on dedicated kinases and phosphatases (Oki et al., 2007). Kinases 
transfer a phosphate group from adenosine triphosphate (ATP) to the amino acid residue. This 
changes the charge of the amino acid to a negative state, which influences DNA histone 
interaction. A few kinases (e.g. ERK2) are known to have DNA binding domains (Hu et al., 
2009) by which they can be recruited to the chromatin. Given the high turnover of H3S10P 
marks by aurora kinase, the phosphatase activity of PP1 phosphatase is probably quite high in 
the nucleus (Bannister and Kouzarides, 2011). Nevertheless far less is known about histone 
phosphatases. 
1.1.5.5 Histone methylation 
Histone methylation predominantly takes place at lysine residues and does not affect the local 
charge of the histone as opposed to phosphorylation or acetylation (Figure 3). Additionally 
lysines can get multiple methylation marks from mono- to tri-methylation and arginine can 
undergo mono- or di-methylation in a symmetric or asymmetric fashion (Bedford and Clarke, 
2009), which adds even more complexity to histone methylation (Bannister and Kouzarides, 
2011; Lan and Shi, 2009; Ng et al., 2009). 
The first histone lysine methyltransferase (HKMT) was found 16 years ago (Rea et al., 2000) 
and since then many more have been described. Almost all HKMTs identified harbor a 
catalytic SET domain, which transfers a methyl group from S-adenosylmethionine (SAM) to 
the ε-nitrogen of lysine. Most of them methylate histone tails, while the DOT1L enzyme lacks 
a SET domain and methylates H3K79 which is localized in the histone core (van Leeuwen et 
al., 2002). HKMTs can discriminate between different lysine residues and their methylation 
states in the cellular context. They are quite specific (Cheng et al., 2005) and can methylate 
their lysine substrate only to a certain degree (Zhang et al., 2003). HKMTs can exhibit gene 
repressing functions, one example being the Enhancer of zeste homolog 2 (EZH2) member of 
the polycomb repressive complex (PRC2), which methylates H3K27 to induce 
heterochromatin formation and gene suppression. Histone methylation can on the other hand 
also be associated with gene activation. H3K4 tri methylation (H3K4me3) is a mark of 
transcriptionally active promoters and H3K4 mono methylation (H3K4me1) additionally 
marks enhancers. H3K4 is methylated by a complex called COMPASS. There are three 
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different complexes associated with SET1 consisting of a central SET1-like methyltransferase 
(SET1A/B, MLL1/2 or MLL3/4) unit surrounded by six to eight other proteins. The 
COMPASS complex can methylate H3K4 (Cheng et al., 2014), which is a hallmark of 
transcriptionally active promoters and distal regulatory elements (H3K4me1) (Ernst et al., 
2011) resulting from the MLL3/4 complex (repression mark), while H3K4me3 results from 
MLL1/2 or SET1A/B and is only found near the TSS of active genes (Heintzman et al., 2007). 
Lysine methylation gets removed by the Lysine-specific demethylase 1 (LSD1) a histone 
lysine demethylase (HKDM) that was discovered in 2004 (Shi et al., 2004). 
LSD1 uses flavin adenine dinucleotide (FAD) as a co-factor to demethylate mono and di 
methylated lysine (e.g. H3K4me1/2). Like HATs LSD1 functions in large complexes that 
guide and influences its activity in a context-specific manner. Another class of lysine 
demethylases was identified later. It is characterized by JmjC-domains (Tsukada et al., 2006) 
(e.g. jumonji, AT rich interactive domain 2 (JARID2)) and the ability to demethylate tri-
methylated lysines (Whetstine et al., 2006).  
Besides lysine, arginine residues can also be methylated. Arginine methyltransferases (PRMT) 
are categorized into two classes: type-I and type-II. Both classes generate mono methylated 
arginine, but type I generates asymmetric and type II symmetric di methylated arginine (Wolf, 
2009). PRMTs transfer the methyl group from SAM to the ω-guanidine group of arginine onto 
a variety of substrates (Bannister and Kouzarides, 2011), while PRMT 1,4,5 and 6 
predominantly methylate histone arginines (Bedford and Clarke, 2009). Methylation of 
arginine is removed in an indirect way named deamination (Cuthbert et al., 2004; Wang et al., 
2004) or directly by the JMJD6 demethylase (Chang et al., 2007; Robinson et al., 2016). 
1.2 Histone modification readers 
Epigenetic readers are proteins with dedicated domains that specifically recognize epigenetic 
modifications and enable downstream signaling that influences gene transcription. Such 
reader domains were initially found in type-A HATs (Dhalluin et al., 1999). Later a large 
number of different domains capable of recognizing modified histones were identified using 
techniques based on either fluorescence (Kim et al., 2006), immobilized histones (Stucki et 
al., 2005) or stable isotype labeling by amino acids in cell culture (SILAC), leading to a 
comprehensive list of histone-binding proteins (Bartke et al., 2010; Vermeulen et al., 2010). 
Introduction 
 
14 
Three major reader domains that can bind to acetylated lysines have been described (Figure 
4), namely plant homeodomain (PHD) (Zeng et al., 2010), YEATS (Andrews et al., 2016) and 
bromo domains (Dhalluin et al., 1999). 
 
Figure 4: Histone modifications and their readers, writers and erasers: Histone proteins of the nucleosome are 
shown in red, orange, green and blue (H2A, H2B, H3 and H4) and DNA in yellow/gray. Histone modification 
reader, writer and eraser proteins of: acetylation (Ac), methylation (Me) and phosphorylation (P) are included. 
HATs = histone acetyltransferases, HMTs = histone methyltransferases, HDACs= Histone deacetylases, DMTs = 
demethylases, PHDs = plant homeodomains, PWWPs = Proline-Tryptophane-Tryptophane-Proline domains, 
MBTs = malignant brain tumor domains, BRCT = carboxy-terminal domain of a breast cancer susceptibility 
protein. From (Filippakopoulos and Knapp, 2014). 
1.2.1 The bromodomain and extra terminal domain family 
In the human genome 61 bromodomains (BRDs) present in 46 proteins have been identified. 
They cluster into eight major classes based on their structural similarity (Figure 5A) 
(Filippakopoulos and Knapp, 2014). The bromodomain and extra terminal domain (BET) 
family belongs to the class II. Bromodomains share a conserved left-handed bundle of four 
alpha helices (αZ, αA, αB, αC) linked by loops of different lengths (ZA and BC) and 
recognize different acetylated lysines (Figure 5B) (Filippakopoulos et al., 2012).  
The BET family includes 4 members: BRDT, BRD2, BRD3 and BRD4 each harboring two 
bromodomains (BD1 and BD2) and an extra terminal region at the C terminus that interacts 
with different protein partners (Figure 6). Interestingly, the BD1 or BD2 similarity is higher 
between the family members than BD1 and BD2 within the same protein (Belkina and Denis, 
2012). While BRD2, BRD3 and BRD4 are expressed ubiquitously in human tissues (Loven et 
al., 2013), BRDT is exclusively found in testis (Gaucher et al., 2012) where it has an 
important role in spermatogenesis (Berkovits and Wolgemuth, 2013). BRD2, 3 and 4 bind to 
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chromatin genome-wide and are regulators of essential cellular processes including 
transcription, DNA replication, cell cycle progression and the maintenance of higher-order 
chromatin structure (Wang et al., 2012). 
 
Figure 5: Phylogenetic tree of bromodomain proteins and structural representation of BRD4-BD1 binding to 
H4K5ac-K8ac peptide. A: Phylogenetic tree showing the eight structurally diverse classes of bromodomains 
(BDs) and protein names. Red box marks the class II cluster which is found in the bromodomain and extra 
terminal domain family (BET). Numbers in brackets indicate the BD number within one protein. B: Structural 
illustration of BRD4 BD1 with its four alpha helices (αZ, αA, αB, αC) linked by loops of different lengths (ZA 
and BC) in white, and the bound di-acetylated histone 4 peptide (H4K5acK8ac) in blue. The peptide engages the 
conserved asparagine (N140) which is highlighted in green. Red spheres indicate conserved water molecules 
forming hydrogen bonds with BD1 (PDB ID: 3UVW). Adapted from (Filippakopoulos and Knapp, 2014). 
 
 
Figure 6: Schematic illustration of bromodomain and extra terminal domain proteins: Boxes delineate the 
conserved domains of BET family members Bromodomains (BD1/2), motifs A and B, extra terminal domain and 
SEED motif. For BRD4 the short isoform is additionally shown and for BRD2, 3 and T only the main isoform is 
shown. Numbers denote the length of each protein. 
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1.2.2 The human cellular BRD4 protein 
The bromodomain-containing protein 4 (BRD4) is the best characterized member of the BET 
family. It was found to bind to a bookmarking histone modification H4K5ac to rapidly re-
activate transcription after mitosis (Zhao et al., 2011) and is generally involved in regulating 
RNA Polymerase II transcriptional activity. Mice knock-out studies show that BRD2 (Gyuris 
et al., 2009; Shang et al., 2009) and BRD4 (Houzelstein et al., 2002) are each essential for 
embryonic development. The two bromodomains (BD1 and BD2) which enable BRD4 to bind 
to acetylated lysines of histones show different preferences. In a SPOT array BD1 shows 
strong binding to acetylated histone 3 at K4, K9, K27, K36, K115 and K122 and histone 4 at 
K44, K77, K79 and K91, while BD2 preferentially binds to histone 3 at K18, K36, K37, K56 
and histone 4 at K5, K20 and K44 (Filippakopoulos et al., 2012). 
It was initially proposed that BRD4 binds to free positive transcription elongation factor-b (P-
TEFb) and recruits it to acetylated promoters (Jiang et al., 1998; Wu and Chiang, 2007), while 
later it was found that BRD4 recruits Mediator protein (Kanno et al., 2014) and transcription 
factors (Roe et al., 2015) to localize to hyper-acetylated promoter and enhancer regions to 
initiate transcription of defined downstream genes (Bhagwat et al., 2016). In addition BRD4 
was found to interact with JMJD6 a histone arginine demethylase. JMJD6 demethylates 
repressive dimethyl marks of H4R3 (H4R3me2s) as well as the 5’ cap of 7SK snRNA, which 
leads to destabilization of 7SK snRNA and a release of P-TEFb from the 7SK/HEXIM snRNP 
inhibitory complex (Figure 7).  
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Figure 7: Schematic illustration the BRD4-JMJD6 mediated pause-release model: JMJD6 is recruited to the 
anti-pause enhancer (A-PE) by BRD4 interacting with histone acetylation, transcription factors or mediator 
complex. Enzymatic activity of JMJD6 leads to removal of the repressive H4R3me2s mark and decapping of 
7SK snRNA, leading to release of P-TEFb (CCNT/1/2 and CDK9) from the inhibitor HEXIM/7SKsnRNA 
complex and finally to pause-release of polymerase II. Adapted from (Liu et al., 2013). 
. 
1.2.3 Tissue-specific expression of genes 
The mammalian genome codes for around 21.000 genes (Weinberg, 2014), which can be 
functionally divided into two classes, namely the housekeeping genes and the tissue-specific 
genes. In a differentiated cell only about 3000-5000 housekeeping genes and 1000 tissue-
specific genes are expressed. This implies that the expression of a large number of genes from 
the genome must be coordinately repressed, while other genes have to be actively expressed 
at specific time points to guarantee cellular viability and tissue-specific functions (van 
Nimwegen, 2003). 
1.2.4 Transcription factors and gene-regulation in eukaryotes 
Transcription factors (TFs) are an essential regulatory unit in the maintenance and state of all 
living cells (van Nimwegen, 2003). Linage specific TFs are responsible for the earliest event 
during cellular differentiation (Arner et al., 2015). About 6% of human genes code for TFs, 
they can be categorized into a few families with similar binding mechanisms. TFs recognize a 
defined short sequence of around 5-10 nucleotides (sequence motif) in the genome. Such 
motifs are found in the upstream region of gene promoters and in distal control elements 
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called enhancer regions. Most TFs interact with co-activators like the mediator complex or 
co-repressors to regulate the transcription machinery (Pollard et al., 2008).  
1.2.5 Gene transcription by RNA polymerase II 
Gene transcription in eukaryotic cells is performed by the RNA polymerases. The three RNA 
polymerases (Roeder and Rutter, 1969, 1970) recognize different promoter regions. RNA 
polymerase I transcribes rRNA precursors and RNA polymerase III transcribes small non-
coding RNAs like transfer RNAs (tRNAs) of typically 76 to 90 nucleotides length, while 
RNA polymerase II (Pol II) transcribes protein-coding genes to pre-mRNAs. The basal 
initiation complexes share a conserved core (Vannini and Cramer, 2012) composed of RNA 
polymerase I/II or III, the TATA box-binding protein (TBP) (Kim and Burley, 1994) and 
transcription factors TFIIB, TFIIE and TFIIF in the case of RNA polymerase II. Transcription 
is initiated by recruitment of the RNA polymerase II-TFIIF complex (Chen et al., 2010; 
Eichner et al., 2010) to the core initiation unit (TFIIB-TBP) bound at the DNA-promoter 
(Kim et al., 1993a; Kim et al., 1993b) followed by binding of general transcription factors 
TFIIE and TFIIH to form the pre-initiation complex (PIC) (He et al., 2013). In the presence of 
nucleoside triphosphates a transcription bubble is produced around the TSS. Conformational 
changes then lead to positioning of a single strand DNA to the active site of the polymerase 
serving as a template for the RNA synthesis (Sainsbury et al., 2015).  
Transcriptional initiation as well as elongation and termination need to be tightly regulated by 
the cell. One way to regulate the throughput by Pol II is pausing, which takes place on 
stimulus-controlled pathway genes and genes involved in development (Jonkers and Lis, 
2015). Pol II-pausing can lead to accumulation at the promoter-proximal region around 30-60 
nucleotides downstream of the TSS, within the first nucleosome positioned (+1 nucleosome) 
(Adelman and Lis, 2012; Kulaeva et al., 2013; Kwak and Lis, 2013). This process is 
dependent on negative elongation factor (NELF) and DRB-sensitivity-induced factor (DSIF). 
To release Pol II, the P-TEFb complex, which consists of cyclin-dependent kinase 9 (CDK9) 
and cyclin T1 or cyclin T2 phosphorylates NELF and the carboxy-terminal domain (CTD) at 
Serine 2 of Pol II and DSIF (Peterlin and Price, 2006). P-TEF-b can associate with eleven-
nineteen lysine-rich leukemia (ELL) elongation factors to form the larger super elongation 
complex (SEC) (Smith et al., 2011). The release of inactive P-TEFb from the inhibitory 
7SK/HEXIM snRNP complex is mediated by BRD4, which also interacts with the mediator 
complex to regulate pre-initiation, initiation and re-initiation in addition to pause-release and 
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elongation (Figure 7). The CTD undergoes dynamic PTMs (Corden, 2013) that include 
phosphorylation (Buratowski, 2009) as well as methylation (Dias et al., 2015). The regulation 
of pause-release seems to be an intricate balance (Jonkers and Lis, 2015) depending on the P-
TEFb recruitment, activation and inhibition (Heinz et al., 2015). 
Termination of transcription is far less understood. In yeast the transcriptional termination of 
mRNA coding genes is mainly dependent on cleavage of polyadenylation factor (CPF) and 
cleavage factor (CF) (CPF-CF) pathway, while the termination of non-coding RNAs depends 
on the Nrd1-Nab3-Sen1 (NNS) complex.  
During the transcription process, pre-mRNAs are modified at their 5’ end by addition of a 7-
methylguanosine cap and polyadenylation at their 3’ end (Bentley, 2014). These modifications 
are unique for mRNAs and protect them against degradation, thus enhancing translation in the 
cytoplasmic compartment (Berg et al., 2007; Pollard et al., 2008). The 5’ capping of the first 
nucleotide transcribed necessitates the enzymatic activity of three dedicated proteins, RNA 
guanylyl triphosphatase (RNGTT), human capping enzyme a guanylyltransferase (hCE) and a 
RNA methyltransferase (RNMT). The poly(A) tail is added to the 3’ of a mRNA after 
cleaving the precursor mRNA (pre-mRNA) by the cleavage polyadenylation specificity factor 
(CPSF) (Bienroth et al., 1993) and the polyadenylate polymerase (PAB).  
1.3 Methods used to identify genome-wide chromatin interactions 
1.3.1  DNase I hypersensitivity sites 
Chromatin is packed in nucleosomes which consist of DNA wound around histone octamers. 
To actively transcribe genes the chromatin has to be in a less compact state. Accordingly, 
when treating gDNA with a DNA cutting enzyme such as DNase I, the more accessible sites 
are preferentially cut. Using next generation sequencing (NGS) technologies, DNase I hyper-
sensitivity sites (DHSs) can be mapped genome-wide, predicting potential cis-regulatory 
elements such as TF binding sites. Understanding the role of the non-protein-coding gene 
regions of the genome is the aim of the ENCODE project (2012; Birney et al., 2007). 
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1.3.2  Chromatin immunoprecipitation  
In addition to DHS another powerful tool to examine protein-DNA interactions is the 
chromatin immunoprecipitation (ChIP) method (Solomon et al., 1988) (Orlando, 2000). Using 
ChIP together with genome-wide sequencing techniques (ChIP-seq) it is possible to map a 
target protein of interest to its binding or interaction sites within chromatin. Besides TF 
binding this also enables to precisely map epigenetic modifications such as histone marks and 
binding of the mediator complex to identify potential enhancers. Recently this method has 
been adapted to map the interaction sites of biotin tagged small molecules with chromatin 
(Chem-seq) (Anders et al., 2014). Nevertheless this assay cannot recapitulate enhancer 
looping and other conformational properties of the chromatin. For this reason other methods 
have been developed. 
1.3.3 Chromosome conformation capture (3C) 
When performing paraformaldehyde-assisted crosslinking, the close proximity interactions 
such as protein-DNA or DNA-DNA interactions can be preserved. Another method to analyze 
chromosome conformation is the C- or 3C technology (Hakim and Misteli, 2012). It is used to 
analyze the conformational organization of chromatin in the cell and has turned into a 
powerful tool to identify and confirm enhancer-promoter interactions in addition to classical 
reporter-gene assays. 
1.4 Gene editing technologies 
Specific experimental manipulation of the genome is crucial to investigate and determine the 
role of genes in the biological context of disease. Gene editing technologies allow to remove, 
add or replace specific parts of the genome using nucleases also called “molecular scissors” 
that introduce specific DNA double strand breaks (DSBs). These include homing 
meganucleases, zinc finger nucleases (ZFNs), transcription activator-like effector-bases 
nucleases (TALENs) and the more recently identified and explored clustered regularly 
interspersed short palindromic repeats (CRISPR)-Cas system. The DSBs at the specific target 
sites are repaired by one of the host cells recombinational repair mechanisms. 
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1.4.1 DNA DSB repair mechanisms 
These mechanisms are either non-homologous end joining (NHEJ), homology directed repair 
(HDR) or micro-homology mediated end joining (MMEJ). NHEJ repairs a DSB by simply re-
ligating the two ends without the need of sequence homology. It is a quite error prone 
mechanism so that small insertions and deletions are often introduced (Ahnesorg and Jackson, 
2007; Moore and Haber, 1996; Pardo et al., 2009). HDR uses a homolog piece of DNA that 
has to be present in the nucleus to repair a DSB. This repair mechanism is used by the cell 
during the G2 or S-phase. Similarly to HDR, MMEJ uses a template to repair the DSB. 
1.4.2 ZFNs and TALENs 
Multiple zinc finger domains (ZFs) that each bind to 3 nucleotides of a target region in the 
genome fused to the FokI cleavage domain (Kim et al., 1996) can precisely introduce a DSB 
at the targeted region (Figure 8). ZFNs normally harbor 3-4 ZFs that form an 18-24 nucleotide 
recognition site that is sufficient to enable unique binding in the genome (Figure 8). 
Nevertheless ZNFs can have off-target effects that sometimes lead to host cell toxicity (Xiong 
et al., 2015). Similarly to ZFNs, TALENs can be customized by combining DNA-binding 
domains that recognize a target sequence. TALENs contain TALE repeats of 33-35 amino 
acids able to recognize a single base pair via their two hyper variable residues (Figure 8). The 
custom design of TALENs and ZFNs can be cost- and time-consuming, which limits their use 
for screening at a larger scale.  
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Figure 8: Schematic illustration of ZNF and TALEN structures and target site recognition. A: “ZNF left” and 
“ZNF right” consist of a nuclear location signal (NLS) at the N-terminus of the protein and 4 individual zinc 
fingers (P1-P4) that specifically bind to 3 nucleotide target sites and are fused to the FokI cleavage domain. FokI 
forms a dimer (blue circle) and introduces a DNA double strand break (DSB) that is repaired by the host cell 
using NHEJ or HDR/MMEJ. B: TALEN consisting of FokI fused to multiple transcription activator-like 
effectors (TALE) that recognize each a single base pair by their repeat-variable di-residues (RVD) marked in 
green red or light/dark blue, leading to target specificity target sequence. A and B are adapted from (Xiong et al., 
2015). 
1.4.3 The CRISPR-Cas system 
The CRISPR system is a prokaryotic immune system which protects Streptococcus 
thermophilus and other bacteria from foreign plasmids or bacteriophage virus DNA. It 
provides an adaptive acquired immunity using exogenous DNA elements to which the 
bacteria were exposed earlier (Barrangou et al., 2007). The short parts of these elements are 
integrated into the genome (protospacer) and separated by repetitive elements (direct repeats) 
close to the CAS gene. They are expressed as CRISPR RNAs (crRNAs) that form a stem-loop 
at the 3’ and have a 5’ region to target the cas effector complex to interfere with the target 
sequence. (Marraffini and Sontheimer, 2010). The eukaryotic RNA interference is very 
different from crRNA interference. It uses distinct protein machineries and recognizes 
different ribonucleotide species (RNA vs. DNA). As crRNAs can detect DNA (Marraffini and 
Sontheimer, 2008) self-immunity is prevented as crRNAs discriminate by a 8 nucleotide (nt) 
repeat sequence at the 5’ of the crRNA from outsite the spacer region between target 
(incomplete binding) and self-DNA (complete binding). The type II CRISPR locus of 
Streptococcus pyogenes SF370 consists of four genes including the Cas9 nuclease (SpCas9), 
two crRNAs: one trans-activating crRNA (tracrRNA) and one precursor crRNA (pre-crRNA). 
These genes have been modified to efficiently work in a mammalian cellular system (Cong et 
al., 2013). The tracrRNA and crRNA can be fused together to form a single-guide RNA 
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(sgRNA). In contrast to TALENs and ZFNs, the CRISPR-Cas9 system derives its target 
specificity from a 20 nucleotide long sequence of the sgRNA that directs Cas9 to its target site 
(Figure 9). The Cas9 nuclease needs a proto-spacer adjacent motif (PAM) region to 
specifically cut the DNA 3 nucleotides upstream of the PAM (Jinek et al., 2012). The PAM 
sequence can differ between Cas9 orthologs. This system was used to generate mutant mice in 
a one-step fashion (Wang et al., 2013) and to perform genome-wide genetic screens (Shalem 
et al., 2014; Wang et al., 2014). Further advances led to the generation of domain specific 
mutation screenings that should enable more efficient and faster drug discovery (Shi et al., 
2015). 
 
Figure 9: CRISPR-SpCas9 targeting: CRISPR-SpCas9 complex targets genomic locus by Watson-Crick base 
pairing (green) and cutting at the protospacer adjacent motif PAM region from Streptococcus pyogenes (red 
nucleotides) leading to a double strand break (DSB) that is repaired by cellular repair mechanisms NHEJ or 
HDR. From (Xiong et al., 2015). 
1.5 Cancer epigenetics 
Cancer designates diseases originating from uncontrolled cell growth and with the potential to 
spread to distant parts of the organism. 
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1.5.1 Hallmarks of cancer 
Hanahan and Weinberg introduced the term “Hallmarks of Cancer” to summarize the 
aberrations that are shared by most cancer types to develop from normal to tumorigenic 
phenotype (Hanahan and Weinberg, 2000). The hallmarks of cancer originally included six 
characteristics (sustained proliferative signaling, evading growth suppression, activation of 
invasion and metastasis, induction of angiogenesis, replicative immortality and resistance to 
cell death), which were completed by additional features in 2011 (avoiding immune 
destruction, tumor-promoting inflammation, genome instability and mutations and 
deregulating cellular energetics) (Hanahan and Weinberg, 2011).  
Multiple oncogenic features can be acquired by the cell largely by overexpression or mutation 
of oncogenes. Some gene functions are needed only during the developmental process of a 
tumor, while others are needed to maintain the malignant state (tumor drivers). Targeting 
these tumor driving genes or dependencies is now the rationale for targeted therapy. A number 
of therapeutics targeting individual hallmarks has been advanced to the clinical stage and 
many more are in pre-clinical development (Figure 10).  
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Figure 10: Hallmarks of cancer: A number of agents targeting cancer dependencies have been identified. They 
include small molecule inhibitors or biomolecules addressing the different hallmarks of cancer: sustaining 
proliferative signaling, evading growth suppressors, avoiding immune destruction, enabling replicative 
immortality, tumor-promoting inflammation, activating invasion and metastasis, inducing angiogenesis, genome 
instability and mutations, resisting cell death and deregulating cellular energetics. Examples are indicated by 
colored boxes. From (Hanahan and Weinberg, 2011) 
1.5.1.1 Resisting cell death 
One of the important features of cancer cells is to bypass programmed cell death (apoptosis). 
During development and tissue maintenance of an organism, apoptosis can be initiated e.g. 
when cells are damaged or infected by viruses. Cancer cells are able to block the pro-
apoptotic signals that can be either extrinsic or intrinsic, by overexpressing anti-apoptotic 
members of the BCL-2-family or by down-regulation of pro-apoptotic protein members. 
Extrinsic signals can be mediated by receptor ligand binding and intrinsic signals by e.g. 
DNA-damage signals. The BCL-2 family can be subdivided into multi domain proteins and 
BH3-only proteins. The multi domain proteins share four BCL-2 homology domains (BH) 1-
4. While Bcl2, BclXL and MCL1 have anti-apoptotic functions BCL-2-antagonist/killer 
(BAK) and BCL-2-associated X protein BAX act in a pro-apoptotic way. 
BAX and BAK are essential to induce outer mitochondrial membrane permeabilization 
(MOMP). This can be enhanced by BH3-only proteins like BIM and BID that interact with 
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the binding grove of anti-apoptotic proteins. A number of drugs are currently being developed 
to inhibit Bcl2 binding to BH3-only proteins. MOMP leads to release of cytochrome C, a 
trigger of apoptosis. Apoptotic protease activating factor 1 (Apaf-1) binds to cytosolic 
cytochrome C and forms the apoptosome complex. This complex activates procaspase-9 one 
of the so-called initiator caspases (Jesenberger and Jentsch, 2002). Caspases are cysteine-
aspartic proteases playing a central role in the induction of apoptosis. Initiator caspases-8, -9 
and -10 are present in the cytosol in their inactive pro-caspase form and get activated by 
cleavage of the pro-domain. They then amplify the pro-apoptotic stimulus by activating the 
downstream effector caspases-3 and-7 (Figure 11A). 
In addition the mitochondria-derived activator of caspases (SMAC) is released to inhibit a 
central negative regulator of apoptosis called the X-linked inhibitor of apoptosis protein 
(XIAP) which is a member of the inhibitor of apoptosis family (IAP). XIAP binds to active 
caspases to inhibit their function with its Baculovirus IAP repeat (BIR) domain (Figure 11B). 
Another negative regulator of caspase activity is the cellular FLICE-like inhibitory protein (c-
FLIP) which exhibits high sequence similarity to caspase-8, but lacks the protease domain 
(Figure 11C). The long isoform of c-FLIP (c-FLIPL) inhibits the activation of pro-caspase-8 
by interfering with the dimerization and binding of pro-caspase-8 to FADD (Fas-associated 
death domain protein) (Hughes et al., 2016). Upon oligomerization of the death receptor after 
binding of a ligand, FADD binds with its death domains (DD) to the DD of the receptor. 
Bound FADD recruits pro-caspase-8 by death effector domain (DED) interaction. This 
triggers self-cleavage of pro-caspase-8 dimers. The active caspases can further initiate the 
MOMP by BID cleavage or activate downstream caspases like caspase-3 (Kallenberger et al., 
2014) (Figure 11A). 
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Figure 11: Cellular apoptosis pathway: extrinsic apoptosis pathway is induced by death receptor ligand binding 
TNF-related apoptosis-inducing ligand (TRAIL), Fas ligand (CD95L) or tumor necrosis factor alpha (TNF-α) 
leads to activation of caspase-8/10 by FADD. This can be inhibited by c-FLIP. Active caspase-8/10 can further 
activate the effector caspase 3 or amplify the pro-apoptotic stimulus by cleaving the BH3-only protein BID 
which leads to BAK/BAK activation. BAX/BAK activation leads to permeabilization of the outer mitochondria 
membrane and release of cytochrome C and Smac. Smac inhibits XIAP and inhibitor of active caspases 3, 7 or 9. 
Cytochrom C is bound by Apaf and leads to apoptosome formation that activates Caspase-9. Caspase-9 activates 
additional caspase 3 leading ultimately to cell apoptosis. B: Schematic illustration of inhibitor of apoptosis 
protein family (IAP). XIAP, cIAP1/2 harbor three baculovirus IAP repeats (BIR) that can interact with active 
caspases and a really interesting new gene (RING) zinc finger domain. C: Schematic illustration of Caspase-8a/b 
isoforms, cellular FLICE like inhibitory protein (c-FLIP) small (s) and large (L) isoforms. Arrows indicate 
cleavage sites of proteins. Caspase-8 gets cleaved at conserved asparagine residues (Asp/D) leading to protein 
p18 and p10 that form active caspase-8 homodimer. Caspase activity also leads to cleavage of c-FLIPL at 
Asp376 and interference with homodimerization of active caspase-8. 
1.5.1.2 Myc proto oncogene transcription factor 
The Myc transcription factor family consists of c-Myc, N-Myc and L-Myc basic helix loop 
helix (bHLH) transcription factors. C-Myc forms a heterodimer with MAX to bind to specific 
e-box consensus sites at gene promoters to regulate gene expression. MYC is a proto-
oncogene coding for c-Myc which is overexpressed in almost all cancers. Translocation of 
MYC can ultimately lead to the development of cancers such as Burkitt lymphoma and 
multiple myeloma (MM). The overexpression of c-Myc in normal cells like fibroblasts 
induces cellular senescence or apoptosis, dependent on the regulatory context of a cell. The 
predominant induction of apoptosis by high c-Myc levels goes through DNA damage 
response pathway and p53 tumor suppressor by activation of cyclin-dependent kinase 2 
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(CdK2). In cell with Wrn depletion, a Cdk2 interacting DNA repair protein, high levels of c-
Myc induce senescence (Larsson and Henriksson, 2010). Importantly when oncogenes BRAF 
(Zhuang et al., 2008) or RAS (Hydbring et al., 2010) are active, c-Myc overexpression 
suppresses the oncogene-induced senescence. This might explain the proto-oncogenic 
function of c-Myc in the context of mutated hyper-active RAS. Depletion of c-Myc function 
in mouse tumor models leads to cell cycle arrest, senescence and tumor regression (Wu et al., 
2007). Targeting c-Myc protein directly remains challenging, while targeting the expression of 
the proto-oncogene has been accomplished by novel drugs like BET inhibitors (Delmore et 
al., 2011; Zuber et al., 2011; Kandela et al., 2015). 
1.5.1.3 KRAS-driven non-small cell lung cancer 
The kirsten rat sarcoma viral oncogene (KRAS) is a mammalian homolog from the RAS gene 
family, which encode a small GTPases. The guanosine triphosphate (GTP) hydrolase 
(GTPase) can switch from a GTP-bound active state to a GDP-bound inactive state. The 
hydrolase activity is enhanced by the RAS GTPase activating protein (GAP), while the 
exchange of bound-GDP from RAS-GDP is enhanced by RAS-guanine nucleotide exchange 
factor (RAS-GEF). Interestingly the two other isoforms of RAS (HRAS and NRAS) that are 
also ubiquitously expressed are mutated at regions that share 100% sequence identity. These 
point mutations can lead to hyper-activation of RAS. The mutation takes place at three 
hotspot positions. The most common mutation is found at codon 12 or 13 in the P-Loop of 
KRAS. This domain interacts with the substrate (GTP) and RAS-GAP. Mutation at codon 12 
or 13 leads to reduced RAS-GAP interaction resulting in a hyper-activated form of KRAS. 
The amino acid at position 61 stabilizes the transition state of GTP during hydrolysis, while 
mutation reduces the energetic state and decreases GTPase activity (de Castro Carpeno and 
Belda-Iniesta, 2013). RAS activity influences a number of important cellular functions 
including cell cycle, survival, growth and endocytosis (de Castro Carpeno and Belda-Iniesta, 
2013) (Figure 12). 
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Figure 12: RAS activity influences a number of important cellular functions. The activity of RAS regulated by 
its GTP binding regulates a number of important cellular functions including cell survival, growth, cycle 
progression and migration. Proteins controlling the state of RAS are RAS-guanine nucleotide exchange factor 
(RAS-GEF) and RAS GTPase activating protein (RAS-GAP) that enhances the hydrolase activity. Adapted from 
(de Castro Carpeno and Belda-Iniesta, 2013). 
KRAS is the most commonly mutated gene (25-30%) in non-small cell lung cancer (NSCLC). 
Other common mutations that can drive NSCLC have been identified and drugs addressing 
these addictions are in clinical development (Figure 13), but until recently there was no direct 
targeted therapy for KRAS mutations. A recently identified small molecule inhibitor (VSA9) 
was shown to specifically inhibit the G12C mutation by binding KRASG12C-GDP covalently, 
but is not effective in other mutations such as types like KRASG12D or KRASG12A (Table 1). 
Table 1: Lung adenocarcinoma mutation specificity of KRAS adapted from (Prior et al., 2012) 
KRAS codon 12: GGT 
DNA change -C- T-- -A- C-- A-- -T- 
amino acid change G12A G12C G12D G12R G12S G12V 
number 106 545 222 27 59 279 
% of total 8 41 17 2 4 21 
KRAS codon 13: GGC 
DNA change -C- T-- -A- C-- A-- -T- 
amino acid change G13A G13C G13D G13R G13S G13V 
number 1 43 31 1 1 1 
% of total 0 3 2 0 0 0 
KRAS codon 61: CAA 
DNA change G-- --C/T A-- -T- -C- -G- 
amino acid change Q61E Q61H Q61K Q61L Q61P Q61R 
number 0 11 1 5 0 2 
% of total 0 1 0 0 0 0 
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Figure 13: Driving mutations of non-small cell lung cancer: A: Identified driving mutations in NSCLC. KRAS = 
kirsten rat sarcoma viral oncogene, EGFR = epidermal growth factor receptor, ALK = anaplastic lymphoma 
kinase, HER2 = human epidermal growth factor receptor 2, BRAF = v-Raf murine sarcoma viral oncogene 
homolog B, PIK3CA = Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, AKT1 = v-akt 
murine thymoma viral oncogene homolog 1, MAP2K1 = mitogen-activated protein kinase kinase 1, NRAS = 
neuroblastoma rat sarcoma viral oncogene, ROS1 = v-ros avian UR2 sarcoma virus oncogene homolog 1, 
KIF5B-RET = kinesin family member 5B - rearranged during transfection (receptor tyrosine kinase) adapted 
from (Pao and Hutchinson, 2012). B: Stars highlight targets with oncogenic driving mutations in NSCLC for 
which drugs are currently in the clinic or in clinical development. Database search performed mid 2010 adapted 
from (Pao and Girard, 2011). 
1.5.2 BET inhibitors as novel epigenetic drugs to target cancer 
Modification of the epigenetic code, can lead to changes of gene regulation, which ultimately 
have different cellular phenotypes or outcomes. Deregulation of driving genes or tumor 
suppressors by changes of HDAC expression was the first epigenetic mechanism identified to 
cause major changes in cancer (Barneda-Zahonero and Parra, 2012; Lee et al., 2012; 
Magnaghi-Jaulin et al., 1998). It led to the clinical development and approval of targeted 
approaches against epigenetic modulator proteins using small molecule inhibitors (Barneda-
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Zahonero and Parra, 2012; Bolden et al., 2006; Filippakopoulos and Knapp, 2014; Garber, 
2007). Besides the HDAC inhibitors Vorinostat and Romidepsin another group of inhibitors 
addressing a different epigenetic protein family, DNMTs, 5-azacytidine and 5-aza-2′-
deoxycytidine, was approved by the food and drug administration (FDA) for the treatment of 
some rare cancer types. Following the promising clinical results of these first generation 
epigenetic drugs, a number of other potential epigenetic drug targets belonging to the writer, 
eraser of reader families were studied in detail. For several of them, potent and selective 
inhibitors were identified which led to the initiation of early clinical studies (Gelato et al., 
2016; Heyn and Esteller, 2012). They include inhibitors of the BET family which includes 
BRD2, 3 and 4 (Figure 14A). The potential of BET inhibition was first demonstrated in the 
context of a rare, aggressive cancer type, NUT midline carcinoma (NMC) which results from 
a gene rearrangement leading to a fusion protein between BRD3 or BRD4 with the nuclear 
protein in testis (NUT) (Figure 14B). BET inhibitors targeting this chimeric protein have 
shown promising anti-tumor activity in pre-clinical NMC models (Filippakopoulos et al., 
2010) and more recently in early clinical trials (Stathis et al., 2016). The oncogenic effect is 
dependent on the BRD3 or BRD4 function to bind to acetylated histones and the recruitment 
of HATs by the NUT fusion part. This leads to hyper-acetylation of enhancers and up-
regulation of the c-Myc proto-oncogene transcription factor and to inhibition of cell 
differentiation (French, 2014). By mimicking acetylated lysine, BET inhibitors competitively 
bind to BET bromodomains and thereby prevent the interaction with chromatin (Alekseyenko 
et al., 2015; Filippakopoulos and Knapp, 2014; Filippakopoulos et al., 2010). 
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Figure 14: Schematic illustration of bromodomain and extra terminal domain proteins and NUT fusions: A: 
Boxes delineate the conserved domains of BET family members Bromodomains (BD1/2), motif A and B, extra 
terminal domain and SEED motif. For BRD4 the short isoform is shown and for BRD2, 3 and T only the main 
isoform is shown. Numbers denote numbers of amino acids. B: Nuclear protein in testis (NUT) protein and 
BRD3, 4 fusions are shown. Arrow shows the amino acid at which NUT is fused to BRD3, 4.  
The beneficial effect of BET inhibition was thereafter found to extend to other cancer types 
with the help of JQ1, a potent and selective tool compound, and of other pan-BET inhibitors 
(e.g. I-BET762 and OTX-015) in a large number of pre-clinical models of hematological and 
solid tumors (Table 2). This strongly supports that BRD4 plays a major role in a number of 
different cancers and that its inhibition is an attractive strategy for cancer treatment. Several 
BET inhibitors are now being evaluated in clinical trials addressing hematological and solid 
tumors. 
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Table 2: Cancer indications of pre-clinical models in which BET inhibitors showed activity 
Cancer type Reference BET inhibitor used in the study 
acute lymphoid 
leukemia (Da Costa et al., 2013; Ott et al., 2012) JQ1 
acute myeloid 
leukemia 
(Rathert et al., 2015; Shen et al., 2015; Zuber et 
al., 2011) JQ1 
B-cell lymphoma (Boi et al., 2015; Trabucco et al., 2015) JQ1;OTX-015 
Burkitt's lymphoma (Mertz et al., 2011; Tolani et al., 2014) JQ1 
mantle cell lymphoma (Sun et al., 2015) JQ1 
leukemia stem cells (Fong et al., 2015) JQ1 
multiple myeloma (Chaidos et al., 2014; Delmore et al., 2011) JQ1;IBET-151;IBET-762 
T-cell acute lymphoid 
leukemia (Loosveld et al., 2014) JQ1 
breast cancer (Sengupta et al., 2015b) JQ1 
Ewing sarcoma (Hensel et al., 2016) JQ1 
glioblastoma (Cheng et al., 2013) JQ1 
Merkel-cell carcinoma (Shao et al., 2014) JQ1 
medulloblastoma 
(Bandopadhayay et al., 2014; Henssen et al., 
2013; Tang et al., 2014; Venkataraman et al., 
2014) 
JQ1 
melanoma (Segura et al., 2013) JQ1 
Merkel cell carcinoma (Sengupta et al., 2015a) JQ1 
neuroblastoma (Henssen et al., 2016; Puissant et al., 2013) JQ1;OTX-015 
NUT- middle line 
carcinoma (Filippakopoulos et al., 2010) JQ1 
non-small cell lung 
cancer 
(Lockwood et al., 2012; Shimamura et al., 
2013) JQ1 
osteosarcoma (Baker et al., 2015) JQ1 
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Cancer type Reference BET inhibitor used in the study 
ovarian carcinoma (Baratta et al., 2015) JQ1 
pancreatic cancer (Kumar et al., 2015; Sahai et al., 2014) JQ1 
prostate cancer (Asangani et al., 2014; Wyce et al., 2013) JQ1 
small cell lung cancer (Lenhart et al., 2015) JQ1 
thyroid cancer (Mio et al., 2016) JQ1;IBET-762 
uveal melanoma (Ambrosini et al., 2015) JQ1 
Interestingly, some kinase inhibitors are also potent inhibitors of BRD4, examples include the 
PLK1 inhibitor BI2536 and the JAK2 inhibitor TG101209 (Ciceri et al., 2014). They bind to 
the bromodomain pocket and mimic acetyl-lysine like the known BET inhibitors do (Ember et 
al., 2014). This suggests that the anti-tumor activity of some clinical or approved kinase 
inhibitors is to a certain degree due to BRD4 inhibition.  
Following the initial positive results with JQ1 in NMC, activity of this compound was also 
shown in models of hematological malignancies (Delmore et al., 2011; Zuber et al., 2011) 
driven by the c-Myc oncogene. Since then the activity of BET inhibitors has been mainly 
attributed to down-regulation of c-Myc (Delmore et al., 2011; Kandela et al., 2015; Zuber et 
al., 2011) or N-Myc (Henssen et al., 2016; Puissant et al., 2013) expression. Later the 
regulation of other oncogenes by BRD4 was evidenced. However, in lung cancer recent 
studies provided rather controversial results about the involvement of c-Myc in the response 
to JQ1 (Lockwood et al., 2012; Shimamura et al., 2013) which is why we initiated a 
comprehensive program to understand the role of BRD4 in this indication. 
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2. Research outline 
The BET family member BRD4 is indispensable for major cellular functions such as cell 
proliferation, transcriptional regulation and DNA damage repair. The bromodomains of BRD4 
facilitate an interaction with acetylated lysines found in chromatin and in transcriptional 
regulators. This interaction can be inhibited by blocking the bromodomain binding pocket 
with small molecule inhibitors. BET inhibitors exhibit potent anti-tumor activity in a wide 
range of tumors due to transcriptional down-regulation of major oncogene drivers. 
Nevertheless this anti-tumor activity can be quite diverse within one indication and a number 
of resistant models always exist. The goal of this study was to characterize the anti-tumor 
activity of BET inhibitors in pre-clinical models of KRAS-mutated NSCLC to identify the 
drivers of anti-tumor activity and to find combination partners that re-sensitize resistant cells 
to BET inhibitors. 
The results have the potential to advance the understanding of the mechanism of the anti-
tumor activity of BET inhibitors in KRAS-mutated NSCLC, an indication with yet unmet 
medical need, and to find attractive combination partners that might improve the clinical 
efficacy of BET inhibitors. 
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3. Materials and Methods 
3.1 Materials 
3.1.1 Equipment and materials 
Table 3: Equipment and materials. 
Name Company 
2100 bioanalyzer Agilent Technologies 
37 °C incubator Hera cell 150i Thermo Scientific 
6, 96-well culture plate clear TPP 
7900HT Fast Real-Time PCR System Applied Biosystems 
8, 12, 16-channel pipettes Thermo Scientific 
96, 384-well culture plate white Perkin Elmer 
Bioruptor Diagenode 
Cell culture flasks (25, 75, 162, 225, 300 cm²) TPP 
Cell incubator Thermo Scientific 
Centrifuge 5417R Eppendorf 
Centrifuge Heraeus Multifuge 3SR+ Thermo Scientific 
Centrifuge RC 5C Plus Sorval 
Countess cell counter Invitrogen 
Covaris S220 device Covaris 
FACSCanto II BD biosciences 
iBlot Invitrogen 
Intelli mixer tube rotator Sky Line 
Inverted Zeiss Axio Observer, Z1 LSM710 
microscope Zeiss 
Menzel Coverglasses Menzel 
Nanodrop 2000 Thermo Scientific 
Nunc Glass Base Dish 27mm Thermo Scientific 
NuPAGE 4-12% Bis-Tris Gel Life technologies 
Odyssey Fc Licor 
Parafilm M Pechiney Plastic Packaging 
Pipet filter tip (10μl, 2000μl, 1000μl) Eppendorf 
Pipet filter tip (10μl, 2000μl, 1000μl) Thermo Scientific 
Pipetboy acu Integra Biosciences 
Pipettes Eppendorf 
Precellysis 24 Bertin technolgies 
Precision wipes Kimtech Science 
Reaction tubes (0.5ml, 1.5ml, 2ml) Eppendorf 
ReadyAgarose Wide Mini gels (8, 12, 20 wells) Bio-Rad 
Stripette (5, 10, 25, 50 ml) Corning 
Tecan M1000 Tecan 
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Name Company 
Thermomixer Comfort Eppendorf 
Thermomixer Comfort Eppendorf 
UV light viewer Biostep 
Victor X3 Perkin Elmer 
X cell sure lock electrophorese chamber Invitrogen 
3.1.2 Chemicals, reagents and kits 
Table 4: Chemicals, reagents and kits 
Name Company 
16% Formaldehyde solution methanol free Thermo Scientific 
Agilent DNA 12000 reagents Agilent Technologies 
Ampicillin Sigma Aldrich 
BCA assay Thermo Scientific 
Bovine serum albumin (BSA) Sigma Aldrich 
CD95L (FasL) Adipogen 
Complete & Complete mini protease inhibitor roche 
Cycloheximid Sigma Aldrich 
DAPI (4',6-Diamidino-2-Phenylindole, 
Dihydrochloride) Biotinum 
DiaMag protein A coated magnetic beads Diagenode 
DMEM/Hams' F12 (1:1) Biochrom 
DMSO (Dimethyl Sulfoxide) Sigma Aldrich 
DNA chips for Agilent 2100 bioanalyzer Agilent Technologies 
DNA ladder low and high range, 1kb Plus Invitrogen 
Dynabeads M-280 Sheep anti-rabbit IgG Invitrogen 
Dynabeads MyOne Streptavidin T1 Invitrogen 
EDTA Sigma Aldrich 
EGTA Bio world 
EndoFree Plasmid Maxi Kit Qiagen 
Ethanol Sigma Aldrich 
Fetal calf serum Biochrom 
Glycerol Sigma Aldrich 
Glycerol 99.5% Alfa Aesar 
HEPES 1M Biochrom 
HEPES pH 7.5 Applichem 
Hyclone pure water GE Healthcare 
Hygromycin B Biochrom 
iBlot gel transfer stacks nitrocellulose Life Technologies 
Isopropanol Acros organics 
iz-Trail Adipogen 
Kanamycin Sigma Aldrich 
LiCl Sigma Aldrich 
Lipofectamine LTX plus Life Technologies 
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Name Company 
Matrigel BD Bio 
MEM Earle's Biochrom 
Methanol Millipore 
MgCl2*6H2O Alfa Aesar 
mircoTUBE AFA Fibre Pre-Slit Covaris 
M-PER Thermo Scientific 
NaCl Sigma Aldrich 
NaCl 5M Sigma Aldrich 
NaCl solution 0.9% Baxter 
Na-deoxycholate Sigma Aldrich 
NaOH 2M Sigma Aldrich 
Non-essential amino acids Biochrom 
NP-40 alternative Calbiochem 
NuPAGE 4-12% Bis-Tris Gels mini & midi Life Technologies 
NuPAGE LDS sample buffer Life Technologies 
NuPAGE MOPS SDS Running buffer 20X Life Technologies 
NuPAGE Sample Reducing Agent (10X) Life Technologies 
Oligofectamine Invitrogen 
Opti-MEM Invitrogen 
Paraformaldehyde Sigma Aldrich 
PIPES Sigma Aldrich 
Ponceau’s solution Fluka 
Precellys-Ceramic Kit peqlab 
Precision Plus Protein Dual Color Standard BioRAD 
Prolong (R) Gold Antifade Reagent Cell Signaling Technology 
Proteinase K Sigma Aldrich 
Puromycin Santa Cruz Biotechnology 
QIAquick PCR purification kit Qiagen 
QIAshredder Qiagen 
Re-Blot Plus Strong Millipore 
RIPA Lysis and Extraction Buffer Thermo Scientific 
RNase A Invitrogen 
RNeasy Plus Mini Kit Qiagen 
RPMI-1640 Biochrom 
RT² First Strand Kit Qiagen 
RT² SYBR green ROX qPCR Mastermix Qiagen 
S.O.C. medium Invitrogen 
SDS 10% Sigma Aldrich 
SDS powder Sigma Aldrich 
Sodium acetate pH 5.0 Thermo Scientific 
Sucrose Sigma Aldrich 
SuperScript III First-Strand Synthesis Supermix Invitrogen 
SuperSignal West Femto Maximum sensitivity 
substrate Thermo Scientific 
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Name Company 
TaqMan Fast Advanced Master Mix Applied Biosystems 
TNF alpha Adipogen 
TPX vials Diagenode 
TRIS-HCl Gibco 
Triton X-100 Sigma Aldrich 
Tryptan Blue staining 0.4% Invitrogen 
Tween 20 Sigma Aldrich 
Ultra Pure Water Biochrom 
Vectashield Mounting medium for fluorescence Vector Laboratories 
 
3.1.2.1 Chemical compounds 
Table 5: Pharmacological inhibitors and chemical compounds  
Name Structure PubChem CID/Ref.: Purchased from 
Bio-JQ1(S) 
(pan-BET inhibitor) 
 
(Anders et al., 2014) 
Bayer 
compound 
repository 
JQ1(S) 
(pan-BET inhibitor) 
 
46907787 
Bayer 
compound 
repository 
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Name Structure PubChem CID/Ref.: Purchased from 
I-BET762 
(pan-BET inhibitor) 
clinical development 
 
52934829 
Bayer 
compound 
repository 
OTX-015 
(pan-BET inhibitor) 
clinical development 
 
9936746 
Bayer 
compound 
repository 
pan-Caspase inhibitor 
Z-VAD-FMK  
(carbobenzoxyvalyl-
alanyl-aspartyl 
fluoromethyl ketone) 
 
5737 Promega 
Caspase-9 inhibitor 
Z-LEHD-FMK 
(carbobenzoxyleucyl-
glutamyl-histidyl-
aspartyl fluoromethyl 
ketone) 
 
10032582 BD Biosciences 
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Name Structure PubChem CID/Ref.: Purchased from 
Caspase-8 inhibitor 
Z-IETD-FMK 
(carbobenzoxyisoleucyl-
glutamyl-threonyl-
aspartyl fluoromethyl 
ketone) 
 
9852146 BD Biosciences 
Intra-strand DNA linker 
Cisplatin 
cis-
diaminedichloroplatinum 
(CDDP) 
 
2767 Sigma Aldrich 
Proteasome inhibitor 
MG-132 
 
462382 Sigma Aldrich 
 
 
3.1.3 Buffers and solutions 
TBS – tris buffered saline: 20 mM Tris-HCl [pH 7.4], 500 mM NaCl 
PBS – phosphate buffered saline: 0.137 M NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 1.8 mM 
KH2PO4 [pH 7.4] 
TBS-T and PBS-T: TBS or PBS, 0.1% (v/v) Tween-20 
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TE buffer: 10 mM Tris-HCl [pH 8.0], 1 mM EDTA 
10x PIPES buffer: 1.5 g PIPES (100 mM), 2 mL 2 M NaOH, 48 mL H2O 
10x Sucrose/MgCl2 buffer: 3 M Sucrose, 30 mM MgCl2*6H2O 
Cytoskeleton (CSK) buffer: 10 mM PIPES, 300 mM Sucrose, 100 mM NaCl, 3 mM 
MgCl2*6H2O 
Detergent washout buffer 1: CSK Buffer, 0.1% (v/v) Triton X-100 
Detergent washout buffer 2: CSK Buffer, 0.5% (v/v) Triton X-100 
Western blot (WB) blocking solution: 5% non-dry fat milk powder (w/v) in PBS or TBS.  
Immunofluorescence blot blocking solution: 10% normal goat serum (v/v) in PBS, 0.3% 
(v/v) Triton X-100. 
ChIP lysis buffer 1: 50 mM HEPES [pH 7.3], 140 mM NaCl, 1 mM EDTA, 10% glycerol, 
0.5% NP-40, 0.25% Triton X-100, 1 tablet protease inhibitors complete (per 50 mL). 
ChIP sonication buffer:, 50 mM Tris-HCl [pH 7.5], 140 mM NaCl, 1 mM EDTA, 1 mM 
EGTA, 1% Triton X-100, 0.1%-0.75% (w/v) SDS, 0.1% Na-deoxycholate (w/v), 1 tablet 
protease inhibitors complete (per 50 mL). 
ChIP sonication buffer high salt:, 50 mM Tris-HCl [pH 7.5], 500 mM NaCl, 1 mM EDTA, 
1 mM EGTA, 1% Triton X-100, 0.1% SDS, 0.1% Na-deoxycholate (w/v), 1 tablet protease 
inhibitors complete (per 50 mL). 
ChIP Li washing buffer: 20 mM Tris [pH 8.0], 1 mM EDTA, 250 mM LiCl, 0.5% NP-40, 
0.5% Na-deoxycholate 
ChIP washing buffer: 10 mM Tris-HCl [pH7.5], 0.1 mM EDTA 
ChIP elution buffer-ChIP: 50 mM Tris-HCl [pH 8.0], 10 mM EDTA, 1% SDS 
ChIP elution buffer-Chem: 50 mM Tris-HCl [pH 8.0], 10 mM EDTA, 10% SDS 
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RIPA buffer: 25 mM 50 mM Tris-HCl [pH 7.6], 150 mM NaCl, 1% NP-40, 1% Na-
deoxycholate (w/v), 0.1% SDS 
Western blot (WB) lysis buffer: RIPA buffer, 100U/mL Benzonase, 5 μM EDTA, 1x Halt 
Protease and Phosphatase Inhibitor Cocktail (Protase inhibitors: Aprotinin, Bestatin, E-64, 
Leupeptin and Phosphatase inhibitors (Sodium Fluoride, Sodium Orthovanadate, Sodium 
Pyrophosphate, β-glycerophosphate) 
M-PER buffer: proprietary detergent in 25 mM bicine buffer [pH7.6] 
Chromatin separation buffer: M-PER buffer, 5 μM EDTA, 1x Halt Protease and 
Phosphatase Inhibitor Cocktail. 
 
 
3.1.4 Human cell lines 
All cell lines used in this study were purchased from the American Type Culture Collection 
(ATCC) or the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ). 
The H441 cell line was from the Bayer cell stock and has been authenticated by finger-
printing at the DSMZ. Cells were maintained in RPMI 1640 or DMEM/F12 supplemented 
with 10% (v/v) FCS. Non-essential amino acids were added in the case of DV90. IMR-90, 
Wi38 and HFF-1 cells were cultured in MEM Earle’s Medium with 10% FCS. 
 
 
Table 6: Human cell lines used in this study with corresponding culture media and source of origin 
Name of cell 
line Culture medium 
Culture medium 
supplement Tissue type Origin 
DV90 RPMI-1640 10% FCS+ NEA NSCLC DSMZ 
NCI-H1373 RPMI-1640 10% FCS NSCLC ATCC 
LCLC97TM1 RPMI-1640 20% FCS NSCLC DSMZ 
NCI-H1792 RPMI-1640 10% FCS NSCLC ATCC 
SKLU-1 RPMI-1640 10% FCS NSCLC ATCC 
NCI-H2122 RPMI-1640 10% FCS NSCLC ATCC 
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Name of cell 
line Culture medium 
Culture medium 
supplement Tissue type Origin 
NCI-H441 RPMI-1640 10% FCS NSCLC authenticated at DMSZ 
NCI-H23 RPMI-1640 10% FCS NSCLC ATCC 
A549 DMEM/Hams' F12 (1:1) 10% FCS NSCLC DSMZ 
NCI-H460 DMEM/Hams' F12 (1:1) 10% FCS NSCLC ATCC 
NCI-H358 RPMI-1640 10% FCS NSCLC ATCC 
NCI-H2347 RPMI-1640 10% FCS NSCLC ATCC 
NCI-H2030 RPMI-1640 10% FCS NSCLC ATCC 
Wi38 MEM Earle's 10% FCS normal lung fibroblast ATCC 
IMR-90 MEM Earle's 10% FCS normal lung fibroblast ATCC 
HFF-1 MEM Earle's 10% FCS normal foreskin fibroblast ATCC 
3.1.5 Mouse strains 
Mouse strains used in this study were FOX chase severe combined immunodeficiency (SCID) 
mice (CB17/Icr-Prkdcscid/IcrIcoCrl) purchased from Charles River Germany.  
3.1.6 Bacterial strains and media 
The Escherichia coli (E. coli) strain used for plasmid amplification and purification was XL1-
Blue competent cells (Stratagene). E.coli bacteria were cultured and grown in LB (Luria 
Bertani) liquid medium or solid medium produced in the Quality Control Biology department 
of Bayer Pharma.  
LB Medium liquid: 0.5% NaCl, 1% Bacto-Pepton, 0.5% Yeast extract  
LB Medium solid: 0.5% NaCl, 1% Bacto-Pepton, 0.5% Yeast extract, 1.7% Bacto-Agar 
3.1.7 Oligonucleotides 
3.1.7.1 TaqMan Probes 
Table 7: TaqMan gene expression assays and RT²-array used in this study 
Gene symbol Name Reference 
MYC c-Myc proto-oncogene Hs00905030_m1 
FLIP FLICE like inhibitor protein Hs00153439_m1 
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XIAP X-linked inhibitor of apoptosis protein Hs00745222_s1 
FOSL1 Fos-related antigen 1 Hs04187685_m1 
BRD4 Bromodomain-containing protein 4 Hs01006453_m1 
BRD3 Bromodomain-containing protein 3 Hs00201284_m1 
BRD2 Bromodomain-containing protein 2 Hs01121986_g1 
PPIA/ Cyclophilin A 4326316E 
Human Apoptosis PCR Array 384HT PAHS-30127 
3.1.7.2 ChIP qRT-PCR primers 
Table 8: ChIP qRT-PCR primer used in this study 
Gene symbol location Company 
XIAP hXIAP NM_001167.2 at -10kb from TSS Qiagen 
XIAP hXIAP NM_001167.2 at -2kb from TSS Qiagen 
XIAP hXIAP NM_001167.2 at +1kb from TSS Qiagen 
XIAP hXIAP NM_001167.2 at +8kb from TSS Qiagen 
FLIP hFLIP NM_003879.4 at -2kb from TSS Qiagen 
FLIP hFLIP NM_003879.4 at +1kb from TSS Qiagen 
 
3.1.7.3 Small interfering RNA (siRNA) 
Table 9: siRNAs used in this study 
Gene symbol Reference Company 
Control siRNA 1027281 Qiagen 
FLIP L-003772-00-0010 GE Dharmacon 
XIAP L-004098-00-0010 GE Dharmacon 
 
3.1.8 Reagents and antibodies 
3.1.8.1 Plasmids 
Human MYC cDNA construct was purchased from OriGene (pCMV6.XL5, pCMV6.XL5-
MYC) and Tag-GFP construct from Evrogen (pTagGFP-C). CRISPR knockout plasmid pools 
of 2-3 guide RNAs (BAX-KO-GFP, BAK-KO-GFP) were purchased from Santa Cruz 
Biotechnology that derived guide sgRNA sequences from a CRISPR Knock-out (GeCKO) v2 
library (Ran et al., 2013; Shalem et al., 2014).  
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Corresponding CRISPR homology directed repair (HDR) plasmids were purchased from 
Santa Cruz Biotechnology (BAX-HDR-RFP-Puro, BAK-HDR-RFP-Puro). HDR plasmid 
overhang arms for the 5’ and 3’ for the specific cutting sites were designed and synthesized by 
Santa Cruz Biotechnologies. 5’ and 3’ arms are flanking LoxP sites and selection marker gene 
cassettes for red fluorescent protein (RFP) and puromycin resistance gene. 
Table 10: Plasmid vectors used in this study or used to produce stable cell lines presented in this study 
Name Source Plasmid map 
pTagGFP-C Evrogen 
 
pcDNA6.2/N-EmGFP-
BRD4 
Structural 
Genomics 
Consortium 
(Oxford) 
 
pCMV6.XL5 
(PCMV6XL5) 
Origene 
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Name Source Plasmid map 
pCMV6.XL5-MYC 
(SC112715) Origene 
 
CRISPR/Cas9 knockout 
Plasmids: 
BAX-KO-GFP 
BAK-KO-GFP 
Santa Cruz 
Biotechnology 
 
Homology-directed repair 
(HDR) Plasmids: 
BAX-HDR-RFP-Puro 
BAK-HDR-RFP-Puro 
Santa Cruz 
Biotechnology 
 
 
3.1.8.2 Antibodies 
Antibodies and beads used for Immunoblotting and Chromatin immunoprecipitation (ChIP) 
antibodies are listed in tables 9-12. 
Table 11: Primary antibodies used for western blot staining 
Antibody Company Concentration 
Mouse-anti-c-Myc Abcam (ab32) 1 μg/ml 
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Antibody Company Concentration 
Rabbit-anti-FOSL1 Cell signaling (#5281) 1 μg/ml 
Mouse-anti-c-FLIP Enzo Life Sciences (7F10) 1 μg/ml 
Rabbit-anti-BCL-XL Cell signaling (#2764) 1 μg/ml 
Rabbit-anti-Mcl1 Cell signaling (#5453) 1 μg/ml 
Rabbit-anti-BCL2 Cell signaling (#2870) 1 μg/ml 
Rabbit-anti-c-IAP1 Cell signaling (#7065) 1 μg/ml 
Rabbit-anti-c-IAP2 Cell signaling (#3130) 1 μg/ml 
Rabbit-anti-Survivin Cell signaling (#2808) 1 μg/ml 
Rabbit-anti-XIAP Cell signaling (#2045) 1 μg/ml 
Rabbit-anti-BID Cell signaling (#2002) 1 μg/ml 
Rabbit-anti-BAX Cell signaling (#5023) 1 μg/ml 
Rabbit-anti-BAK1 Cell signaling (#12105) 1 μg/ml 
Rabbit-anti-PARP Cell signaling (#9542) 1 μg/ml 
Rabbit-anti-LKB1 Cell signaling (#27D10) 1 μg/ml 
Rabbit-anti-p53 Cell signaling 1 μg/ml 
Rabbit-anti-p21 Cell signaling 1 μg/ml 
Rabbit-anti-GAPDH Abcam (ab9485) 0.5 μg/ml 
Rabbit-anti-β-ACTIN Abcam (ab8227) 0.125 mg/ml 
 
Table 12: Primary antibodies used for ChIP 
Antibody Company 
Rabbit-anti-BRD4 Bethyl Laboratories (A301-985A) 
rabbit IgG Sigma Aldrich (R2004-5X1MG) 
Rabbit-anti-H3K27Ac Abcam (ab4729) 
Rabbit-anti-H3K4me1 Diagenode (C15410194) 
Rabbit-anti-H3K4me3 Diagenode (C15410003) 
Rabbit-anti-MED1 Bethyl Laboratories (A300-793A) 
Rabbit-anti-Pol2 Santa Cruz Biotechnologies (sc-899X) 
 
 
 
Table 13: Antibodies used for immunofluorescence 
Antibody Company Concentration 
Rabbit-anti-BRD4 Abcam (ab128874) 3.63 μg/mL 
Mouse- anti-tubulin-Alexa Fluor 488 conjugate Abcam (ab195887) 2.5 μg/mL 
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Table 14: Secondary conjugate antibodies used for western blot staining immunofluorescence 
Antibody Company Concentration 
Anti-rabbit-HRP invitrogen (656120) 0.1 μg/ml 
Anti-mouse-HRP Santa Cruz Biotechnologies (sc-2005) 0.2 μg/ml 
Anti-rabbit-Alexa Fluor 647 Thermo Fisher Scientific (A-21245) 4 μg/mL 
3.1.9 Software 
Table 15: Software and scripts used in this study 
Name Version Company/link 
bamToGFF - Bradner laboratory 
Bdg2bw - https://gist.github.com/taoliu/2469050 
bedGraphToBigWig - https://gist.github.com/2469050 
bedTools 2.26.0 Quinlan laboratory 
Bowtie 2 Langmead laboratory 
DAVID 6.7 https://david.ncifcrf.gov/home.jsp 
EndNote X4 Thomas Reuters 
Excel 2010 Microsoft 
FACSDiva software 8.0.1 BD 
GraphPad Prism 6 GraphPad Software 
GSEA 2.2 Broad Institute 
IGV 2.3.81 Broad Institute 
Illustrator CS5 Adobe 
Image Studio 5.2 Li-Cor 
Magellan 7.2 Tecan 
Model-bases Analysis for ChIP-seq 2 Liu laboratory 
Nanodrop 2000 Fisher Scientific 
Peakanalyzer 1.4 Bertone laboratory 
PerkinElmer Manager 2030 PerkinElmer 
Powerpoint 2010 Microsoft 
ROSE - Young laboratory 
RQ Manager 1.21 Applied Biosystems 
SAMtools 1.3.1 www.htslib.org/ 
SDS 2.4 Applied Biosystems 
SeqPlots 1.10.2 http://github.com/przemol/seqplots 
Word 2010 Microsoft 
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3.2 Methods 
3.2.1 Cell lines and culture conditions 
3.2.1.1 Thawing of cryo-conserved cell lines 
Cells were frozen in 90% fetal calf serum (FCS) and 10% dimethyl sulfoxid (DMSO) before 
storing in liquid nitrogen gas-phase at around -270 °C (cryo-conservation). Thawing of cell 
lines was done at 37 °C before transfer into pre-warmed appropriate culture medium 
containing FCS. Cells were centrifuged at 300 g to separate them from residual DMSO. Cells 
were re-suspended and transferred into a 75 cm² culture flask (T75) which was cultured in an 
incubator at 37 °C, 5% CO2 and >80% humidity (incubation). Culture medium was replaced 
after 24 h. Cells were passaged when reaching 80-90% confluence. 
3.2.1.2 Passaging of cells 
Cells were grown in the incubator until 80-90% confluence was reached. To detach adherent 
cells, the culture media was removed, cells were washed once with magnesium and calcium 
free phosphate-buffered saline (DPBS) and treated with trypsin 0.25% / 
ethylenediaminetetraacetic acid (EDTA) solution at 37 °C. Detachment of cells was ensured 
using a microscope. Detached cells were re-suspended in culture media containing FCS to 
quench trypsin activity. Cells were counted and viability was determined by mixing 10 μL of 
cell suspension with 10 μL trypan blue and subjected to the automated counting system 
Countess. Cell suspension was then diluted and re-seeded into a new culture flask for the 
maintenance of the cell line or to culture plates, flasks or plates to perform subsequent 
experiments.  
3.2.2 Determination of cell doubling time and optimal seeding density for viability 
assays 
To optimize conditions for cell viability assays and drug testing, cell doubling time and 
optimal cell seeding number were determined. Cells were seeded at 1,000, 2,000, 3,000, 
4,000, 6,000 and 10,000 cells/well in 50 μL. Cells were seeded in 6 replicate wells per cell 
density on a 96-well plate. After 24 h (day 0) incubation, 50 μL culture medium containing 
0.1% DMSO were added. The ATP content of each well which is representative of the number 
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of viable cells was determined using CellTiter-Glo One Solution (CTG) every 24 h for 4 
subsequent days starting on day 0. In accordance to the manufacturer’s instructions 100 μL 
CTG were added to 100 μL cell suspension. The plates were equilibrated at room temperature 
(RT) for 20 min prior to addition of CTG at RT and subsequent sealed before incubation for 
15 min at RT on a shaker at 500 rpm, to ensure complete lysis of the cells. The luminescence 
signal was determined on a plate reader (VictorX3) using a protocol of an intensity count of 1 
second per well.  
The cell doubling time (Dt(x)) in hours was determined by dividing log(2) by the cell line 
specific calculated slope of the logarithmic signal increase per day (x) multiplied by 24. The 
cell density that still showed log-growth on day 3-4 and not reaching a plateau was considered 
as the optimal cell number. 
ܦݐሺݔሻ ൌ ሺʹሻݔ כ ʹͶ 
ݔǣ ሺݏ݈݅݃݊ܽ݅݊ܿݎ݁ܽݏ݁ሻ݀ܽݕ  
3.2.3 Drug treatment and determination of cell viability 
Cells were seeded at the pre-optimized density which was between 1000-2000 cells/50 
μL/well in the 96-well plate format, on the day before treatment. On day 0, cells were treated 
with 50 μL of medium containing 0.1% DMSO or 0.1% DMSO and small molecule inhibitor. 
The 2x drug concentrated medium was generated by adding 1 μL of serial diluted drug in 
DMSO to 500 μL culture media. The final drug concentration range was between 10-8.5 and 
10-5 mol/L (M) with half log fold steps. The cells were cultured in presence of drug or vehicle 
for 72 h. The on-plate positive control wells were treated with 1 μM MG-132, a proteasome 
inhibitor toxic to most cell lines. On day 3 post-treatment the cell viability was assessed in 
triplicate using CTG assay according to the manufacturer’s instructions as described above 
(3.2.2). 
Values were normalized to 100%, which was equivalent to the average of the negative control 
DMSO and to 0%, which was equivalent to the average of the positive control MG-132. 
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The cellular half-inhibitory concentrations of each inhibitor (IC50) values were calculated 
using a non-linear regression model in GraphPad Prism 6 calculating an IC50 and a Hill Slope 
value that can be used to calculate ICx. Resulting IC50 values were expressed as an average of 
two or three independent experiments. 
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3.2.4 Drug combination and synergy calculation 
3.2.4.1 Drug combination with cisplatin 
A549 cells were seeded at pre-optimized density of 350 cells/well in 384-well plate format on 
the day before treatment and cultured in presence of drug or vehicle for 72h. The drug 
combination ratio (R) between JQ1 and cisplatin is described as Ra for JQ1 and Rb for 
cisplatin. Ra to Rb ratios generated by mixing 10 mM stock solutions of JQ1 and cisplatin 
ratios R1-5: 1) 0.8/0.2; 2) 0.6/0.4; 3) 0.4/0.6; 4) 0.2/0.8; 5) 0.1/0.9. Starting from the stock 
ratios the final drug ratio concentration ranged from 10-8.5 to 10-5 mol/L (M). The dilution was 
made in half log fold steps. The twofold drug concentrated medium was generated by adding 
1 μL of serial diluted drug in DMSO to 500 μL culture media. On-plate positive control wells 
were treated with 1 μM MG-132. Values were normalized to 100%, which was equivalent to 
the average of the negative control DMSO and to 0%, which was equivalent to the average of 
the positive control MG-132. Viability was assessed in duplicate using CellTiter-Glo One 
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Solution (CTG) assays according to the manufacturer’s instructions as described above 
(3.2.2).  
Combined drug effects were calculated by the combination-index (CI) analysis. The CI values 
were calculated from a range of drug ratios (R) and the corresponding IC50 values. 
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[R[1-5] (Ra(JQ1)/Rb(cisplatin)): 0.8/0.2; 0.6/0.4; 0.4/0.6; 0.2/0.8; 0.1/0.9] 
IC50 values were calculated using non-linear regression model in GraphPad Prism 6. The 
resulting IC50 and CI values were expressed as the average of two independent experiments. 
3.2.4.2 Drug combinations with TRAIL ligand 
Cells were seeded in 96-well plates at 4000 cell/well/45 μL density 24 h prior to combination 
treatment (day-1). On day 0 cells were treated with 45 μL of 2x small molecule containing 
media. Final concentrations of JQ1 ranged from 0.5-2.5 μM. After 2 h of incubation at 37 °C 
wells were subjected to 100 μL 10x concentrated 0.1% BSA-PBS containing diluted TRAIL 
ligand. Final TRAIL concentrations ranged from 0.01-1,000 ng/mL. After 24 h the viability of 
the cells was determined using the CTG assay as described above (3.2.2).  
3.2.5 Cell cycle analysis 
Cell lines growing in exponential phase were detached and 100,000 – 200,000 cells were 
seeded in 1 mL culture media in six-well plates. After 24 h in the incubator, the seeding 
medium was removed and replaced with 2 mL BET inhibitor or DMSO vehicle containing 
culture medium and incubated for 18 h. Cells were then subjected to 10 μM EdU, a cell 
permeable nucleotide analog that gets incorporated into the DNA during synthesis (S)-phase, 
and further incubated for 6 h before staining. Cells were washed once with cold PBS and 
detached using Trypsin/EDTA solution, and medium and washing buffer were collected. Cells 
were re-suspended in the collected culture medium and washing buffer, and filtered through a 
70- μm mesh cap of a flow cytometry tube. Cells were spun down at 300 g using a centrifuge. 
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Medium was removed and cells were washed with 3 mL 1% BSA containing PBS and then 
centrifuged at 300 g. Washing solution was removed and cell pellet was re-suspended in 100 
μL fixative solution containing formaldehyde from Click-iT EdU Alexa Fluor 647 Flow 
Cytometry Assay Kit. Cells were incubated in fixation solution for 15 min in the dark at RT 
and washed with 3 mL 1% BSA containing PBS and centrifuged at 300 g. Washing buffer was 
removed and 100 μL saponin-based buffer (1% BSA in PBS) was used to permeabilize the 
cells. EdU Click-it staining solution containing 10 μL copper sulfate, 438 μL PBS, 50 μL 
reaction buffer additive and 2.5 μL Alexa Fluor 647 azide per sample was prepared and 
added. Cells were stained for 30 min at RT in the dark, washed with 3 mL saponin-based 
buffer after and centrifuged at 300 g. Washing buffer was removed and cells were re-
suspended in saponin-based buffer containing 1 μg/mL 4′,6-Diamidin-2-phenylindol (DAPI) 
for 1 h at 4 °C in the dark to stain the DNA. EdU+ and EdU- populations were determined and 
separated by DNA content using a FACS-Canto II Flow Cytometry system and BD 
FACSDiva software. FACS analysis enabled the separation of EdU+ S-Phase population and 
EdU- subG1, G1 and G2/Mitosis (M) populations. 
3.2.6 Annexin V/PI staining 
3.2.6.1 Annexin V/PI staining of BET inhibitor treated cells 
Cell lines growing in exponential phase were detached and 300,000 cells were seeded in 1 mL 
culture media in six-well plates. After 24 h in the incubator seeding medium was removed and 
replaced with 2 mL of 0.5 μM or 2.5 μM BET inhibitor or DMSO vehicle containing culture 
media and incubated for 48 h. Cells were washed once with cold PBS and then detached using 
Trypsin/EDTA solution. Medium and washing buffer were collected. Cells were re-suspended 
in collected culture medium and washing buffer, and filtered through a 70- μm mesh cap of a 
flow cytometry tube. Cells were spun down at 300 g using a centrifuge. Medium was 
removed and cells were washed with 2 mL PBS and then centrifuged at 300 g. Washing 
solution was removed and the cell pellet was re-suspended in 300 μL binding buffer from 
FITC Annexin-V Apoptosis Detection kit I. 100,000 cells were stained in 100 μL binding 
buffer containing 5 μL PI solution and 5 μl Annexin V-FITC solution for 15 min in the dark at 
RT. Viable (Annexin V-/PI-), early apoptotic (Annexin V+/PI-), late apoptotic (Annexin 
V+/PI+) and necrotic population (Annexin V-/PI+) were determined by a flow cytometer. 
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3.2.6.2 Annexin V/PI staining of JQ1 and death ligand combination 
Cells growing in exponential phase were detached and 300,000 cells were seeded in 1 mL 
culture media in six-well plates. After 24 h in the incubator seeding media was removed and 
replaced with 2 mL of 1 μM JQ1 or DMSO vehicle containing culture media and pre-
incubated for 2 h before addition of TRAIL for 24 h at 10 ng/mL or 100 ng/mL final 
concentration. Cells were stained as described above (3.2.6.1) and analyzed by a flow 
cytometer. 
3.2.6.3 Annexin V/PI staining of JQ1 and death ligand combination rescue 
H1373 cells growing in exponential phase were detached and 300,000 cells were seeded in 1 
mL culture media in six-well plates. After 24 h in the incubator seeding medium was removed 
and replaced with 2 mL of JQ1 or DMSO vehicle containing culture media and pre-incubated 
for 2 h before addition of TRAIL for 24 h at 10 ng/mL final concentration together with a 
final concentration of 20 μM Caspase-8 (z-IETD-FMK), Caspase-9 (z-LEHD-FMK) or pan-
Caspase inhibitor (z-VAD-FMK). Cells were stained as described above (3.2.6.1) and 
analyzed by a flow cytometer. 
3.2.6.4 Annexin V/PI staining of BET inhibitor and cisplatin combination 
A549 cells growing in exponential phase were detached and 200,000 cells were seeded in 1 
mL culture medium in six-well plates. After 24 h in the incubator seeding medium was 
removed and replaced with 2 mL of culture media containing 1 μM JQ1 or DMSO vehicle in 
combination with 20 μM cisplatin and incubated for 48h. Cells were stained as described 
above (3.2.6.1) and analyzed by a flow cytometer. 
3.2.7 Western blot 
Culture medium was removed from cells. Cells were washed in cold PBS, and then lyzed 
using WB lysis buffer (radioimmunoprecipitation assay (RIPA) buffer containing Halt 
Protease and Phosphatase inhibitor mixture and 100 U/mL Benzonase. Tumor tissues samples 
were disrupted in tubes containing ceramic beads and WB lysis buffer at 5000 rpm for 15 s 
using the Precellys 24 system. Lysates were incubated at 4 °C overnight and clarified by 
centrifugation at 13,000 x g for 10 min. To determine the protein concentration the Pierce 
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BCA Protein Assay kit was used. For that 1 μL of total lysate was added to 199 μL of 1x BCA 
staining solution, a mixture of 1 part solution A and 25 parts solution B, and incubated for 1 h 
at 37 °C. Absorbance was determined at 562 nm wavelength. An on-plate BSA protein 
standard with a concentration range from 0,069 - 4.41 μg was used to determine the amount 
of protein in the total cell lysates. Equivalent amounts of lysate were denatured in 1x LDS 
sample buffer together with 1x sample reducing agent and denatured at 70 °C for 10 min. The 
lysates were loaded on SDS gels together with 10 μL of protein marker (Precision Plus 
Protein Dual Color Standard) and run at 100-120 mA for 1 h. Proteins were blotted on 
Nitrocellulose membrane using the iBLOT protein transfer system at program 3 for 9 min. 
Membrane was stained and checked using Ponceau S solution for 2 min and washed with 
water for 5 min to confirm successful protein transfer. Membranes were blocked in 5% non-
dry fat milk containing PBS or TBS for 30 min at RT on a rocking plate. Primary antibody 
incubation was done in 5% non-dry fat milk containing PBS or TBS at 4 °C overnight. 
Membranes were washed 5 times for 5 min with PBS or TBS containing 0.1% tween 20 
(PBS-T or TBS-T). Horseradish peroxidase (HRP)-conjugated secondary antibody was 
diluted in 5% non-dry fat milk containing PBS or TBS for 1 h and washed 5 times for 5 min 
with PBS-T or TBS-T. Membranes were developed using HRP substrate (SuperSignal West 
Femto Maximum sensitivity substrate) by mixing luminol enhancer solution and peroxide 
buffer 1:1 and adding it onto the membrane followed by detection of the signal on an Odyssey 
Fc imaging system. 
3.2.8 RNA extraction 
Cells were seeded at 100,000-300,000 cells/well in a 6-well culture plate on the day before 
treatment. Total RNA was extracted using the RNeasy Plus Mini kit. Culture medium was 
removed from cells. Cells were washed with cold PBS, and then lysed using 350 μL of 
guanidine-isothiocynate and 2 M DTT-containing high salt RLT Plus Buffer. Lysate was 
transferred to QIAshredder tubes and centrifuged for 2 min at 13,000 g for homogenization. 
Samples were frozen at -80 °C or RNA extraction was performed directly afterwards. Lysates 
were passed through gDNA Eliminator spin column to eliminate genomic DNA from the 
sample. 350 μL of 70% ethanol were added to provide optimal conditions for the RNA to bind 
to the silica membrane of the RNeasy spin column. Samples were transferred to the RNeasy 
spin column and centrifuged for 1 min at >10,000 g. The flow through was discarded and 700 
μL washing Buffer RW1 were added and passed through the column by centrifugation (1 min 
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at 13,000 g). The RNA was washed twice with 500 μL RPE and the flow through was 
discarded. The column was moved to a new collection tube and centrifuged for additional 2 
min at 13,000 g to dry the membrane. RNA was eluted from the column by using 50 μL 
RNase-free water and centrifugation for 1 min at 13,000 g. RNA was kept on ice and 
concentration was determined using the spectrophotometer NanoDrop 2000 system. 
3.2.9 Gene expression analysis 
3.2.9.1 TaqMan 
Total RNA of cells was extracted using the RNeasy Plus Mini kit as described above (3.2.8). 
Total RNA was transcribed to cDNA using SuperScript III First-Strand Synthesis Supermix. 
The cDNA was synthesized from 500 – 1000 ng of total RNA. 0.5 μL of TaqMan Gene 
Expression assay was mixed with 1 μL cDNA, 3.5 μL H2O and 5 μL TaqMan Fast Advanced 
Master Mix and transferred into a 384 well plate. A number of different TaqMan Gene 
Expression assays were used to determine expression of target genes (Table 7). The 384-well 
plates were centrifuged for 1 min at 500 g to spin down the reaction mixes. The plates were 
then kept in the dark at 4 °C until measurement in the HT7900 system using the following 
PCR protocol: 95 °C for 20 s, 40 cycles of 95 °C for 1 s followed by 60 °C for 20 s. The 
relative gene expression was calculated with the ∆∆Ct method, using the average threshold 
for PPIA (peptidylprolyl isomerase A) to normalize gene expression between samples. All 
samples were measured in triplicate.  
∆∆Ct method 
1. οܥݐ ൌ ܥݐ௧௔௥௚௘௧௚௘௡௘ െ ܥݐ௛௢௨௦௘௞௘௘௣௜௡௚௚௘௡௘ 
2. οοܥݐ ൌ οܥݐ௧௥௘௔௧௠௘௡௧௦௔௠௣௟௘ െ οܥݐ௖௢௡௧௥௢௟௦௔௠௣௟௘ 
3. οοܥݐ ൌ οܥݐ െ ܥݐ 
4. ݂݋݈݀݁ݔ݌ݎ݁ݏݏ݅݋݊ ൌ ʹିοο஼௧ 
3.2.9.2 Apoptosis PCR array 
Total RNA of cells was extracted using the RNeasy Plus Mini kit as described above (3.2.8). 
The cDNA was synthesized from 1000 ng total RNA using RT² First Strand Kit. It was added 
to 1048 μL H2O and 1150 μL 2x RT² SYBR Green ROX qPCR Mastermix. The cDNA qPCR 
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Mastermix was transferred into a Human Apoptosis PCR Array 384HT plate containing 384 
specific primer pairs each being pre-coated in separate single wells. The plates were then kept 
in the dark at 4 °C until measurement. The following qRT-PCR protocol was run: 95 °C for 
10 min, 40 cycles of 95 °C for 15 s followed by 60 °C for 60 s on the HT7900 system and the 
Ct values were determined using SDS software. Relative expression was calculated with the 
∆∆Ct method (3.2.9.1), using the average threshold for the human housekeeping genes B2M, 
GAPDH, HPRT1 and RPLP0 to normalize gene expression between samples. 
3.2.9.3 Genome-wide expression profiling using microarray 
The genome-wide expression data were generated by the Target Discovery Department at 
Bayer Pharma as described before (Hernando et al., 2016). In brief: total RNA was extracted 
from 200,000 human NSCLC DV90 cells seeded into six-well culture plates on the day before 
treatment. RNA was extracted from 4-5 replicate wells. Cells were treated with DMSO or the 
corresponding IC50 (135 nM) or IC90 (785 nM) dose of JQ1 in DV90 cells. RNA was 
extracted using RNeasy Kit. 250 ng of total RNA were amplified using the Affymetrix 
GeneChip WT PLUS Reagent Kit in accordance to the manufacturer’s manual (“Target 
Preparation for GeneChip Whole Transcript (WT) Expression Arrays”). The Affymetrix 
Human Gene 2.1 ST 96-array plates were hybridized with 3 μg of fragmented and labeled 
single-strand cDNA. Microarrays were processed in accordance to the manufacturer’s manual 
and scanned on an Affymetrix GeneTitan instrument. Data can be accessed at the gene 
expression omnibus (GEO) database (GSE75960). 
3.2.10 Chromatin immunoprecipitation (ChIP) experiments 
3.2.10.1 ChIP-sequencing (seq) 
3.2.10.1.1 Optimization of DNA shearing conditions 
Besides optimal immunoprecipitation conditions it is critical to optimize the DNA shearing 
conditions to produce the right fragment size for downstream applications like next generation 
sequencing techniques. The optimal fragment size of the DNA is around 150-900 base pairs 
(bps) length. The shearing conditions were optimized for the human NSCLC cell lines DV90 
and H1373. To find the optimal conditions, 6 x 107 cells were detached by removing the 
culture medium through washing with cold PBS and addition of 5 ml Trypsin/EDTA to the 
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300 cm² culture flasks. Harvested cells were cross-linked using 1% methanol-free 
formaldehyde containing PBS for 10 min at RT before adding 1.25 M glycine containing PBS 
for 5 min at RT. The cells were lysed using 10 mL cold ChIP lysis buffer 1 on ice for 10 min 
split into separate tubes with an equivalent of 106 cells per tube each and centrifuged for 5 
min at 2,000 g and 4 °C. The nucleus pellet was lysed using sonication buffer with ChIP 
sonication buffer containing either 0.1% or 0.75% SDS. The chromatin samples were 
transferred to 1.5 mL TPX vials. The samples were kept on ice and sonicated in an ice cold 
water bath in the Bioruptor with 1, 2 or 3 rounds of 7 cycles of 30 sec on / 30 sec off at 
highest intensity. Sheared chromatin was cleared by centrifugation for 10 min at 13,000 g and 
4 °C. Crosslinking was reversed by adding 1 μL 5 M NaCl and incubating the samples at 65 
°C overnight. 1 μL RNase was added to each sample and incubated for 1 h at 37 °C followed 
by addition of 1 μL proteinase K and 1 h incubation at 50 °C. Samples were then purified 
using the QIAquick PCR purification kit in accordance to the manufacturer´s manual. Buffer 
PB was added to each sample at 500 μL together with 10 μL of 3 M sodium acetate pH 5.0 to 
lower the pH for optimal DNA silica-membrane column binding conditions. The mixture was 
passed through the column by centrifugation at 13,000 g for 1 min. DNA was washed on the 
column using 750 μL of washing buffer Buffer PE followed by centrifugation at 13,000 g for 
1 min. Residual buffer was removed by additional centrifugation at 13,000 g for 1 min after 
discarding the flow through. DNA was eluted by addition of 50 μL DNase/RNase free H2O 
and centrifugation for 1 min at 13,000 g. DNA was handled on ice and concentration was 
determined using the spectrophotometer NanoDrop 2000 system. Samples were diluted 
between two- to tenfold to adjust the DNA concentration to a range of 5-50 ng/ μL.  
Samples were analyzed on 2100 bioanalyzer using the DNA1200 Assay. Gel-dye mix was 
generated by adding 25 μL DNA dye concentrate to the DNA gel matrix and mixed for 10 s. 
Gel-dye mix was spin-filtered at 1,500 g and 9 μL were transferred to a DNA chip and 
distributed on the chip with equal pressure for 30 sec using a syringe. 5 μL DNA marker were 
loaded on all 12 sample wells. DNA ladder was at a volume of 1 μL on the chip followed by 1 
μL of the sheared purified DNA samples (5-50 ng). The 6 shearing optimization samples were 
measured in duplicates. The analysis showed that for both cell lines DV90 and H1373 2 
rounds of 7 cycles of 30 sec on / 30 sec off at highest intensity together with 0.75% SDS 
containing ChIP sonication buffer yielded the optimal fragment size of DNA (150-900 bps) 
for ChIP-seq experiments. These conditions were therefore chosen to perform chromatin 
preparation at a larger scale. 
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3.2.10.1.2 ChIP-seq and Chem-seq sample preparation 
Human NSCLC cells DV90 and H1373 were seeded into 15 x 300 cm² flasks. Cells were 
grown until they reached about 80-90% confluence and then harvested. Cells were detached 
by removing the culture medium, washing with cold PBS and adding 5 ml Trypsin/EDTA to 
each 300 cm² culture flasks. Harvested cells were cross-linked using 1% methanol-free 
formaldehyde containing PBS for 10 min at RT before adding 1.25 M glycine containing PBS 
for 5 min at RT. The cells were lysed using 10 mL cold ChIP lysis buffer 1 on ice for 10 min 
and centrifuged for 5 min at 2,000 g and 4 °C. The nucleus pellet was lysed using sonication 
buffer with ChIP sonication buffer containing either 0.75% SDS. The chromatin of an 
equivalent of 107 cells in 300 μL buffer was transferred to each 1.5 mL TPX vials. The 
samples were kept on ice and sonicated in an ice-cold water bath in the Bioruptor with 2 
rounds of 7 cycles of 30 sec on / 30 sec off. Sheared chromatin from the same preparation was 
cleared by centrifugation for 10 min at 13,000 g and 4 °C and pooled after that. An equivalent 
of 6 x 107 cells was used as input for each IP. The 1.8 mL sheared chromatin was added to 7.2 
mL ChIP sonication buffer without SDS to reduce the SDS concentration to 0.15% (w/v). 285 
μL Dynabeads were incubated with either 12 μg of targeting antibody (Table 12) or 100 μM 
of biotin tagged BET inhibitor JQ1 (bio-JQ1) in the case of streptavidin Dynabeads on a 
rotator for 2 h at 4 °C prior addition to diluted ChIP samples. Samples were then incubated at 
4 °C overnight on an overhead rotator at 15 rpm. Bound beads from the samples were 
collected using a magnetic rack. Beads were washed three times with 300 μL using ChIP 
shearing buffer containing 0.1% SDS. Samples were next washed with 300 μL of ChIP 
sonication buffer high salt followed by washing with 300 μL ChIP Li washing buffer. Samples 
were washed once more with 300 μL ChIP washing buffer before eluting samples using 100 
μL of ChIP elution buffer-ChIP for antibody bound beads or 50 μL ChIP elution buffer-Chem 
in the case of bio-JQ1 bound beads. After elution 450 μL ChIP elution buffer-chem without 
SDS were added to Chem-seq samples. Input samples were prepared by using 1% input 
sample (18 μL) of sheared material and adding 82 μL ChIP sonication buffer without SDS. 
Crosslinking was reversed by adding 3.2 μL/100 μL sample of 5 M NaCl and incubating the 
samples at 65 °C overnight. 1 μL/100 μL sample of RNase A was added to each sample and 
incubated for 1 h at 37 °C followed by addition of 1 μL/100 μL sample of proteinase K and 1 
h incubation at 50 °C. Samples were then purified using the QIAquick PCR purification kit in 
accordance to the manufacturer’s manual. Buffer PB was added at a volume of 500 μL to each 
sample together with 10 μL of 3 M sodium acetate pH 5.0 to lower the pH for optimal DNA 
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silica-membrane column binding conditions. The mixture was passed through the column by 
centrifugation at 13,000 g for 1 min. DNA was treated using 750 μL of washing buffer Buffer 
PE followed by centrifugation at 13,000 g for 1 min. Residual buffer was removed by 
additional centrifugation at 13,000 g for 1 min after discarding the flow through. DNA was 
eluted by addition of 30 μL DNase/RNase free H2O and centrifugation for 1 min at 13,000 g. 
DNA was kept on ice and its concentration was determined using the spectrophotometer 
NanoDrop 2000 system. Samples were diluted between two- and tenfold to adjust the DNA 
concentration to a range of 5-50 ng/ μL. 
3.2.10.1.3 ChIP-seq and Chem-seq sample library preparation and sequencing 
The downstream processing of samples was performed by the Target Discovery Department at 
Bayer Pharma including quality control, library preparation and genome-wide sequencing. In 
brief, samples were analyzed on a 2100 bioanalyzer using the DNA high sensitivity assay 
described above (3.2.10.1.1). Concentration was determined using High Sensitivity DNA Kit. 
End repair and phosphorylation, ligation of TrueSeq index adaptor and amplification before 
subjection to sequencing (HiSeq Sequencing System) were done in accordance to the 
TrueSeq® ChIP Sample Preparation Guide (illumine). 
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Figure 15: ChIP sequencing sample preparation: Including crosslinking of chromatin in the nucleus (A), 
chromatin immuoprecipitation/binding of biotin compound and enrichment of sheared DNA fragments (B) and 
library preparation steps end repair and phosphorylation (C), A-tailing (D), ligation of TruSeq index adaptors (E) 
and amplification of adaptor-sample DNA sequences (F). Process C-F was performed by the Target Discovery 
Department at Bayer Pharma. Adapted from (http://www.illumina.com). 
3.2.10.2 ChIP quantitative real time-polymerase chain reaction (qRT-PCR) 
Cells were seeded in 300 cm² culture flasks and treated with 500 nM JQ1 or DMSO vehicle 
for 6 h. Cells were washed and fixed with 1% formaldehyde containing PBS for 10 min at RT 
before adding 1.25 M glycine containing PBS for 5 min at RT. Cells were washed twice using 
cold PBS, harvested, snap-frozen and stored at -80 °C. 6x107 cells were lysed using 5 mL cold 
ChIP lysis buffer 1 on ice for 10 min. Samples were centrifuged at 2,000 g for 5 min at 4 °C. 
Chromatin was isolated using 260 μL ChIP sonication buffer containing 0.1% SDS and 
transferred to Adaptive Focused Acoustics (AFA) fibre microtubes. Chromatin was sheared 
using a Covaris S220 device (10% duty cycle, intensity 5, cycle/burst 200) for 12 min at 20 
W. Immunoprecipitation was performed using 3 μg of anti-BRD4 or non-specific IgG rabbit 
antibody. Antibodies were bound to magnetic beads coated with protein A at 4 °C for 2 h 
using a tube rotator at 25 rpm. Bound beads were washed 3 times with 300 μL ChIP 
sonication buffer containing 0.1% SDS, one time with ChIP sonication buffer high salt 
containing 500 mM NaCl, one time with ChIP LiCl washing buffer, one time with ChIP 
washing buffer. Bound complexes were eluted in 100 μL ChIP elution buffer-ChIP at 65 °C 
for 10 min. Crosslinking was reversed overnight at 65 °C in a thermixer followed by protein 
and RNA digestion using 1 μL proteinase K and 1 μL RNase A. DNA purification was 
performed using the QIAquick PCR Purification Kit. The qRT-PCR was performed mixing 1 
μL ChIP sample, 3 μL H2O, 1 μL primers (Table 8) 5 μL 2x Maxima SYBR Green ROX 
qPCR Mastermix on a 384-well plate on the HT7900 system. The qRT-PCR protocol was run 
(95 °C for 10 min, 40 cycles of 95 °C for 15 s followed by 60 °C for 60 s) on the HT7900 
system and the Ct values were determined using RQ manager software. Relative occupancy of 
BRD4 at the promoter target sites was calculated relative to the input control using the percent 
input method. 
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Percent input method 
1. ܥݐ݅݊݌ݑݐሺଵ଴଴Ψሻ ൌ ܴܽݓܥݐ݅݊݌ݑݐሺଶΨሻ െሺଶሺͳͲͲሻ െ ͳሻ 
2. ܫ݊݌ݑݐሺூ௉ሻ ൌ ʹ஼௧௜௡௣௨௧ሺభబబΨሻି஼௧௜௡௣௨௧ሺ಺ುሻ 
3. ܲ݁ݎܿ݁݊ݐ݅݊݌ݑݐሺூ௉ሻ ൌ ͳͲͲݔ݅݊݌ݑݐሺூ௉ሻ 
3.2.11 Plasmid amplification using bacteria culture and maxi preparation 
For bacterial transformation competent XL1.blue cells were thawed on ice. 60 μL of bacteria 
were used for each transformation and were transferred to a 1.5 mL reaction tubes and 1 μL of 
β-mercapto-ethanol was added. Cells were mixed and incubated for 10 min on ice. 100 ng of 
the corresponding plasmid were added to the cells and incubated on ice for 1 h. Bacteria were 
heat-shocked at 42 °C in a thermomixer for 45 sec and after that transferred to ice for 2 min. 
240 μL of 37 °C pre-warmed S.O.C medium were added and bacteria were incubated for 1 h 
at 37 °C and 500 rpm on a thermomixer. Bacterial suspension was then transferred to an agar 
plate containing the antibiotic (100 μg/mL for ampicillin and 50 μg/mL for kanamycin) 
addressed by the resistance cassette transferred by the plasmid used for transformation. Plates 
were incubated at 37 °C overnight. Resistant colonies were picked and incubated in 1 mL 
liquid LB medium containing the appropriate antibiotic for 6 h at 37 °C and 1000 rpm on a 
thermomixer. Medium was transferred to 200 mL liquid LB media containing the appropriate 
antibiotic for overnight incubation at 37 °C and 225 rpm shaking. Amplified plasmids were 
harvested using the EndoFree Plasmid Maxi kit in accordance to the manufacturer’s manual. 
3.2.12 BRD4 washout experiments 
3.2.12.1 Chromatin separation assay 
Cells were seeded at 1-2 x 105 cells/well in a 6-well plate on the day before treatment. On the 
day after, cells were treated with a dose range of JQ1 (0.01 μM – 5 μM) for 24 h. Culture 
medium was removed from cells. Cells were washed in cold PBS, and then lysed using WB 
lysis buffer (Mammalian protein extraction reagent (M-PER) buffer containing Halt Protease 
and Phosphatase inhibitor mixture). Lysates were incubated at RT for 10 min and chromatin 
and chromatin-bound factors were removed by centrifugation at 13,000 x g for 10 min. 
Protein concentrations were determined and equivalent amounts of the cytosolic chromatin-
unbound fraction were subjected to western blot analysis as described (3.2.7). 
Materials and Methods 
 
64 
3.2.12.2 BRD4-GFP overexpression washout experiment 
Glass base dishes were incubated with culture media 1/20 matrigel basement at 37 °C for 1 h 
in the incubator to coat the glass bottom. H1373 cells were seeded in 1 mL culture medium at 
a density of 200,000 per well onto coated 27 mm-glass base dishes. Cells were transfected 
with 2 μg BRD4-GFP plasmid (pcDNA6.2/N-EmGFP-BRD4) (Table 10) using 
Lipofectamine LTX 24 h before washout. Plasmid was diluted in 150 μL Opti-MEM and 2 μL 
Plus Reagent was added. Lipofectamine LTX transfection reagent (10 μL) was diluted in 150 
μL Opti-MEM and added to the diluted plasmid. After gentle mixing the mixtures were 
combined and incubated for 5 min. 250 μL were drop wise transferred to the H1373 cell 
covered with 2 mL FCS containing culture media. 24 h after transfection H1373 cells were 
inspected under the microscope to ensure expression of GFP in the cells. Cells were treated 
with 1 mL of 1 μM JQ1 or DMSO control containing culture medium for 2 h in the incubator. 
Culture medium was removed from the cells which were then washed in 1 mL PBS once. The 
detergent washout buffer 1 and CSK buffer were freshly prepared and kept at 4 °C. Cells were 
washed once with 700 μL cold CSK buffer. CSK buffer was then removed, 700 μL detergent 
washout buffer 1 were added and dishes were incubated for 5 min at 4 °C. Detergent washout 
buffer 1 was removed and cells were covered with 500 μL PBS containing 4% formaldehyde 
for fixation. Cells were fixed for 15 min at RT. After fixation cells were washed twice with 
500 μL PBS and covered with 1 mL PBS containing 1 μg/mL DAPI and incubated for 1 h in 
the dark at 4 °C. The washout of BRD4-GFP was assessed using a laser scanning microscope 
and imaging was processed using Zeiss software. 
3.2.12.3 BRD4 endogenous immunocytochemistry and washout experiment 
The 4-well-chamber slides were incubated with culture media 1/20 matrigel basement at 37 
°C for 1 h in the incubator to coat the glass surface. H1373 and A549 cells were seeded in 0.5 
mL culture medium at a density of 50,000 per well onto coated 4well-chamber slides. One 
day after seeding H1373 cells were treated with 0.5 mL of 1 μM JQ1 or DMSO control 
containing culture medium for 2 h in the incubator. Culture medium was removed from the 
cells which were then washed in 0.5 mL PBS once. The Detergent washout buffer 1 and CSK 
buffer were freshly prepared and kept at 4 °C. Cells were washed once with 350 μL cold CSK 
buffer. CSK buffer was removed and 350 μL Detergent washout buffer 2 were added and 
dishes were incubated for 8 min at 4 °C. Detergent washout buffer 2 was removed and cells 
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were covered with 0.5 mL ice-cold methanol for fixation. Methanol fixation was chosen as 
PFA fixation led to unspecific staining of the anti-BRD4 antibody. Cells were fixed for 8 min 
on ice. After fixation cells were washed twice with 500 μL PBS. Cells were blocked using 
350 μL of Immunofluorescence blot blocking solution for 45 min at RT. Cells were stained 
with 300 μL Immunofluorescence blot blocking solution containing 1/100 diluted anti-BRD4 
antibody and 1/200 diluted anti-tubulin conjugated antibody ( 
Table 13) for 1 h at RT in the dark. Staining solution was removed and cells were washed 4 
times with 500 μL PBS. Cells were then stained with 300 μL Immunofluorescence blot 
blocking solution containing 1/500 diluted anti-rabbit conjugated antibody for 30 min in the 
dark at RT. Chambers were removed from the slide and stained cells were covered with one 
drop ProLong Gold Antifade Reagent containing 1 μg/mL DAPI followed by addition of 
cover glass. Slides were kept in the dark overnight to dry. The washout of endogenous BRD4 
was assessed using a laser scanning microscope at 630x magnitude and imaging was 
processed using Zeiss software. 
3.2.13 Transfection of cell lines with small interfering RNAs (siRNAs) 
For siRNA knockdown 200,000 cells per 6-well were seeded on the day before transfection 
with ON-TARGETplus-SMARTpool siRNAs using Oligofectamine Transfection Reagent, 
according to the manufacturer’s instruction. Then culture medium was removed and cells 
were washed with culture medium without FCS. Washing medium was removed and 800 μL 
of FCS free medium were added to each 6-well. 5 μL of 20 μM siRNA stock solution (100 
pmol) were diluted in 175 μL Opti-MEM. Oligofectamine of 4 μL volume was diluted in 15 
μL Opti-MEM and incubated for 10 min at RT. Oligofectamine mixture and Oligonucleotide 
mixture were combined and incubated for 20 min at RT. Mixture containing complexes were 
transferred dropwise to the cells at a volume of 200 μL. Cells were incubated for 4 h in the 
incubator at 37 °C before 500 μL culture medium containing 3x the normal FCS 
concentration were added. 
3.2.14 Gene knockout using CRISPR-Cas9 and HDR dependent selection 
For CRISPR knockout 100,000 cells per 6-well were seeded on the day before transfection. 
Cells were transfected with 1-3 μg of CRISPR KO plasmid pool and equal amount of 
corresponding HDR plasmid pool (Table 10) using Lipofectamine LTX 24 h before selection 
of stable knockout clones. Plasmids were diluted in 150 μL Opti-MEM and 2-6 μL Plus 
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Reagent was added. Lipofectamine LTX transfection reagent of 5-10 μL volume was diluted 
in 150 μL Opti-MEM and added to the diluted plasmids. After gently stirring the mixtures 
were combined and incubated for 5 min. The transfection mixture containing formed 
complexes of 250 μL volume was transferred drop wise to the cells covered with 2 mL FCS 
containing culture medium. One day after transfection cells culture medium was removed and 
replaced with culture media containing 1-3 μg/mL puromycin. The selection media was 
replaced every second day. Selection was ensured using a microscope.  
Cells were co-transfected as described above using pooled CRISPR-Cas9 knockout (KO) 
plasmids and homology-directed DNA repair (HDR) plasmids, corresponding to the cut sites 
generated in the coding region of the target gene by the CRISPR/Cas9 KO plasmids. HDR of 
the cell leads to integration of the CMV promoter driven puromycin resistance cassette and 
red fluorescent protein (RFP) (Table 10). Stable knockout cells were selected using previously 
optimized doses of puromycin dihydrochloride and cultured for 2 weeks. Stable gene 
knockout was confirmed by western blot. 
3.2.15 MYC overexpression rescue experiments 
For the MYC overexpression rescue 300,000 H1373 cells per 6-well were seeded on the day 
before transfection. Cells were co-transfected as described above using a human c-Myc cDNA 
construct or empty control vector and TagGFP construct (Table 10) using Lipofectamine LTX 
24h before treatment with JQ1. About 5 μg of c-Myc cDNA construct or empty vector 
plasmid and 1 μg of TagGFP construct were diluted in 150 μL Opti-MEM and 6 μL Plus 
Reagent were added. Lipofectamine LTX transfection reagent of 10 μL volume was diluted in 
150 μL Opti-MEM and added to the diluted plasmids. After gentle stirring the mixtures were 
combined and incubated for 5 min. The transfection mixture containing formed complexes of 
250 μL were transferred drop wise to the cells covered with 2 mL FCS containing culture 
medium. One day after transfection cell culture medium was removed and replaced with 
culture media containing 500 nM JQ1 or DMSO control. After 24 h cells were stained using 
EdU-staining kit and DAPI, and then analyzed as described above (3.2.5). 
3.2.16 In vivo mouse studies 
All experiments were performed in accordance to the German Animal Welfare Law. Animals 
were housed following institutional guidelines of Bayer Pharma AG. 
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Six to eight weeks old female SCID mice from Charles River were acclimated for at least 
seven days before tumor cell injection. 
3.2.16.1 Subcutaneous xenograft mouse model H1373  
H1373 tumor cells growing exponentially in cell culture were detached using trypsin/EDTA, 
resuspended in culture media and cell number and viability was determined. The right number 
of viable cells was calculated and cells were washed in PBS and re-suspended in cold 
matrigel/culture media without FCS mixture (1:1). H1373 tumor cells were inoculated 
subcutaneous (s.c.) into the right flank of the mice (3 x 106 cells/mouse in 0.1 mL).  
For intra peritoneal (i.p.) injection, JQ1 was dissolved in 30% 2-hydroxypropyl-beta-
cyclodextrin (HP-β-CD) in water, pH6 and applied daily with a volume of 10 mL/kg.  
3.2.16.2 Subcutaneous xenograft mouse model A549  
A549 tumor cells were prepared as described above and inoculated s.c. in female SCID mice 
at 3 x 106 cells/mouse in 0.1 mL matrigel. Tumor growth was assessed twice a week using a 
caliper and tumor volume was calculated as described below (3.2.19.1). Tumor bearing mice 
were randomized before start of treatment. Mouse body weight was determined at least twice 
a week. For i.p. injection, JQ1 was dissolved in 20 or 30% 2-hydroxypropyl-beta-cyclodextrin 
(HP-β-CD) in water, pH5-6 and applied daily with a volume of 10 mL/kg. Cisplatin was 
diluted in NaCl 0.9% pH4-5 and applied 5 times daily intra venouse (i.v.) with a volume of 10 
ml/kg or i.p.. 
3.2.16.3 Evaluation of antitumor efficacy  
Tumor growth was assessed using a caliper and tumor volume was calculated using the 
empiric formula for calculation of tumor volume. 
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Tumor-bearing mice were randomized before start of treatment. Mouse body weight was 
determined at least twice a week. Treated over control ratio (T/C) was calculated as mean 
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tumor weight of the treated group divided by mean tumor weight of the vehicle control group 
at the end of the study (%T/C ≤42% was declared active in agreement with NCI criteria). 
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Tumor volumes were log10 transformed for statistical analysis. For in vivo experiments One-
way analysis of variance (ANOVA) with Sidak’s correction for multiple comparisons or two-
tailed t-test from GraphPad Prism 6.0 was used. Adjusted p values are indicated using * for p 
< 0.05, ** for p < 0.01, *** for p < 0.001.  
 
3.2.17 Bioinformatics 
3.2.17.1 Gene expression profiling of DV90 NSCLC and gene set enrichment analysis 
Cells were treated with DMSO or JQ1 before RNA was extracted and profiled with 
Affymetrix HuGene-2.1ST arrays as described above (3.2.9.3). Data are available at the GEO 
database (GSE75960). Probe set intensities were condensed to meta-probe set levels in 
Genedata Expressionist 9.0 using Robust Multi-array (RMA) algorithm followed by 
LOWESS normalization. A 2 group t-test was used to compare each treatment condition: 4 h 
IC50 (135 nM) or IC90 (785 nM) and 24 h treatment period with JQ1 with the 4 h or 24 h 
DMSO control group. The resulting p-values were corrected for multiple testing using 
Benjamini-Hochberg correction (BH-q). Genes with a BH-q value < 0.05 were considered to 
be significantly altered by the treatment. Additionally a cut-off level of a log2 (fold change) of 
± 0.5 was used to define a list of significantly differentially expressed genes. 
3.2.17.2 Gene set enrichment analysis of JQ1-treated DV90 NSCLC expression profile 
For the standardization the median value for each gene across replicates (n = 4-5) from DV90 
micro-array expression profiling was taken. Gene set enrichment analysis (GSEA) 
(http://www.broadinstitute.org/gsea) was used to determine enrichment of genes down-
regulated by JQ1 treatment in DV90 cells. To test which gene sets were associated with a 
given phenotype (here 24h of IC50 JQ1 treatment), all current gene sets from the Molecular 
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Signatures Database were used (Msigdb.v5.0). Gene sets enrichment calculates whether a 
given gene set is enriched at the top or the bottom of a given ranked gene list. The ranked list 
here consists of all genes identified by expression profiling with the Affymetrix HuGene-
2.1ST array and Affymetrix HuGene-2.1st annotation. Duplicate gene identifiers were 
removed leaving the probe set identifiers with the highest expression. The list was ranked by 
the difference between expression of DMSO control and JQ1 treated cells. The resulting 
enrichment score (ES) quantifies the degree of overrepresentation of given gene from a gene 
set at the top or bottom of the list. A p-value is estimated on the base of the empirical 
permutation test based on the phenotype. The ES is further normalized to the variation 
depending on the set size resulting in a normalized enrichment score (NES). The 
corresponding false discovery rate (FDR) is calculated based on a permutation test, testing a 
null hypothesis on the distribution of all gene sets used for the given NES. The resulting plots 
indicate a NES for each gene in an enriched list on the left for the DMSO phenotype or the 
right for the JQ1 treatment phenotype. Most gene sets locate either on the left or on the right 
are significantly enriched when the normalized p-value was p < 0.05 and FDR < 0.1. 
3.2.17.3 Patient expression profile analysis using gene set enrichment analysis 
Publicly available mRNA expression profiles of lung adenocarcinoma patients - accessible 
from GEO database (GSE32863) (Selamat et al., 2012) were used. The datasets were accessed 
by loading the data into Genedata Expressionist and robust spline normalized prior to log2 
transformation. Datasets from patients with defined KRAS mutation status were exported and 
analyzed using GSEA as described above (3.2.17.2). The analyzed gene sets were all 
Hallmark gene sets (h.all.v5.0). The rank gene list was defined by the difference of expression 
levels between the average of KRAS mutant (n= 21) and the average of KRAS wild-type 
patient (n= 36) expression profiles. Core enrichment profile for the “Hallmark Myc gene 
signature” was generated using the GSEA tool. 
3.2.17.4 Processing of FASTQ ChIP sequencing files 
Sequencing data were provided by the Target Discovery Department at Bayer Pharma. The 
provided FASTQ file containing the raw sequencing reads were aligned using Genedata 
Refiner Genome integrated script Bowtie (version 2). Bowtie is a high performance alignment 
tool designed to perform multiple alignments of next generation sequencing data to a 
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reference genome. The FASTQ files were aligned to the human genome hg19, sorted and 
indexed using SAMtools. Model-bases Analysis for ChIP-seq (MACS2) software was used on 
the aligned paired-end reads of ChIP and input samples as a reference to call peaks from 
enriched regions. Broad peaks from histone marks were called using MACS2 broad mode. 
The cutoff used for broad and regular peaks was q < 0.1. MACS2 was used to generate 
bedGraph files containing fragment pileup per million reads. Log likelihood ratio (logLR) of 
treatment vs. input control samples tracks were generated using MACS2 bdgcmp command. 
LogLR subtracts the background noise from the treatment samples signal based on a dynamic 
Poisson model. Pseudocount of 0.00001 was added to avoid log10(0) during logLR 
calculation. Files were sorted using bedSort (bedTools v2.26.0) 
In order to transform bedGraph files to bigwig bedGraphToBigWig script was used. It uses a 
combination of slopBed (bedTools) and bedClip (bedTools) together with the chromosome 
size from the hg19 genome (http://hgdownload.cse.ucsc.edu/goldenPath/hg19/) to remove the 
section expanding beyond chromosome range, followed by conversion to BigWig using 
bdg2bw script. ChIP-seq tracks were generated using IGV software. Heatmaps and line plots 
were generated using seqplots software. 
3.2.17.5 Super-enhancer annotation and ranking 
Rank ordering of super-enhancers (ROSE) script (Loven et al., 2013; Whyte et al., 2013) was 
used to generate stitched enhancers and to separate super-enhancers from typical enhancers. 
Therefore ROSE stitches putative enhancers of close proximity, no farther than 12.5 kb, from 
one another. Putative enhancers were H3K27Ac+ peaks identified from ChIP-seq datasets as 
described above. The 2.5 kb region around the TSS of genes was excluded. The bamToGFF 
script is used to calculate the read density of the ranking BAM file (MED1) and the control 
BAM file (whole cell lysate input control) in units of reads-per-million-mapped per bp 
(rpm/bp). Finally the stitched enhancers were sorted by signal (ranking BAM density – 
control BAM density) into two groups, namely super-enhancers and typical enhancers. Super-
enhancers were annotated to their closest coding gene using PeakAnalyzer v1.4. 
PeakAnalyzer annotation was done using the Homo_sapiens.GRCH37.64gtf as a reference. 
Even though this method is not very accurate in assigning typical enhancers to their genes 
(Mora et al., 2015) it has been shown to be quite accurate in case of super-enhancer 
assignment (Whyte et al., 2013). 
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3.2.18 Statistical analyses 
For statistical analyses of experiments, One-way analysis of variance (ANOVA) with Sidak’s 
correction for multiple comparisons or two-tailed t-test from GraphPad Prism 6.0 or 
GeneData Expressionist was used. Adjusted p values are indicated using * for p < 0.05, ** for 
p < 0.01, *** for p < 0.001.  
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4. Results 
4.1 BET inhibitors show differential anti-tumor activity in a panel of NSCLC cell 
lines 
BET inhibitors are active in a wide range of tumor types (Table 2). Nevertheless their anti-
tumor activity can be quite diverse, even within a defined cancer indication. Recent studies 
have proposed the transcriptional deregulation of oncogenes like GLI (Tang et al., 2014), 
FOSL1 (Lockwood et al., 2012), MYCN or MYC (Delmore et al., 2011; Zuber et al., 2011) by 
BET inhibitors to be a critical factor for the anti-tumor activity in a number of indications 
including lung cancer (Lockwood et al., 2012; Shimamura et al., 2013). A number of mouse 
models recapitulating the development and growth of malignant tumors are available to study 
cancer biology. Among these, the KRAS-driven mouse model has become the golden standard 
to study NSCLC. This genetically engineered mouse model (GEMM) harbors a lox-STOP-lox 
KRASG12D cassette in the second exon of the endogenous KRAS gene. Time- and tissue-
specific expression of the CRE-recombinase introduced by adenovirus transduction leads to 
mutation of the KRAS gene in lung epithelial cells and formation of tumors. Recently the 
inhibition of c-Myc transcription factor by its engineered dominant-negative form Omomyc, 
provided evidence that c-Myc function was essential for continuous growth and survival of 
KRAS-driven tumors in the GEMM (Soucek et al., 2013). 
4.1.1 Human KRAS mutant adenocarcinomas are enriched for the hallmark c-Myc 
target gene signature 
The expression profiles of adenocarcinomas from patients with defined KRAS status 
(publically available at GEO database (GSE32863)) were compared to evaluate the 
enrichment of hallmark gene sets (3.2.17.2). Gene set enrichment revealed that the KRAS-
mutated NSCLC patient population (n=21) had a significant enrichment of c-Myc hallmark 
target genes compared to patients with wild-type KRAS (n=36) with a normalized enrichment 
score (NES) of 1.72 (Figure 16A). KRAS signature, which served as a control, was also 
enriched in the KRAS mutant population (Figure 16B). In addition the KRAS mutant patient 
population had significantly increased MYC expression levels, which would explain the 
enrichment of its target genes (Figure 16C). 
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Figure 16: Gene set enrichment analysis comparing expression profiles of KRAS mutant and wild-type 
adenocarcinomas from GEO database (GSE32863). A, B: Enrichment plots indicating the enrichment score of 
HALLMARK_MYC_TARGETS_V1 and HALLMARK_KRAS_SIGNALING_UP gene sets comparing KRAS 
mutant (n=21) and KRAS wild-type (n=36), Normalized enrichment score (NES) and the corresponding false 
discovery rate (FDR). C: Heatmap of core enriched genes from the HALLMARK_MYC_TARGETS_V1 gene 
set comparing KRAS mutant and KRAS wild-type samples. The color code indicates the relative expression levels 
of the genes listed on the right and ranked by position in the overall rank list (red = high expression to blue = low 
expression). KRAS mutant samples names are highlighted in grey and KRAS wild-type in yellow. D: Plot 
showing the expression of MYC after Robust Spline normalization (RSN) and log2 transformation. Dots indicate 
the expression of the individual patient samples within the KRAS wild-type (wt) and KRAS mutant (mut) 
populations. ** p > 0.01 unpaired parametric two-tailed t-test. 
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Following this observation, the first aim of this work was to evaluate and characterize the 
effect of BET inhibitors on a number of defined KRAS mutant NSCLC cell lines in vitro, as 
BET inhibitors potently reduce the growth of MYC-dependent malignancies like MM and 
acute myeloid leukemia (AML) (Delmore et al., 2011; Zuber et al., 2011). 
4.1.2 Determination of cellular half-inhibitory concentrations of BET inhibitors in a 
panel of NSCLC cell lines 
To investigate the effects of the pan-BET inhibitors JQ1 and I-BET762 on cell growth and 
cell viability, a panel of 12 KRAS-mutated NSCLC cell lines were seeded at optimal cell 
density (3.2.2) and treated for 72 h with different doses of BET inhibitors (10-8.5 M to 10-5 M). 
The cellular half-inhibitory concentration (IC50) served as an indicator to identify distinct 
subgroups of cell lines that were either particularly sensitive or resistant to BET inhibition 
(Figure 17A). The BET inhibitors JQ1 and I-BET762 showed a similar activity pattern in the 
12 cell lines tested, providing evidence that the effect seen was target dependent. However, in 
vitro JQ1 showed an overall higher activity compared to I-BET762. The growth of the cell 
lines DV90, H1373 and LCLC97TM1 was particularly sensitive towards BET inhibition with 
IC50 values of 106 nM, 154 nM and 405 nM for JQ1 and 139 nM, 350 nM and 752 nM for I-
BET762 respectively. The NSCLC cell lines showed overall a low mutation frequency of 
additional oncogenic drivers known in this tumor type, with the exception of a HER2 
mutation in DV90 cells, a MEK1 and PIK3CA mutation of H460 cells and a NRAS mutation 
in H2347 (Figure 17B). Interestingly the mutation status of the p53 tumor suppressor gene 
was independent from the sensitivity towards BET inhibition, while another tumor suppressor 
Liver kinase B1 (LKB1) was frequently mutated in the less sensitive cell lines H23, A549, 
H460 and H2030. This was in accordance with a recent study demonstrating that KRAS/LKB1 
double mutant cells were less sensitive to BET inhibition (Shimamura et al., 2013). Co-
occurring genetic alterations of KRAS and the LKB1 tumor suppressor gene leads to a more 
aggressive type of lung cancer and define a major subgroup of KRAS-mutated NSCLC (18-
32%) (Ji et al., 2007; Skoulidis et al., 2015). 
Results 
 
75 
 
Figure 17: Determination of the cellular half inhibitory concentration (IC50) of BET inhibitors in 12 KRAS-
mutated NSCLC cell lines. A: Log10IC50 from cell viability assays using KRAS mutant NSCLC cell lines after 72 
h treatment with JQ1 or I-BET762. The data are represented as the mean IC50 of 2 or 3 independent experiments. 
B: Mutation status from the Cancer Cell Line Encyclopedia (CCLE) and Catalogue of Somatic Mutations in 
Cancer (COSMIC) databases of the tested NSCLC cell lines sorted by JQ1 sensitivity. 
It was then evaluated whether the cell lines which were most sensitive to BET inhibition were 
also the fastest growing ones. No big differences in terms of growth rate was observed when 
comparing the cell doubling time in vitro at three different cell densities and still growing 
exponentially after 4 days, except for two cell lines growing significantly faster (A549 Dt= 
25.3h; H460 Dt= 18.3h) and 2 others growing significantly slower (H2347 Dt= 40.3h; H358 
Dt= 37.7h) (Figure 18A). The sensitivity to BET inhibition was not dependent on the 
respective basal growth rate of the cell lines. 
Gene expression patterns of cancer cell lines can differ significantly, dependent on their 
genetic and epigenetic status. Gene expression of the BET family (BRD2, BRD3 and BRD4) 
was therefore compared between the 12 cell lines, normalized to the expression of the stem 
cell derived normal human lung fibroblast cell line WI38 and to the expression of early 
passage primary fibroblast cells IMR-90. BRD2, BRD3 and BRD4 are ubiquitously found in 
human cells (Loven et al., 2013) and there were only slight differences in their expression 
levels (Figure 18B), in line with their essential cellular functions including transcriptional 
regulation, DNA replication, cell cycle progression and maintenance of higher-order 
chromatin structure (Jung et al., 2015; Wang et al., 2012). 
Results 
 
76 
 
Figure 18: Correlation of JQ1 sensitivity and cell doubling time or basal expression of BRD2, 3 or 4. A: Plot 
showing the cell doubling time of the 12 NSCLC cell lines test. JQ1 sensitive cells ( < 1 μM) and insensitive 
cells (> 1 μM) against the log10IC50 of JQ1 from the 72h cell viability assay are highlighted. The average 
doubling time of all 12 NSCLC cell lines is indicated in red. Data represent mean ± SEM. B: Relative expression 
of the 12 NSCLC cell lines. Basal expression of BRD2, BRD3 and BRD4 was calculated using ∆∆Ct method 
normalized on the endogenous housekeeping gene cyclophilin A (PPIA) and normal lung fibroblast expression. 
Error bars denote SEM (n=3). 
 
4.1.3 Analysis of functional BRD4 inhibition and resulting cellular phenotypes 
4.1.3.1 Cell cycle distribution analysis and determination of apoptosis after BET 
inhibition 
To further characterize the effect of BET inhibitors on the cellular phenotype a cell cycle 
distribution assay was performed using a flow cytometry EdU staining assay. EdU is a 
nucleotide analog that gets incorporated into the genomic DNA during the synthesis (S) phase 
of the cell. EdU can be specifically stained and used, together with the DNA content stained 
by DAPI, to determine the cell cycle phases of the cell.  
In both sensitive and resistant cell lines the cell cycle distribution was determined after 24 h 
of treatment with the BET inhibitors JQ1, OTX-015 or I-BET762. H1373 and DV90 cells 
showed a dose-dependent shift from S phase towards G0/G1-population upon treatment 
(Figure 19A, B), with a stronger effect in H1373 compared to DV90 cells. 
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Figure 19: Cell cycle distribution analysis of two sensitive cell lines H1373, DV90 and two insensitive cell lines 
A549 and H460 after BET inhibitor treatment. A: Representative cell cycle distribution of viable H1373 or A549 
cells 24 h after 1 μM JQ1 treatment. The S-phase cell population is shown in green, G0/G1 in blue and G2 in 
purple. B: Cell cycle analysis of sensitive DV90 and H1373 and resistant A549 and H460 cells following 24 h of 
JQ1, OTX-015 or I-BET762 treatment. Data are shown as the mean (n=2) for JQ1. 
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Additionally, induction of programmed cell death was determined in H1373, DV90, H460 
and A549 cells. Dose-dependent induction of apoptosis after 48 h of JQ1 or OTX-015 
treatment was observed in sensitive DV90 and H1373 cells but not in resistant A549 and 
H460 cells, irrespective of the p53 status of the cells (Figure 20). Interestingly, in sensitive 
cell lines, the induction of apoptosis was stronger in DV90 compared to H1373 cells, 
suggesting that the predominant response in DV90 cells is induction of apoptosis, while in 
H1373 it is primarily cytostatic. It is noteworthy that both DV90 and H1373 cells were quite 
sensitive towards detachment from the culture surface and re-suspension, a procedure needed 
for flow cytometer analysis, which explains the higher apoptotic rates of DMSO control 
samples. 
 
 
Figure 20: Analysis of apoptosis in two sensitive cell lines H1373, DV90 and two insensitive cell lines A549 
and H460 after BET inhibition. Flow cytometry results showing percentage of viable and apoptotic cells of 
H1373 and H460 cells after JQ1 or OTX-015 treatment for 48 h followed by AV-FITC and PI staining. AV- 
positive only population (red: early apoptotic), AV/PI- double positive population (green: late apoptotic), AV/PI 
negative population (black: viable) and PI positive only (yellow: necrotic). 
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4.1.3.2 Functional analysis of BET inhibition in the cellular context 
BET inhibitors are competitive binders of the bromodomain pockets and interfere with BET – 
chromatin interactions. In order to investigate the cellular function of BET inhibitors in 
removing BRD4 from chromatin of the cell, H1373 cells were treated with 1 μM of JQ1 24h 
post transfection with a pcDNA6.2 plasmid overexpressing N-EmGFP-BRD4. Expression of 
BRD4-GFP was visually confirmed using microscopy. The unbound BRD4 was washed out 
of the nucleus using a detergent buffer containing Triton X-100 and PIPES (3.2.12.2). Cells 
were then fixed using paraformaldehyde and counterstained with DAPI in PBS before 
visualization using microscopy. BRD4-GFP was localized only in the nucleus, as seen by the 
overlap of DAPI and BRD4-GFP. In the DMSO-treated control, nuclei still containing BRD4-
GFP were observed, while no BRD4-GFP could be detected in the nuclei of JQ1-treated cells 
after the washout was performed (Figure 21). 
 
 
Figure 21: Chromatin-unbound washout experiment of BRD4-GFP overexpression plasmid transfected H1373 
cells. H1373 cells were transfected with N- terminal tagged BRD4 full-length overexpression plasmid 24 h prior 
treatment with 1 μM JQ1 and chromatin-unbound washout using Detergent washout buffer 1 before fixation 
using para-formaldehyde and DAPI counter staining (3.2.12.2). Fluorescence was visualized using microscopy 
and 500-fold magnification. White bar indicates 20 μm. 
While most small molecules can penetrate into the cells by passing the cellular membrane 
without active transport, cancer cells have been described to export small molecules actively 
by transporters like P-glycoprotein or Multidrug-Resistance-Protein-1 (MDR-1) and thereby 
acquiring resistance to chemotherapy. To investigate whether the differential response of the 
different cell lines was linked to a reduced intracellular function of JQ1, endogenous BRD4 
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was washed out after treatment of sensitive H1373 cells and insensitive A549 cells. Similar to 
the BRD4-GFP fusion, the endogenous BRD4 was strongly removed by the washout 
detergent when cells were treated with 1 μM JQ1 2 h before the washout (3.2.12.2). To be 
noted that harsher washout conditions were needed (3.2.12.3). Potentially due to the stronger 
interaction of the  native form compared to the BRD4-GFP fusion protein , even though it was 
taken care of adding GFP at the N terminal site in order to maintain the interactions of the 
extra-terminal domain and the C terminal motif (Figure 6). JQ1 was able to reduce BRD4 
chromatin interaction in sensitive H1373 cells and insensitive A549 cells (Figure 22). 
 
 
Figure 22: Washout experiments of chromatin-unbound endogenous BRD4 after JQ1 treatment of sensitive 
H1373 cells and insensitive A549 cells. H1373 cells were treated with 1 μM JQ1 for 2 h and chromatin-unbound 
washout using Detergent washout buffer 2 before fixation using Methanol and stained with primary BRD4 
antibody, alexa 488-conjugated tubulin antibody and DAPI (3.2.12.3). Fluorescence was visualized using 
microscopy and 630-fold magnification. White bar indicates 20 μm.  
To confirm this finding, a chromatin separation assay was used to separate the chromatin-
bound fraction from the chromatin-unbound and cytosolic fractions. Sensitive DV90 and 
H1373 cells and insensitive H2030 cells were treated with varying doses of JQ1 (0.01 μM – 5 
μM) for 24 h followed by complete lysis of the cells using M-PER buffer containing protease 
inhibitor and centrifugation (3.2.12.1). Chromatin free lysates were analyzed using western 
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blot staining for BRD4 and GAPDH loading control. In all 3 cell lines JQ1 treatment led an 
increase of chromatin-unbound BRD4 in a dose-dependent manner. In DV90 cells a low level 
of BRD4 was chromatin-unbound even in the DMSO control, but increasing doses of JQ1 led 
to an even higher unbound fraction (Figure 23). The effective removal of BRD4 from the 
chromatin by JQ1 was seen in all 3 cell lines and was independent of the anti-proliferative 
activity of the compound. 
 
 
Figure 23: Western blot analysis of chromatin-unbound BRD4 after JQ1 treatment of sensitive DV90, H1373 
cells and insensitive H2030 cells. For the separation of chromatin-bound and chromatin-unbound/cytoplasmic 
fraction DV90, H1373 and H2030 cells were treated with varying doses of JQ1 24 h before lysis using M-PER-
Buffer containing protease inhibitor. Equal amounts of lysate were analyzed using western blot.  
It is therefore assumed that the differential cellular response to BET inhibition might depend 
on gene regulatory changes defined by the epigenetic state of the cells. To follow up on this 
the effect of BET inhibition on gene expression was examined in a genome-wide transcription 
study of the sensitive DV90 cells. 
4.1.4 Analysis of whole transcript profiling of JQ1 treated sensitive DV90 cells 
To fully analyze the transcriptional changes induced by BET inhibition, the whole transcript 
of DV90 was profiled after treatment with IC50, IC90 dose of JQ1 or DMSO control for 4 h 
and 24 h in 4-5 replicates using micro-array technology (data provided by the Target 
Discovery Department at Bayer Pharma) (3.2.9.3). This enabled the characterization of early 
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transcriptional responses and secondary downstream transcriptional responses due to the cell 
response phenotype e.g. apoptosis or cell cycle arrest. The expression profiles after JQ1 
treatment (IC50 (135 nM) and IC90 (785 nM)) were compared with the corresponding each 
DMSO control treatment samples and a 2 group test (t-test) was used to compare the 
expression of the control and treated samples. The genes with a BH-q value (corrected p-
value) of q < 0.05 were considered to be statistically significantly regulated. After 4 h the 
expression of only 36 genes was significantly altered with a fold change cut off value of ±0.5 
log2 (FC), while after 24 h the expression of 324 genes was significantly altered. Treatment 
with IC90 (785 nM) dose of JQ1 had a stronger impact on the expression of genes with 301 
genes altered at 4 h, while 2,117 genes were significantly altered after 24 h (Figure 24).  
This suggests that there is either a small number of fast responding genes that leads to 
downstream transcriptional regulation or a number of genes with fast turn-over transcripts and 
a number of slower turn-over transcripts that are directly regulated by BET bromodomain 
proteins. Additionally it is possible that the expression of some primary BET target genes can 
be re-initiated by the cell upon BET inhibitor treatment through alternative transcriptional 
regulatory mechanisms as described recently (Rathert et al., 2015). 
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Figure 24: Venn Diagram showing the number of genes with expression changes after treatment of DV90 cells 
with different doses of JQ1 for 4 h or 24 h: Toggle represents the genes modulated by treatment at IC50 (135 
nM) for 4 h (blue) and 24 h (green), and by treatment at IC90 for 4h (yellow) and 24h (red), Overlapping areas 
indicate common genes within the groups. BH-Q value (corrected p-value) cut off of 0.05 was considered as 
statistically significant. Numbers in brackets indicate the total number of genes with significantly changed 
expression level after JQ1 treatment. Diagram was generated using Venny 2.1 software 
(http://bioinfogp.cnb.csic.es/tools/venny/). 
The significantly differentially expressed genes after 4 h treatment with IC50 or IC90 dose of 
JQ1 were categorized using the functional annotation tool Database for Annotation, 
Visualization and Integrated Discovery (DAVID). Gene ontology term annotation 
(GOTERM_BP_ALL) clustering revealed that the regulated genes were involved in 
regulation of cellular biosynthetic process, transcriptional and apoptosis (Top three clustered 
GO terms shown in Table 16 and Table 17). 
Among the 10 genes commonly regulated by JQ1 (Figure 24) 4 genes were coding for 
transcription factors: GTF2B, JUNB, ZNF280C and MYC. GFT2B codes for a general 
transcription factor TFIIB, ZNF280C for a (C2H2) zinc finger containing protein with yet 
undescribed function, JUNB for the proto-oncogene transcription factor JunB (Eckhoff et al., 
2013) and MYC for the proto-oncogene transcription factor c-Myc that can largely influence 
Results 
 
84 
the malignant state and fate of a cell (Ott, 2014). Among these 4 genes, only MYC expression 
was reduced. 
To further look into the transcriptional networks regulated by BET inhibition, gene set 
enrichment was used to identify significantly altered expression of target gene sets after BET 
inhibition. The expression profile of the DV90 cells treated for 24 h at IC50 was ranked by the 
difference between the untreated control replicates and the JQ1 treatment replicates. All 
current gene sets in the molecular signature database (MsigDB) were used for the GSE 
analysis. Strikingly 4 among the top 8 ranked gene sets were MYC target gene sets (Figure 
25A). This shows that the genes down-regulated by JQ1 were enriched for MYC target genes, 
implicating an important role of down-regulation of MYC expression and its target genes in 
the response to BET inhibition. Looking at the list of significantly differentially expressed 
genes additional interesting genes were identified including FLIP, BCL2 and MCL1, which 
are involved in the negative regulation of apoptosis, HEXIM which forms the cellular 
inhibitory complex of transcriptional elongation P-TEFb and BRD2, a member of the BET 
family. Importantly the expression of BRD3 and BRD4 remained unchanged (Figure 25B). 
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Figure 25: Gene set enrichment analysis of DV90 expression profiles after 24 h treatment with JQ1 (IC50) and 
heatmap of the depicted differentially expressed genes: A: Table showing the top significantly enriched gene sets 
ranked by normalized enrichment scores (NES). False discovery rate (FDR) and number of genes in the gene set 
(N) are shown. Below, 2 depicted gene set enrichment plots showing significantly enriched c-Myc target gene 
sets: MYC_UP.V1_UP and SCHUHMACHER_MYC_TARGETS_UP. Genes of the gene sets are indicated by 
the black bars and show an enrichment of genes with the DMSO phenotype. B: Heatmap of the log2 fold change 
(FC) of all differentially expressed genes which shows the ranking of MYC, FLIP, BCL2, MCL1, HEXIM and 
BRD2 gene after 24 h of treatment with JQ1 (IC50). 
4.1.5 Analysis of BET bromodomain gene regulatory function in NSCLC cell lines 
4.1.5.1 Characterization of enhancers in DV90 cells 
To characterize the putative enhancers in DV90 cells, ChIP-seq experiments using antibodies 
directed against BRD4 and Mediator (MED1) and histone marks H3K27Ac and H3K4me1 
were performed. (Sequencing data were provided by the Target Discovery Department at 
Bayer Pharma) Peak-calling from Model-based analysis software MACS2 was used to 
identify statistically enriched regions in the H3K27Ac ChIP-seq dataset. These regions were 
used to discriminate between typical enhancers and super-enhancers. Super-enhancers are 
large enhancer sites recently identified to regulate and drive expression of genes defining the 
identity of a cell (Whyte et al., 2013). Heatmaps and line plots of H3K27Ac, H3K4me1 and 
BRD4 coverage at regions around ± 5 kb of typical and super-enhancer sites were generated 
(Figure 26A). Enhancer regions had characteristic H3K4me1 and H3K27Ac peaks. In 
addition, BRD4 was found to bind to the H3K27Ac+/H3K4me1+ enhancer regions with a 
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similar profile, in accordance with earlier studies in models of small-cell lung cancer (SCLC) 
and MM (Loven et al., 2013). The Chem-seq method (Anders et al., 2014) was used to map 
the interaction sites of the BET inhibitor JQ1 on the genome and showed strong correlation 
with the BRD4 binding profile. 
In contrast, BRD4 occupancy was less pronounced at regions around TSS of gene-coding 
regions, when compared to H3K27Ac and H3K4me1 marks (Figure 26 B). 
 
Figure 26: ChIP-seq heatmaps and profiles of H3K27Ac, H3K4me1, BRD4 and JQ1-biotin binding at enhancers 
and TSS regions. A: Occupancy around ±5 kb of the midpoint of the enhancer regions. Regions were sorted 
descending by peak weights and characterized super-enhancer and typical enhancers are marked. B: Occupancy 
around ±5 kb of the midpoint of the TSS regions. 
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4.1.5.2 BRD4 is bound at MYC super-enhancers 
The identification of super-enhancers was performed using genome-wide listing of potential 
enhancer sites marked by H3K27Ac marks followed by analysis of enhancer-binding factors 
like mediator 1 (MED1) occupancy clustering (Figure 27A). Small nearby clusters not further 
away than 12.5kb of enhancer binding factors were summarized into large clusters to form a 
super-enhancer site. The super-enhancers were identified and ranked using the background 
corrected MED1 signal as reads per million per base pair (rpm/bp) calculated by the ROSE 
software. This led to the identification of 873 super-enhancers and 20,960 typical enhancers. 
The nearest coding gene to each super-enhancers was annotated using PeakAnalyzer software. 
Even though this method is not very accurate in assigning typical enhancers to their genes 
(Mora et al., 2015) it has been shown to be more accurate in the case of super-enhancer 
assignment (Whyte et al., 2013). In total 4 super-enhancer regions have been annotated to the 
MYC gene, namely MYC-E1, MYC-E2, MYC-E3 and MYC-E4 (Figure 27A). The 
H3K27Ac+/H3K4me1+ MYC super-enhancers were occupied by the mediator complex 
together with BRD4 (Figure 27 B). Chem-seq was used to map the interaction sites of the 
BET inhibitor JQ1 on the genome and the strong binding at MYC super-enhancer regions was 
found to correlate with BRD4 binding (Figure 27B). This leads to the assumption that the 
MYC expression is regulated and dependent on BRD4 occupancy at MYC super-enhancers. 
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Figure 27: Super-enhancer identification using clustered MED1 signal on putative enhancer regions and ChIP-
seq tracks at MYC super-enhancers. A: Dot plot showing ranked enhancers normalized by MED1 signal (MED1 
signal – input signal in rpm/bp). B: Chem-seq/ChIP-seq tracks of JQ1-biotin (JQ1-bio), BRD4, RNA polymerase 
2 (Pol2), mediator complex 1 (MED1) and histone marks H3K27Ac, H3K4me1 and H3K4me3. Enrichment of 
signal is presented as log likelihood ratio (log LR) over background signal. Tracks are shown as an overlay of 
two independent ChIP experiments. 
4.1.5.3 JQ1 treatment leads to down-regulation of proto-oncogenes 
Given the contradictory results of two studies in lung cancer proposing the effects of BET 
inhibition to be driven by regulation of FOSL1 (Lockwood et al., 2012) or MYC expression 
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(Shimamura et al., 2013) we looked more closely at both transcription factors. The expression 
of MYC and FOSL1 was determined 24 h after treatment with 0.1 μM or 1 μM JQ1 in all 12 
NSCLC cell lines using qRT-PCR. The relative mRNA levels were normalized to the DMSO-
treated control (0.1%). Interestingly the relative mRNA levels of MYC were reduced in a 
dose-dependent manner but only in 5 out of 12 cell lines: DV90, H1373, LCLC97TM1, H441 
and H2347, including the 3 most BET inhibitor sensitive cell lines (Figure 28A). The 
expression of FOSL1 on the other hand was reduced in most of the cell lines upon BET 
inhibition except for H1373, H1792 and SKLU-1 (Figure 28B). The basal expression of MYC 
was increased in almost all cell lines, except for LCLC-97TM1, H358 and H2030 compared 
to normal lung fibroblasts. FOSL1 expression was only relatively increased in H441 cells 
(Figure 28C). This leads to the assumption that neither the basal gene expression of FOSL1 
nor the basal expression of MYC is predictive of response to BET inhibition. The down-
regulation of MYC expression on the other hand was seen in the three most sensitive cell 
lines, while its regulation was largely unaffected in insensitive cell lines. 
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Figure 28: Gene expression analysis of MYC and FOSL1 proto oncogene transcription factor basal expression 
and change of expression level after JQ1 treatment of all 12 tested NSCLC cell lines. A, B: qRT-PCR analysis of 
MYC and FOSL1 mRNA expression 24 h after treatment with 0.1 μM or 1 μM of JQ1 normalized to the 
housekeeping gene human cyclophilin A and DMSO-treated control. Error bars denote SEM (n=3). C: qRT-PCR 
analysis of basal MYC mRNA expression of NSCLC cell lines normalized to the housekeeping gene human 
cyclophilin A and normal fibroblast cell lines IMR-90 and Wi-38. Error bars denote SEM (n=3) 
4.1.5.4 Down-regulation of c-Myc oncoprotein by JQ1 
This needed to be confirmed at the protein level, as post-translational modifications could 
influence the stability and thereby the abundance and turnover rate of c-Myc in the cell. 
Western blot analysis of 24 h JQ1 treated cells showed that c-Myc protein level was only 
reduced in DV90, H1373, LCLC97TM1, H441 and H2347 cells, consistent with the reduction 
of mRNA level, while the c-Myc protein level was largely unaffected in insensitive cell lines 
(Figure 29A). Time- and dose-dependent down-regulation of c-Myc was confirmed in H1373 
cells (Figure 29B), while c-Myc levels were consistently unaffected in insensitive A549 
(Figure 29C) and H2030 cells (Figure 29D).The c-Myc protein level in H1373 cells was 
significantly down-regulated after 6 h of 1 μM JQ1 treatment. A CHX-chase experiment was 
performed to determine the turnover rate of c-Myc in H1373 cells. Cycloheximide (CHX) is a 
potent translation inhibitor that can be used to determine the stability of a protein of interest in 
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the cellular context. It was found that c-Myc had a fast turnover rate in cells with a protein 
half-life of around 150 min (Figure 30). 
 
 
Figure 29: Western blot analysis of c-Myc and FOSL1 protein levels after JQ1 treatment. A: Western blot 
analysis of c-Myc and FOSL1 expression 24 h after DMSO (-) or 1 μM JQ1 (+) treatment. Sensitivity of cell 
lines to JQ1 is represented by log (IC50 μM). B-D: Western blot analysis of c-Myc expression in cell lines with 
different sensitivities to JQ1. H1373 (B) A549 (C) and H2030 (D) cells were treated with different doses of JQ1 
for 24 h or 1 μM JQ1 for different times. 
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Figure 30: Determination of cellular turnover rate of c-Myc in H1373 cells. H1373 cells were treated with 10 
μM cycloheximide (CHX) for a maximum of 3 h. Cells were lysed after indicated treatment times. Western blot 
analysis of c-Myc was performed and normalized to ß-ACTIN levels using Image Studio software. The time 
until the half maximal relative level c-Myc was reached was determined and defined as protein half-life.  
4.1.6 Anti-tumor efficacy of JQ1 in vivo the subcutaneous H1373 xenograft mouse 
model  
Given the promising anti-proliferative activity of BET inhibitors in H1373 cells, the 
subcutaneous H1373 xenograft mouse model was chosen to evaluate the anti-tumor activity of 
JQ1 in vivo. FOX chase severe combined immunodeficiency (SCID) mice (CB17/Icr-
Prkdcscid/IcrIcoCrl) were inoculated with 3 x 106 cells/mouse (3.2.16.1). Once tumor burden 
was measurable, mice were randomized into groups of 12 mice and daily intra peritoneal (i.p) 
treatment with vehicle or JQ1 given at 50 mg/kg (10 ml/kg) was performed for 15 days. 
JQ1 at 50 mg/kg, was active with a percent treatment vs. control tumor weight ratio (%T/C) 
of 32% on day 15 after start of treatment (Figure 31A) and was tolerated with a maximal 
mean body weight loss (BWL) of 5% (Figure 31B). The tumor weight was determined on the 
final day and showed significant reduction of the tumor (p < 0.01). Down-regulation of c-
Myc, as previously shown in vitro, was also observed in tumor tissue lysates using western 
blot analysis, 24 h after JQ1 treatment (Figure 31C). 
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Figure 31: In vivo anti-tumor efficacy of JQ1 in the subcutaneous H1373 xenograft mouse model. A: Growth 
curve of H1373 xenograft treated with vehicle or 50 mg/kg JQ1 i.p. daily. Error bars denote SEM (n=12 mice per 
group) ** p < 0.01 two-tailed unpaired Student’s t-test on log10 -transformed tumor volume on day 15 after start 
of treatment. B, Box and whiskers plot of tumor weight in the H1373 xenograft study on day 15 after start of 
treatment. Error bars denote SEM (n=12 mice per group). ** p < 0.01 two-tailed unpaired Student’s t-test on 
log10 -transformed tumor weight. C, Western blot analysis of c-Myc protein levels in tumor tissue from the 
H1373 xenograft study treated with vehicle or 50 mg/kg JQ1. 
 
4.1.7 c-Myc overexpression rescues the effects of JQ1 
The function of c-Myc in driving proliferation of cancer cells is well established and loss of c-
Myc can lead to cell cycle arrest and cell death in tumors (Hydbring et al., 2010; Soucek et 
al., 2013; Wu et al., 2007). To investigate whether the anti-tumor activity of BET inhibition in 
H1373 cells was truly mediated by loss of c-Myc oncoprotein, an overexpression rescue 
experiment was performed. H1373 cells were co-transfected with a GFP expression plasmid 
and either c-Myc cDNA expression plasmid or empty vector control, followed by treatment 
with JQ1 (0.5 μM). As JQ1 leads to cell cycle arrest in H1373 cells, a flow cytometry EdU 
staining assay was used (Figure 32A).  
Cells transfected with a c-Myc overexpression vector or with empty vector were compared 
after selection of the positively transfected (GFP+) population. Also, the positively transfected 
and un-transfected populations in DMSO control and JQ1-treated samples were compared 
(GFP+ vs. GFP-). Ectopic overexpression of c-Myc significantly increased the EdU+ 
population of JQ1-treated cells (60% EdU+ transfected with c-Myc vector vs. 26% EdU+ 
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transfected with empty vector control) (Figure 32B, C), while un-transfected cells were not 
rescued (GFP- 33% vs GFP+ 60%) (Figure 32B, D). Interestingly ectopic expression of c-Myc 
could not completely rescue the effect of JQ1. This suggests that BET inhibition had 
additional effects on the apoptotic pathway. 
 
 
Figure 32: c-Myc overexpression rescues anti-proliferative activity of JQ1 in H1373 cells. A: Workflow of 
rescue experiment in H1373. Cells were transfected with empty vector or c-Myc expressing vector and GFP 
vector, and then subsequently treated with JQ1 (0.5 μM) or DMSO and stained using EdU.B: Representative 
histogram of EdU staining following c-Myc overexpression rescue and JQ1 treatment. The GFP+ population is 
marked in red and the GFP- population is marked in grey. C and D: Results of overexpression rescue 
experiments comparing empty vector vs c-Myc vector transfected cells (C) and GFP- vs GFP+ cells co-
expressing c-Myc (D). EdU+ population was normalized to DMSO-treated control sample. Error bars denote 
SEM (n=3). *** p < 0.001 two-tailed unpaired Student’s t-test. 
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4.2 Combinatory potential of BET inhibition with pro-apoptotic therapy 
The transcriptional regulation of 370 apoptosis-pathway genes was compared in the JQ1-
sensitive H1373 cells and the JQ1-resistant H2030 cell lines. Cells were treated with 1 μM 
JQ1 for 6 h, followed by analysis of gene expression using qRT-PCR. Among the non-
overlapping and overlapping expression changes observed, the levels of two cellular caspase 
inhibitors FLIP and XIAP, which exhibit key regulatory functions in the apoptosis pathway, 
were strongly reduced in both cell lines (Figure 33). Looking at the extrinsic and intrinsic 
apoptosis pathways of mammalian cells led to a strong rationale for combining BET 
inhibition with pro-apoptotic therapy like TRAIL or the standard of care chemotherapy agent 
cisplatin. 
The regulatory effects of JQ1 on gene expression of the BCL-2 and IAP family was analyzed 
using western blot in sensitive H1373 and insensitive A549 and H2030 cells. The expression 
of the members of the BCL-2 and of the IAP family remained largely unaffected by BET 
inhibition in most of the cells tested (Figure 34A, B, C). However c-FLIP and XIAP protein 
levels were reduced in all of the cell lines in a dose-dependent manner. It was interesting to 
see whether the expression of these genes was dependent on BET proteins and would be 
reduced by BET inhibition in all of the tested NSCLC cell lines.  
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Figure 33: Profiling of 370 apoptosis related genes in relation to BET inhibition. QRT-PCR analysis of 370 
genes involved in apoptosis regulation, in JQ1-sensitive H1373 cells (left) and JQ1-resistant H2030 cells (right) 
after 6 h of treatment with 1 μM JQ1. Data were normalized to housekeeping genes, and the fold-change 
compared to DMSO treatment was calculated. 
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Figure 34: Western blot analysis of BCL-2 and IAP family in cell lines treated with JQ1. A, B and C: Western 
blot analysis of apoptosis-related genes in cell lines with different sensitivities to JQ1. H1373 (A) A549 (B) and 
H2030 (C) cells were treated with increasing doses of JQ1 for 24 h. 
 
4.2.1 Expression of the apoptosis regulators c-FLIP and XIAP is dependent on BET 
proteins 
Indeed, JQ1 treatment reduced the mRNA levels of FLIP and XIAP in all 12 NSCLC cell 
lines tested (Figure 35A, B). Chromatin immunoprecipitation (ChIP) was performed in H1373 
cells and showed that BRD4 occupancy at the promoter sites of FLIP and XIAP was 
significantly reduced after JQ1 treatment (Figure 35C, D), in line with the reduction of FLIP 
and XIAP mRNA expression, thus leading to the hypothesis that BRD4 bound to promoter 
sites of XIAP and FLIP and thereby drove gene expression. 
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Figure 35: Regulation of the apoptosis regulators c-FLIP and XIAP expression is dependent on BET proteins. A 
and B: qRT-PCR analysis of XIAP and FLIP mRNA expression 24 h after treatment with 0.1 μM or 1 μM of JQ1 
normalized to the expression levels of the housekeeping gene human cyclophilin A and the DMSO-treated 
control. Error bars denote SEM (n=3). C and D, ChIP-qPCR analysis of BRD4 binding at the XIAP and FLIP 
promoters (primer distance from transcription start site (TSS) is indicated) in H1373 cells treated with DMSO or 
JQ1 (0.5 μM). Error bars denote SEM (n=3). * p < 0.05, ** p < 0.01, two-tailed unpaired Student’s t-test. 
 
Reduction of both c-FLIP and XIAP at the protein level was also observed in all NSCLC cell 
lines tested after addition of 1 μM JQ1 for 24 h (Figure 36A). Time-course and dose-response 
experiments confirmed the effect of BET inhibition at the protein levels in 3 cell lines with 
different sensitivities to JQ1 (Figure 36B, C, D). Treatment of H1373, A549 and H2030 with 
a dose of 0.25 μM to 1 μM JQ1 strongly reduced the protein levels of both c-FLIP and XIAP 
after 24 h. The time-course experiments revealed that treatment with 1 μM JQ1 led to a strong 
reduction of c-FLIP and XIAP protein level after 4-6 h. 
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Figure 36: Western blot analysis showing down-regulation of c-FLIP and XIAP protein levels following BET 
inhibition. A: Western blot analysis of c-FLIP and XIAP 24 h after DMSO (-) or 1 μM JQ1 (+) treatment. B, C 
and D: Western blot analysis of c-FLIP and XIAP in cell lines with different sensitivities to JQ1. H1373 (B) 
A549 (C) and H2030 (D) cells were treated with increasing doses of JQ1 for 24 h or with 1 μM for different 
times. 
4.2.2 Loss of XIAP and c-FLIP leads to enhanced TRAIL-induced apoptosis 
XIAP and c-FLIP have key inhibitory functions in the extrinsic apoptosis pathway and were 
reduced in both resistant and sensitive cells treated with JQ1, although their loss did not 
consistently lead to apoptosis in all cell lines. Therefore JQ1 was combined with the death 
receptor ligand TRAIL to test whether cell death can be stimulated, especially in the 
insensitive cell lines. Death receptor binding of TRAIL is known to strongly activate the 
extrinsic apoptosis pathway through the cleavage of caspase-8/10, leading to downstream 
activation of caspase 3 and amplifying activation of the intrinsic apoptosis pathway. As the 
time-course experiments revealed that treatment with 1 μM JQ1 led to a reduction of c-FLIP 
and XIAP protein level after 4-6 h, H1373 cells were pretreated with 1 μM JQ1 2 h prior to 
addition of TRAIL (Figure 37A). Significantly enhanced TRAIL-dependent induction of 
apoptosis was evidenced by Annexin-V staining and PARP-cleavage in H1373 cells (Figure 
37B, C). While addition of 1 μM JQ1 and 10 ng/mL TRAIL alone induced apoptosis in a 
small number of cells, the combination of both strikingly reduced the number of viable cells 
down to 15.5%.  
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To further increase the understanding on which components of the apoptotic pathway were 
affected by JQ1 and to establish whether enhanced TRAIL-induced apoptosis was truly 
dependent on caspase activity, extended analyses were performed. To investigate the 
dependency of the JQ1 enhanced TRAIL-induced apoptosis on caspase activity, H1373 cells 
were treated with pan-caspase inhibitor z-VAD-FMK, caspase-9 inhibitor z-LEHD-FMK or 
caspase-8 inhibitor z-IETD-FMK (Figure 37D). Impressively the addition of the pan-caspase 
inhibitor z-VAD-FMK completely rescued H1373 cells from induction of apoptosis, while the 
caspase-9 inhibitor z-LEHD-FMK and the caspase-8 inhibitor z-IETD-FMK did only partially 
rescue the effect. 
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Figure 37: Combination of JQ1 and TNF related apoptosis inducing ligand (TRAIL) in H1373 cells. A: 
Workflow of combination treatment using JQ1 and TRAIL: Cells were pre-treated with JQ1, subsequently 
treated with TRAIL, and stained using AV-FITC/PI for analysis of apoptosis by flow cytometry (results showing 
the percentage of viable population (% AV-FITC / PI negative (-/-)) are reported in top of panels C and D; 
western blot results showing PARP cleavage are on the bottom of panels C and D). B: Representative plot of 
flow cytometry analysis showing Annexin-V, propidium iodide stained H1373 cells following TRAIL treatment 
for 24 h. C: treatment of H1373 cells with TRAIL (10 ng/mL) and JQ1 (1 μM) alone or in combination. D: as in 
panel B but with 20 μM of the caspase inhibitors Z-VAD-FMK (pan-caspase inhibitor), Z-IETD-FMK (caspase-
8 inhibitor), or Z-LEHD-FMK (caspase-9 inhibitor). Error bars denote SEM (n=3-5). * p < 0.05, ** p < 0.01, 
*** p < 0.001, non-parametric one-way ANOVA with Sidak’s correction for multiple comparisons. 
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The pro-apoptotic proteins BAX and BAK are essential to induce outer mitochondrial 
membrane permeabilization (MOMP) leading to activation of the intrinsic apoptosis pathway 
and apoptosome formation (1.5.1.1). BAX and BAK have redundant functions (Lindsten et 
al., 2000), they induce apoptosis with preference towards specific BH3 only proteins (Figure 
11A). However a recent study reported chemotherapy and TRAIL-induced apoptosis to be 
dependent on the pro-apoptotic proteins BAX and BAK, while TRAIL-induced apoptosis was 
rather dependent on BAK (Sarosiek et al., 2013). To further investigate whether the 
combination of JQ1 and TRAIL was dependent on either BAX or BAK, H1373 cells depleted 
of BAX or BAK were produced using the CRISPR-Cas9 technology (1.4.3). Interestingly the 
enhanced TRAIL-induced apoptosis was independent of pro-apoptotic proteins BAX or BAK, 
as knockout did not significantly affect the combination potential of JQ1 and TRAIL (Figure 
38A). However knockout of BAX or BAK also did not block the apoptosis induction of 
TRAIL alone compared to wild-type cells. In order to confirm that the enhancing effect of 
JQ1 was linked to the down-regulation of XIAP and c-FLIP, siRNA knockdown experiments 
were performed. Simultaneous knockdown of c-FLIP and XIAP in H1373 cells using pooled 
targeted siRNAs nearly completely recapitulated the enhancing effects of JQ1 when combined 
with TRAIL (37% viability) (Figure 38 A, B). This suggested that the enhancing effect of JQ1 
was largely dependent on loss of c-FLIP and XIAP. Knock-down efficiency of siRNA 
treatment was confirmed by western blot analysis. 
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Figure 38: Combined treatment with JQ1 and TRAIL in H1373 BAX or BAK knockout cells. A: results of the 
rescue experiment after treatment of H1373 BAX or BAK knockout cells with TRAIL (10 ng/mL) and JQ1 (1 
μM) alone or in combination. B: Flow cytometry results plotting percentage of viable population (% AV-FITC / 
PI negative (-/-)) of H1373 cells treated with TRAIL (10 ng/mL) 24 h after siRNA knockdown of c-FLIP or 
XIAP. Error bars denote SEM (n=3). * p < 0.05, ** p < 0.01, *** p < 0.01, non-parametric one-way ANOVA 
with Sidak’s correction for multiple comparison. C and D: Western blot analysis of knockdown efficiency using 
single or pooled siRNAs targeting FLIP or XIAP transcripts. 
 
It was furthermore interesting to see whether JQ1 treatment did also increase TRAIL-induced 
apoptosis in JQ1-insensitive cell lines, and enabled the combination treatment to overcome 
resistance. H2030 and A459 cells were treated with JQ1 and 2 h later TRAIL was added as 
described before (Figure 37A). Even though A549 cells were less sensitive to TRAIL, the 
combination of JQ1 and TRAIL reduced the viability of A549 cells to 57% at 100 ng/mL 
TRAIL (Figure 39A). In the case of H2030 cells, the combination also enhanced the effect of 
TRAIL and reduced the viability to 68% using a 10 ng/mL TRAIL dose (Figure 39B). These 
results were confirmed in 5 NSCLC models with different sensitivities to BET inhibition 
which were treated either with JQ1 alone or in combination with TRAIL (Figure 39C). 
Importantly, combination of TRAIL and JQ1 did limit the viability of all 5 NSCLC models 
tested (Figure 39D-H), while the combination did not reduce the viability of normal fibroblast 
HFF-1 cells (Figure 39I). 
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Figure 39: Combination of JQ1 and TRAIL in NSCLC cells. A and B: H2030 or A549 cells after treatment with 
TRAIL (10 ng/mL or 100ng/mL) and JQ1 (1 μM) alone or in combination. C: Workflow of combination 
treatment with JQ1 and TRAIL. Cells were pretreated with 1 μM JQ1 and subsequently treated with TRAIL, 
followed by assessment of cell viability using Cell TiterGlo. Five NSCLC cell lines with different sensitivities to 
JQ1 were treated with different doses of JQ1 prior to treatment and with increasing doses of TRAIL. D: H1373, 
E: H358, F: H460, G: A549, H: H2030, NSCLC cells ; I: HFF-1 normal fibroblast cells. Data were normalized to 
DMSO-treated cells. Error bars denote SEM (n=3-5). * p < 0.05, ** p < 0.01, *** p < 0.01, non-parametric one-
way ANOVA with Sidak’s correction for multiple comparison. 
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4.2.3 In vitro combination of JQ1 and cisplatin synergistically reduces cell viability and 
overcomes resistance in the A549 cell line 
The sensitizing effect of BET inhibition towards pro-apoptotic agents through down-
regulation of c-FLIP and XIAP led to explore the combination of JQ1 with pro-apoptotic 
chemotherapy such as cisplatin, which is frequently used as a single agent to treat NSCLC 
patients. Combination of JQ1 and cisplatin significantly increased apoptosis in all 3 cell lines 
tested, as measured by Annexin-V staining and PARP cleavage (Figure 40A, B). To determine 
a potential synergistic effect of JQ1 and cisplatin a drug combination assay was performed 
(3.2.4.1) combining JQ1 and cisplatin in various ratios and treating A549 cells with ranging 
doses of these ratios (Figure 40C). The resulting IC50 values were used to calculate a potential 
synergy of the two agents using the Chou-Talalay method which considers a combinatory 
index below 1 (CI < 1) to be synergistic (3.2.4.1). Indeed cisplatin and JQ1 synergistically 
reduced viability of A549 cells when combined with JQ1, with a combination index (CI) of 
0.34-0.54 (Figure 40C). In order to confirm that the enhancing effect of JQ1 was linked to the 
down-regulation of XIAP and c-FLIP, siRNA knockdown experiment was performed. 
Interestingly knockdown of c-FLIP alone using pooled targeted siRNAs recapitulated the 
enhancing effects of JQ1 when combined with cisplatin in A549 cells (54.2% viability) 
(Figure 40E). This suggested that the enhancing effect of JQ1 was largely dependent on the 
loss of c-FLIP. 
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Figure 40: Combination of JQ1 and cisplatin in NSCLC cells. A: Representative plots of flow cytometry 
analysis showing Annexin-V, propidium iodide stained A549 cells following cisplatin treatment for 48 h. B: 
Flow cytometry results showing the percentage of viable population (% AV-FITC / PI negative (-/-)) after 
treatment of H1373, A549 and H2030 cells with cisplatin and JQ1 (1 μM) alone or in combination. Error bars 
denote SEM (n=3). ** p < 0.01, *** p < 0.001, non-parametric one-way ANOVA with Sidak’s correction for 
multiple comparison. C: Western blot analyses of PARP cleavage following treatment with cisplatin and JQ1 (1 
μM) alone or in combination. D: Assessment of the degree of synergy between cisplatin and JQ1 in A549 cells 
using the Chou Talalay method. Calculated CI is plotted against drug ratios. Results are shown as the mean 
(n=2). The cutoff point for synergy is defined by CI < 1.0. E: Flow cytometry results plotting percentage of 
viable population (% AV-FITC / PI negative (-/-)) of A549 cells treated with cisplatin (20 μM) 4 h after siRNA 
knockdown of c-FLIP or XIAP. Error bars denote SEM (n=3). * p < 0.05, ** p < 0.01, *** p < 0.01, non-
parametric one-way ANOVA with Sidak’s correction for multiple comparison. 
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4.2.4 In vivo combination of JQ1 and cisplatin overcomes resistance in the A549 
xenograft model 
Given the strong synergy of the combination of cisplatin and BET inhibition in A549 cells in 
vitro, the subcutaneous A549 xenograft mouse model was chosen to evaluate the anti-tumor 
activity of the combination of cisplatin and JQ1 in vivo. FOX chase severe combined 
immunodeficiency (SCID) mice were inoculated with 3 x 106 cells/mouse (3.2.16.1). After 
tumor burden was established mice were randomized into groups of 10 mice and 
intraperitoneal (i.p) treatment was initiated with vehicle or JQ1 given at 50 mg/kg or 80 
mg/kg (maximal tolerated dose) (10 ml/kg) or cisplatin 1.2 mg/kg injected intravenous (i.v.) 
as a bolus (10 ml/kg) (Figure 41A).Vehicle and JQ1 were given for 28 days and cisplatin was 
administered at its optimal schedule, for 5 days (i.v.).The combination of JQ1 and cisplatin 
was given for 5 days within the first week of treatment, followed by JQ1 maintenance from 
day 14 until the end of the study on day 28. 
Cisplatin and JQ1 were well tolerated as single agents with a maximum mean BWL of 6% for 
cisplatin, and 5% and 7% for JQ1 at 50 mg/kg and 80 mg/kg, respectively. Combination of 
cisplatin and JQ1 led to slightly increased mean BWL of 10%. The mice were therefore given 
1 week drug holiday before starting the JQ1 maintenance. The activity of the treatment was 
evaluated on day 28 after start of treatment comparing the mean tumor weights of the control 
group and treated groups (%T/C) (3.2.16.2). 
The activity of cisplatin and JQ1 alone in this study was classified as not active according to 
standard National Cancer Institute criteria (active treatment: %T/C < 42%) with a %T/C of 
88% for cisplatin, and 79% and 60% for JQ1 at 50 mg/kg and 80 mg/kg, respectively (Figure 
41B). The combination of cisplatin and JQ1 followed by JQ1 maintenance however, was 
active with a %T/C of 41% on day 28, and resulted in a statistically significant lower tumor 
weight and tumor volume, compared with either agent alone (Figure 41 A, B). 
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Figure 41: Combination of JQ1 and cisplatin in the subcutaneous A549 xenograft mouse model. A, Growth 
curve of A549 xenograft treated with vehicle, JQ1 (50 mg/kg, 80 mg/kg) i.p. QDx28, cisplatin 1.2 mg/kg i.v. 
QDx5 or in combination (50 mg/kg JQ1 + 1.2. mg/kg QDx5 cisplatin followed by 7 days off and JQ1 
maintenance). Error bars denote SEM (n=10 mice per group) * p < 0.05, ** p < 0.01, *** p < 0.001 two-tailed 
unpaired Student’s t-test on log10 transformed tumor volume on day 28 after start of treatment. B, Box and 
whiskers plot of tumor weight on day 28 after start of treatment. Error bars denote SEM (n=10 mice per group). 
* p < 0.05, ** p < 0.01, *** p < 0.001 two-tailed unpaired Student’s t-test on log10-transformed tumor weight. 
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5. Discussion 
In recent years epigenetic regulators have become attractive targets for therapy of complex 
diseases like cancer, in which both genetic and epigenetic alterations play essential roles. 
Since the approval of the first-generation epigenetic therapies targeting DNA 
methyltransferases and histone deacetylases for the treatment of hematological malignancies, 
the field has expanded to several other protein families such as bromodomain proteins, 
histone methyltransferases, and histone demethylases (Valdespino and Valdespino, 2015). 
Understanding and defining the roles of these epigenetic regulators at the cellular level is an 
important part of pre-clinical drug development. BET (BRD2, BRD3, BRD4 and BRDT) 
inhibitors block the interaction between members of the BET family and acetylated lysine 
residues of histone tails (Filippakopoulos et al., 2010). Anti-tumor activity of potent and 
selective inhibitors of BET proteins like JQ1, I-BET762 and OTX015 has been shown in a 
large number of pre-clinical models of hematological and solid tumors (Table 2). However the 
anti-tumor activity of BET inhibitors can be quite diverse among cell lines. Given the 
potential of BET bromodomain proteins in cancer therapy, a detailed understanding of their 
functional activity becomes more and more important. 
5.1 Functional effects of BET inhibition in NSCLC 
5.1.1 Activity of BET inhibitors in KRAS-mutated NSCLC cell lines 
The activity of BET inhibitors has been linked to a reduction of gene expression for a number 
of oncogene drivers such as members of the MYC family, GLI and FOSL1 transcription 
factors (Delmore et al., 2011; Kandela et al., 2015; Lockwood et al., 2012; Tang et al., 2014). 
A recent study (Soucek et al., 2013) has shown that the MYC proto-oncogene is essential for 
KRAS-driven tumors. The expression profiles of tumors from patients diagnosed with lung 
adenocarcinoma comparing the KRAS wild-type and mutant populations identified MYC 
expression together with an enrichment of the MYC transcriptional profile as characteristic of 
the KRAS mutant cohort. 
BET inhibitors potently reduce the growth of MYC-dependent malignancies like MM and 
AML (Delmore et al., 2011; Zuber et al., 2011).They were already tested on a number of 
KRAS mutant NSCLC cell lines but their activity could not always be linked to transcriptional 
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suppression of MYC (Lockwood et al., 2012). In the present work, the activity of JQ1 was 
characterized using a viability assay in a panel of 12 KRAS mutant NSCLC cell lines. Strong 
effects leading to a reduction of cell growth and viability were observed in a sub-population 
of cell lines, defining them as particularly sensitive to BET bromodomain inhibition. This 
subset of 3 out of 12 cell lines accounted for 25% of the tested cell lines. 
5.1.2 Mutation status, cell doubling time of the NSCLC cell lines and basal expression 
of BET family members 
The mutational status of the 12 NSCLC cell lines revealed that the tumor suppressor p53 and 
Liver kinase B1 (LKB1) were frequently mutated and that LKB1 mutation was enriched in 
the BET inhibitor insensitive cell lines population. P53 mutation has a high incidence in all 
cancer types and can lead to loss of wild-type p53 or gain of function p53 supporting the 
malignant state of a cancer cell (Muller and Vousden, 2014). Co-occurring genetic alterations 
of KRAS and LKB1 on the other hand lead to a more aggressive type of lung cancer with 
lower levels of immune markers, and define a major subgroup (18-32%) of KRAS-mutated 
NSCLC (Ji et al., 2007; Skoulidis et al., 2015).  
Additionally LKB1 knockdown was described to reduce the sensitivity of KRAS-driven lung 
tumors to the BET inhibitor JQ1 (Shimamura et al., 2013) but the underlying mechanism 
remains unclear. Basal levels of BRD2, BRD3 and BRD4 were determined using qRT-PCR 
and showed that their expression did not predict the activity of BET inhibitors. Also, the 
doubling time of the cells did not influence the activity of BET inhibitors either. 
5.1.3 Effect of BET inhibitors on cell cycle and apoptosis induction  
To further characterize the effect of BET inhibitors on the cellular phenotype, cell cycle 
distribution and apoptosis assays were performed. Using a flow cytometry based EdU staining 
assay, DV90 and H1373 cells treated for 24 h with BET inhibitors showed a dose-dependent 
reduction of the S phase population, while the G1/G0 phase population increased. Exposure 
of DV90 and H1373 cells with BET inhibitors for 48 h lead to increased induction of 
apoptosis in a dose-dependent manner, while being independently of the p53 mutation status 
of the cells. Neither cell cycle arrest nor induction of apoptosis was seen in the BET inhibitor 
insensitive A549 and H460 cells.  
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This suggested that induction of cell cycle arrest was a sign of early response, while induction 
of apoptosis only took place at a later stage and that the two effects were induced by BET 
inhibitor treatment. Also the data revealed that insensitive cell lines showed no change in cell 
cycle distribution or cellular viability when exposed to BET inhibitors. 
5.1.4 BET inhibitor effect on BRD4 function in sensitive and insensitive cell lines  
It was interesting to see whether JQ1 might still be functionally active in the insensitive cell 
line, as some tumors have been described to develop multi-drug resistance by up-regulation of 
exporter proteins such as P-glycoprotein or Multidrug-Resistance-Protein-1 (MDR-1), thereby 
acquiring resistance to chemotherapy. These exporters actively pump the small molecules out 
of the cytosol, leading to reduced drug concentrations inside the cell and acquired drug 
resistance.  
BET inhibition was shown before to efficiently block BRD4 chromatin interaction. Therefore 
the activity of JQ1 was determined in the cellular context. Detergent washout of BRD4-GFP 
fusion protein overexpressed in H1373 cells showed that BRD4 was unable to bind to 
chromatin anymore after cells were treated with JQ1. Immunocytochemistry confirmed that 
JQ1 was functionally active in the sensitive H1373 cells but also in the insensitive A549 cells. 
Additionally, western blot analysis showed that JQ1 treatment led to increased chromatin-
unbound fraction of BRD4 in a dose-dependent manner, independently of the anti-tumor 
activity of JQ1 in the cell line. 
Altogether this confirmed that BET inhibitors were functionally active in sensitive and 
resistant cell lines. This led to the hypothesis that the anti-tumor activity of BET inhibition is 
linked to changes in gene regulation following functional inhibition of BET-chromatin 
interactions. 
5.1.5 BET bromodomain gene regulatory functions 
Microarray-based whole transcript analysis was used to identify the global changes induced 
by BET inhibition in the sensitive DV90 cells. The early (4 h) significant change of gene 
expression induced by JQ1 treatment at IC50 were quite limited and revealed MYC as one of 
the early response genes. 
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The protein half life time of c-Myc is quite fast with 150 min. Accordingly, MYC 
transcriptional programs were among the top enriched gene sets after 24 h of JQ1 treatment. 
Even though MYC down-regulation was reported in a number of indications following BET 
inhibition (Delmore et al., 2011; Kandela et al., 2015; Zuber et al., 2011), its regulation was 
not a common feature of BET inhibition in NSCLC. However, the most sensitive cell lines 
showed strong down-regulation of c-Myc confirmed by western blot, while insensitive cell 
lines were largely unaffected. The H2347 cell line shown not to be not very sensitive to BET 
inhibition, also showed down-regulation of c-Myc. A possible explanation for this might be 
that the growth of these cells is dependent on other oncogenic drivers unaffected by c-Myc, as 
suggested by its low expression level in this cell line. On the other hand, BET inhibition 
showed anti-proliferative activity in H1792 cells even though c-Myc expression was not 
altered, suggesting that additional effects of BET inhibition, independent of c-Myc down-
regulation can lead to anti-proliferative activity. 
The members of the BET family and in particular BRD4 bind genome-wide to chromatin and 
exhibit regulatory functions, however the number of gene with expression changes found by 
micro array analysis was rather limited. A possible explanation is that only a limited number 
of genes and enhancers would be sensitive to loss of occupancy by BRD4. Recent studies 
described large enhancer sites called super-enhancers that regulate and drive expression of 
genes defining the identity of a cell were recently identified (Whyte et al., 2013). Here the 
identification of super-enhancers was made possible by genome-wide listing of potential 
enhancer sites marked by H3K27Ac marks followed by analysis of enhancer binding factors 
like mediator 1 (MED1) occupancy clustering. Small nearby clusters of enhancer binding 
factors are concentrated in large clusters forming a super-enhancer site. In the DV90 cells 873 
super-enhancers were identified. The nearest coding gene of those super-enhancers was 
annotated. Among these there were 4 super-enhancers in close proximity to the MYC TSS, 
called MYC E1-4. BRD4 was found to occupy a large number of super-enhancers and loss of 
BRD4 at those sites ultimately led to strong loss of expression of the target genes (Loven et 
al., 2013). It is assumed that absence of BRD4 can destabilize protein complexes that bind to 
these enhancers, strongly reducing the activity of these complexes and the expression of 
downstream genes. Among the NSCLC models tested, the differential down-regulation of 
MYC upon JQ1 treatment may be explained by the occurrence of different enhancer 
landscapes with variable dependencies on BRD4 occupancy.  
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In AML a distant super-enhancer was identified that drives MYC expression in a BRD4-
dependent manner (Roe et al., 2015; Shi et al., 2013). Also, the enhancer landscapes of 
initially sensitive cancer cells can change under the pressure of BET inhibitors, as recently 
described in in vitro and in vivo in models of AML (Fong et al., 2015; Rathert et al., 2015). 
The cells acquired resistance to BET inhibition by changing the enhancer landscape nearby 
the promoter of MYC leading to a rebound of MYC expression. Constant expression of c-Myc 
in spite of treatment with BET inhibitors may therefore play a role in inherent JQ1 resistance. 
As in vitro assays are unable to completely recapitulate the pharmacological properties of a 
compound which will ultimately determine its applicability in cancer treatment, the anti-
tumor activity of BET inhibition was evaluated in an in vivo setting. H1373-xenografted 
SCID mice were treated with 50 mg/kg JQ1 daily. The treatment with JQ1 significantly 
reduced tumor growth in vivo with a %T/C value of 32%, in agreement with recent findings 
describing the efficacy of BET inhibitors in a KRAS-driven NSCLC mouse model 
(Shimamura et al., 2013). In addition, western blot analysis of the tumor tissue showed a 
down-regulation of c-Myc protein level 24 h after treatment with JQ1. 
Loss of c-Myc can lead to cell cycle arrest and cell death in tumors (Hydbring et al., 2010; 
Soucek et al., 2013; Wu et al., 2007), however whether the overexpression of c-Myc could 
rescue the cells from the BET inhibitory effect had not been evaluated so far. A rescue 
experiment showed that the proliferation inhibition induced by JQ1 in H1373 cell, as 
evidenced by EdU staining, could be at least partially rescued by c-Myc overexpression thus 
establishing a link between reduced NSCLC cell proliferation and c-Myc protein levels. 
However the only partial rescue indicates that there are probably additional effects induced by 
JQ1, in line with the finding that some cells are sensitive to BET inhibitor without changes in 
c-Myc protein levels.  
Overall these results support the role of BET inhibition in the suppression of oncogene 
expression such as MYC. They also show that the differential gene regulatory role of BET 
proteins depends on the enhancer landscape of the cell.  
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5.2 Combinatory potential of BET inhibition 
Even though depletion of the MYC oncogene can strongly reduce the growth of KRAS mutant 
NSCLC, only a distinct sub-group of NSCLC was affected in this way by JQ1 treatment. 
Beyond the regulation of the MYC oncogene, the transcriptional changes of 370 genes in 
sensitive H1373 and insensitive H2030 cells were evidenced using qRT-PCR and showed that 
two key negative regulators of apoptosis, c-FLIP and XIAP, were both strongly down-
regulated in the two cell lines after JQ1 treatment. Western blotting showed that in contrast to 
MYC, the expression of these two genes was reduced in all NSCLC cell lines tested.  
ChIP-qPCR revealed that BRD4 indeed occupies the promoter site of FLIP and XIAP and can 
be effectively removed by BET inhibitors, leading to strong down-regulation of the two 
genes. Cellular FLICE-like inhibitory protein (c-FLIP) is one of the key anti-apoptotic 
regulators overexpressed in NSCLC. It binds to pro-caspase-8 and thereby regulates its 
activation by FADD (Fas-associated death domain protein) bound to death receptors such as 
Fas, DR4, DR5 and TNF-R1 (Hughes et al., 2016; Shirley and Micheau, 2013). Additionally, 
cytoplasmic overexpression of c-FLIP has been linked to poor overall survival in NSCLC 
patients (Riley et al., 2013). Because of its structural similarity with caspase-8, direct 
targeting of c-FLIP with small-molecules has been challenging. Another frequently 
overexpressed anti-apoptotic regulator is X-linked inhibitor of apoptosis (XIAP), a member of 
the inhibitor of apoptosis protein (IAP) family, which blocks the activity of caspase-3, -7 and -
9. Endogenous inhibitors of XIAP function such as second mitochondria-derived activator of 
caspases (SMAC) released from the mitochondria have been described and molecules that 
mimics SMAC are already in clinical development as apoptosis inducers or drug-sensitizers 
(Obexer and Ausserlechner, 2014).  
This observation of reduced c-FLIP and XIAP levels led to the rationale of combining the 
BET inhibitor JQ1 with a pro-apoptotic agent such as TRAIL. Death receptor targeting agents 
inducing extrinsic apoptosis are currently in clinical development (Lemke et al., 2014b) and 
down-regulation of two key anti-apoptotic proteins MCL1 and c-FLIP by CDK9 inhibition 
was recently identified to have enhanced effects in NSCLC when combined with death-
receptor ligand TRAIL (Lemke et al., 2014a). While finishing these studies, another group 
also proposed that JQ1 enhances TRAIL-induced apoptosis (Yao et al., 2015), although the 
molecular mechanism was not described. In this work, the combination of JQ1 with TRAIL 
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treatment showed potent induction of apoptosis in the treated H1373 cells (sensitive to BET 
inhibition) as well as in the A549 and H2030 cells (not sensitive to BET inhibition). Enhanced 
TRAIL-induced apoptosis was shown to be generally caspase dependent, and not depending 
solely on either initiator caspase-8 or -9. TRAIL induces the apoptotic extrinsic pathway by 
binding the death receptor at the extra cellular matrix, inducing activation of caspase-8. The 
apoptotic signal can then be amplified by mitochondria outer-membrane permeabilization 
(MOMP) and caspase-9 activation. MOMP-dependent apoptosis is mediated by the pro-
apoptotic proteins BAX and BAK which interact with BH3-only proteins such as BID and 
BIM. BAX and BAK possess redundant functions in releasing cytochrome C from 
mitochondria in mice. Recently the pro-apoptotic activity of BET inhibitors was described to 
be dependent on BAX and BAK function (Xu et al., 2016), while TRAIL was shown to 
preferentially induce BID-BAK dependent apoptosis (Sarosiek et al., 2013).  
In this study, JQ1-enhanced TRAIL-induced apoptosis was shown to be largely unaffected by 
loss of either BAX or BAK, in agreement with previous observations showing that XIAP 
down-regulation enhances TRAIL activity in a BAX/BAK-independent manner (Gillissen et 
al., 2013). Using siRNA knockdown, the simultaneous loss of expression of the key apoptotic 
proteins XIAP and c-FLIP was identified as the major driver of caspase-8 and -9-dependent 
TRAIL-induced cell death by JQ1. Interestingly, BET inhibition led to down-regulation of 
XIAP and c-FLIP in all the NSCLC cell lines tested and accordingly, JQ1 treatment showed 
enhancing effects on TRAIL-induced apoptosis induction in all cell lines tested. Importantly 
combination of JQ1 and TRAIL did not affect the viability of normal HFF-1 fibroblast cells. 
Interestingly, combination of JQ1 with the pro-apoptotic agent cisplatin synergistically 
induced apoptosis as well as cell viability, independently of the sensitivity of the cell line to 
JQ1 as a single agent. Experiments with siRNAs showed that although the combination of 
JQ1 and cisplatin may result in broad effects on transcriptional programs and signaling 
pathways, down-regulation of the anti-apoptotic protein c-FLIP is a key driver for the 
enhanced cell death induction.  
The increased anti-proliferative effect also translated in vivo in the A549 xenograft model, 
where treatment with either cisplatin or JQ1 alone showed limited activity.  
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Promising first results of the clinical phase I trials with BET inhibitors have been reported 
(Amorim et al., 2016; Berthon et al., 2016; Stathis et al., 2016), and the present results show 
that characterization of the effect of BET inhibition on apoptosis-related genes can be 
valuable for the identification of attractive combination partners. The results also suggest that 
epigenetic therapy targeting BET proteins may be a useful approach to improve outcomes and 
overcome resistance compared to current standard-of-care treatments for NSCLC patients. 
5.3 Final conclusion 
This work contributes to a better understanding of BET bromodomain inhibition in cancer and 
should help to increase both the knowledge of the biology of the BET protein family and of 
the mode of action of BET inhibitors such as JQ1 or early clinical candidates such as I-
BET762 and OTX-015. Initially the MYC oncogene was identified as the driving gene 
responding to BET inhibition in a subpopulation of KRAS-mutated NSCLC cell lines, which 
were particularly sensitive to BET inhibition. 
Additionally two key negative regulators of apoptosis XIAP and c-FLIP were identified to be 
expressed in a BET-dependent manner. The loss of XIAP and c-FLIP increases the cellular 
susceptibility to caspase-dependent induction of apoptosis. Accordingly the effect of pro-
apoptotic agents like TRAIL and the chemotherapeutic agent cisplatin was significantly 
enhanced in combination with the BET inhibitor JQ1. These combinations were able to re-
sensitize cell lines resistant to BET inhibition alone. 
5.4 Outlook 
NSCLC has the highest incidence of cancer-related death worldwide and a high medical need 
for more effective therapies. About 80 percent of lung cancers can be histologically classified 
as NSCLC (VanderMeer et al., 2015), of which 30% harbor an activating oncogenic mutation 
in the GTPase domain of the KRAS signaling protein (Pylayeva-Gupta et al., 2011). A 
number of driving gene mutations have been identified and are characteristic of more than 
50% of NSCLC cases (Figure 13). While a number of therapies are in clinical development 
and EGFR inhibitors are already on the market, no therapy for mutant KRAS is available. 
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Anti-tumor activity of the potent and selective inhibitors of BET proteins like JQ1, I-BET762 
and OTX015 has been shown in a large number of pre-clinical models of hematological and 
solid tumors (Table 2). However the anti-tumor activity of BET inhibitors can be quite diverse 
in pre-clinical models, which is consistent with the first results from the clinic. This work 
showed that BET inhibitor treatment could potentially become an attractive therapeutic option 
for the treatment for patients with malignant aggressive KRAS-mutated NSCLC.  
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Summary 
Non-small cell lung cancer (NSCLC) has the highest incidence of cancer-related death 
worldwide and a high medical need for more effective therapies. Small molecule inhibitors of 
the bromodomain and extra terminal domain (BET) family such as JQ1, I-BET762 and OTX-
015 are active in a wide range of different cancer types, including lung cancer. While their 
activity on oncogene expression such as c-Myc has been addressed by many studies, the 
effects of BET inhibition on the apoptotic pathway remain largely unknown. This work 
evaluates the activity of BET bromodomain inhibitors on cell cycle distribution and on 
components of the apoptotic response. Genome-wide transcriptional analyses together with 
chromatin immunoprecipitation followed by sequencing helped to identify the MYC gene and 
associated super-enhancers as a primary target of JQ1. Using a panel of twelve KRAS-mutated 
NSCLC models, it was found that cell lines responsive to BET inhibitors underwent apoptosis 
and reduced their S-phase population, concomitant with down-regulation of c-Myc 
expression. Conversely, ectopic c-Myc overexpression rescued the anti-proliferative effect of 
JQ1. In the H1373 xenograft model, treatment with JQ1 significantly reduced tumor growth 
and down-regulated the expression of c-Myc. The effects of BET inhibition on the expression 
of 370 genes involved in apoptosis were compared in sensitive and resistant cells and the 
expression of the two key apoptosis regulators FLIP and XIAP was found to be highly BET-
dependent. Consistent with this, combination treatment of JQ1 with the tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL) or the pro-apoptotic chemotherapeutic agent 
cisplatin enhanced induction of apoptosis in both BET inhibitor sensitive and resistant cells. 
Furthermore the combination of JQ1 with cisplatin led to significantly improved anti-tumor 
efficacy in A549 tumor-bearing mice. Altogether these results show that the identification of 
BET-dependent genes provides guidance for the choice of drug combinations in cancer 
treatment. They also demonstrate that BET inhibition primes NSCLC cells for induction of 
apoptosis and that a combination with pro-apoptotic compounds represents a valuable strategy 
to overcome treatment resistance. 
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Zusammenfassung 
Nicht-kleinzelliger Lungenkrebs (NSCLC) hat die höchste Inzidenz an krebsbedingten 
Todesfällen weltweit und gleichzeitig einen hohen medizinischen Bedarf an effektiveren 
Therapien. Molekulare Inhibitoren der Bromodomain and extra-terminal domain (BET) 
Familie wie JQ1, IBET-762 und OTX-015 wirken in einem breiten Spektrum von 
verschiedenen Krebsarten, einschließlich Lungenkrebs. Während ihre Aktivität auf die 
Expression von Onkogenen wie c-Myc in vielen Studien untersucht wurde, bleibt der Effekt 
von BET-Inhibition auf den Apoptose Signalweg weitgehend unbekannt. In dieser Arbeit 
wurde die Aktivität von BET Bromodomain-Inhibitoren auf den Zellzyklus und auf 
Komponenten der Apoptose-Antwort der Zelle untersucht. Genomweite 
Transkriptionsanalysen haben zusammen mit Chromatin Immunpräzipitation und 
anschließender Sequenzierung geholfen das MYC Gen und dessen assoziierte Super-enhancer 
als primäres Ziel des BET-Inhibitors JQ1 zu identifizieren. Mittels einer Gruppe von 12 
NSCLC Modellen mit KRAS Mutation belegt diese Arbeit, dass Zelllinien die auf die BET-
Inhibitoren reagieren in Apoptose gehen und eine Reduktion der S-Phasen Population 
zusammen mit gleichzeitiger Herunterregulation der c-Myc Expression aufwiesen. 
Andererseits konnte die ektopische Überexpression von c-Myc der anti-proliferativen 
Wirkung entgegenwirken. In dem H1373-Xenograft Modell reduzierte die Behandlung mit 
JQ1 das Tumorwachstum und die Expression von c-Myc signifikant. Die Auswirkung von 
BET-Inhibition auf die Expression von 370 Genen, die in der Apoptose Regulation involviert 
sind, wurde in sensitiven und resistenten Zellen verglichen und dabei wurde die starke BET-
Abhängigkeit der Expression von zwei Schlüsselgenen der Apoptose FLIP und XIAP 
festgestellt. Damit übereinstimmend verstärkte die Kombination von JQ1 mit dem tumor 
necrosis factor-related apoptosis-inducing ligand (TRAIL) oder dem pro-apoptotischen 
Chemotherapeutikums Cisplatin die Induktion von Apoptose in sowohl BET-Inhibitor 
sensitiven als auch in resistenten Zellen. Des Weiteren zeigte die Kombination einen 
signifikant verbesserten Antitumor-Effekte in A549 tumortragenden Mäusen. Insgesamt 
zeigen diese Ergebnisse, dass die Identifizierung von BET-abhängigen Genen unterstützend 
für die Wahl von therapeutischen Kombinationspartnern in der Krebsbehandlung sein kann. 
Sie zeigen auch, dass die Inhibition von BET Proteinen, NSCLC Zellen für die Induktion von 
Apoptose sensibilisiert und dass eine Kombination mit pro-apoptotischen Verbindungen eine 
wertvolle Behandlungsstrategie, um Resistenzen zu überwinden, bieten kann.  
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Abbreviations 
Name Abbreviation 
Chromosome conformation capture 3C 
Acetyl coenzyme A acetyl-CoA 
Adaptive Focused Acoustics AFA 
V-akt murine thymoma viral oncogene homolog 1 AKT1 
Apoptotic protease activating factor 1 Apaf-1 
Adenosine triphosphate ATP 
BCL-2-antagonist/killer BAK 
BCL-2-assoociated X protein BAX 
Bromodomain 1 BD1 
Bromodomain 2 BD2 
Bromodomain and extra terminal domain BET 
BCL-2 homology domains BH 
V-Raf murine sarcoma viral oncogene homolog B BRAF 
Carboxy-terminal domain of a breast cancer 
susceptibility protein BRCT 
Bromodomain-containing protein 2 BRD2 
Bromodomain-containing protein 3 BRD3 
Bromodomain-containing protein 4 BRD4 
Bromodomain-containing protein in testis BRDT 
Bovine serum albumin BSA 
Cancer Cell Line Encyclopedia CCLE 
Cyclin-dependent kinas 9 CDK9 
Cleavage factor CF 
Chromatin immunoprecipitation ChIP 
Chromatin immunoprecipitation sequencing ChIP-seq 
Catalogue of Somatic Mutations in Cancer COSMIC 
Cleavage of polyadenylation factor CPF 
Cleavage of polyadenylation factor and cleavage 
factor CPF-CF 
Cleavage/polyadenylation specificity factor CPSF 
Clustered regularly interspersed short palindromic 
repeats CRISPR 
CRISPR RNA cr-RNA 
Carboxy-terminal domain CTD 
Database for Annotation Visualization and Integrated 
Discovery DAVID 
Death domain DD 
DNA damage response DDR 
Death effector domain DED 
DNase I hypersensitivty sites DHSs 
Demethylases DMTs 
Deoxyribonucleic acid DNA 
De novo methyltransferase DNMT 
DNA methyltransferases DNMTs 
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Name Abbreviation 
Dulbecco's Phosphate-Buffered Saline DPBS 
Double strand brake DSB 
DRB-sensitivity-induced factor DSIF 
Dithiothreitol DTT 
Escherichia coli E. coli 
Ethylenediaminetetraacetic acid EDTA 
Epidermal growth factor receptor EGFR 
Eleven-nineteen lysine-rich leukemia ELL 
Enhancer of zeste homolog 2 EZH2 
Flavin adenine dinucleotide FAD 
Fas-associated death domain protein FADD 
Fetal calf serum FCS 
Food and drug administration FDA 
FLICE like inhibitor protein FLIP 
Earth gravity g 
Guanosine diphosphate GDP 
Genetically engineered mouse model GEMM 
Guanosine triphosphate GTP 
Histone acetyltransferaces HATs 
Histone deacetylases HDACs 
Homology directed repair HDR 
Human epidermal growth factor receptor 2 HER2 
Histone lysine demethylase HKDM 
Histone lysine methyltransferase HKMT 
Histone methyltransferase HMT 
Horseradish peroxidase HRP 
Inhibitor of apoptosis family IAP 
Immunocytochemistry ICC 
Immunofluorescence IF 
Jumonji, AT rich interactive domain 2 JARID2 
Jumonji C-domain-containing protein 6 JMJD6 
Lysine K 
Kilo base pairs kb 
Kinesin family member 5B - rearranged during 
transfection (receptor tyrosine kinase) KIF5B-RET 
V-Ki-RAS Kirsten rat sarcoma viral oncogene KRAS 
Mitogen-activated protein kinase 1 MAP2K1 
Malignant brain tumour domains MBTs 
Microhomology-mediated end joining MMEJ 
Messenger-RNA mRNA 
Nicotinamide adenine dinucleotide NAD+ 
Negative elongation factor NELF 
Next generation sequencing NGS 
Next generation sequencing NGS 
Non-homologous end joining NHEJ 
NUT middle line carcinoma NMC 
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Name Abbreviation 
Nrd1-Nab3-Sen1 NNS 
Nucleotide nt 
Amino terminal ends of about 30 amino acids N-terminal tails 
Polyadenylate polymerase PAB 
Protospacer adjacent motif PAM 
Phosphate-Buffered Saline PBS 
PBS or TBS with 0.1% tween 20 PBS-T/TBS-T 
Plant homeodomain PHD 
Phosphatidylinositol-4,5-bisphosphate 3-kinase 
catalytic subunit alpha PI3KCA 
PCR polmerase chain reaction 
Peptidylprolyl isomerase A PPIA 
Precursor crRNA pre-crRNA 
Pre mature messenger-RNA pre-mRNA 
Protein arginine methyltransferases PRMT 
Post-translational modification PTM 
Pro-Trp-Trp-Pro domain PWWP 
quantitative real time-PCR  qRT-PCR 
Arginine R 
Radioimmunoprecipitation assay RIPA 
Ribonucleic acid RNA 
Pol II RNA polymerase II 
V-ros avian UR2 sarcoma virus oncogene homolog 1 ROS1 
Rounds per minute rpm 
Robust Spline normalization RSN 
Room temperature RT 
Serine S 
Synthesis Phase S phase 
S-adenosylmethionine SAM 
Standard deviation SD 
Sodium dodecyl sulfate SDS 
Super elongation complex SEC 
Standard error of the mean SEM 
Stable Isotype Labeling by Amino acids in Cell culture SILAC 
Mitochondria-derived activator of caspases SMAC 
Threonine T 
Culture flask with 75 cm² surface T75 
Transcription activator-like effector-based nucleases TALENs 
TATA box-binding protein TBP 
Tris-buffered saline TBS 
Positive transcription elongation factor-b TEFb 
Ten-eleven translocation TET 
Transcription factors TFs 
Trans-activating crRNA tracrRNA 
Transcription start site TSS 
X-linked inhibitor of apoptosis protein XIAP 
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Tyrosine Y 
Zinc finger nucleases ZFNs 
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Table 16: Gene Ontology terms of significantly differentially regulated genes upon 4 h IC50 JQ1 treatment 
IC50 JQ1 treated DV90 cells     
Annotation Cluster 1 Enrichment Score: 1.17 n = 23 
Term Count % PValue Fold Enrichment 
GO:0045449~regulation of transcription 9 32 0.036 2.124 
GO:0019219~regulation of nucleobase, nucleoside, nucleotide and 
nucleic acid metabolic process 9 32 0.055 1.963 
GO:0010556~regulation of macromolecule biosynthetic process 9 32 0.057 1.952 
GO:0051171~regulation of nitrogen compound metabolic process 9 32 0.058 1.946 
GO:0010468~regulation of gene expression 9 32 0.059 1.934 
GO:0031326~regulation of cellular biosynthetic process 9 32 0.070 1.874 
GO:0009889~regulation of biosynthetic process 9 32 0.072 1.862 
GO:0060255~regulation of macromolecule metabolic process 9 32 0.113 1.695 
GO:0080090~regulation of primary metabolic process 9 32 0.118 1.678 
     
Annotation Cluster 2 Enrichment Score: 1.05 n = 23 
Term Count % PValue Fold Enrichment 
GO:0006350~transcription 9 32 0.011 2.629 
GO:0034645~cellular macromolecule biosynthetic process 9 32 0.055 1.964 
GO:0009059~macromolecule biosynthetic process 9 32 0.057 1.950 
GO:0010467~gene expression 9 32 0.076 1.842 
GO:0006139~nucleobase, nucleoside, nucleotide and nucleic acid 
metabolic process 9 32 0.139 1.620 
GO:0044249~cellular biosynthetic process 9 32 0.145 1.605 
GO:0009058~biosynthetic process 9 32 0.164 1.559 
GO:0034641~cellular nitrogen compound metabolic process 9 32 0.190 1.505 
GO:0006807~nitrogen compound metabolic process 9 32 0.214 1.462 
Annotation Cluster 3 Enrichment Score: 0.95 n = 23 
Term Count % PValue Fold Enrichment 
GO:0051173~positive regulation of nitrogen  
compound metabolic process 4 14 0.076 3.812 
GO:0031328~positive regulation of cellular biosynthetic process 4 14 0.088 3.584 
GO:0009891~positive regulation of biosynthetic process 4 14 0.091 3.532 
GO:0031325~positive regulation of cellular metabolic process 4 14 0.155 2.790 
GO:0009893~positive regulation of metabolic process 4 14 0.170 2.666 
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Table 17: Gene Ontology terms of significantly differentially regulated genes upon 4 h IC90 JQ1 treatment 
IC90 JQ1 treated DV90 cells 
Annotation Cluster 1 Enrichment Score: 4.40 n = 234 
Term Count % PValue Fold Enrichment 
GO:0010556~regulation of macromolecule biosynthetic process 75 24 0.000 1.599 
GO:0031326~regulation of cellular biosynthetic process 75 24 0.000 1.535 
GO:0009889~regulation of biosynthetic process 75 24 0.000 1.525 
Annotation Cluster 2 Enrichment Score: 2.39 n = 234 
Term Count % PValue Fold Enrichment 
GO:0042981~regulation of apoptosis 25 8 0.004 1.876 
GO:0043067~regulation of programmed cell death 25 8 0.004 1.857 
GO:0010941~regulation of cell death 25 8 0.004 1.850 
Annotation Cluster 3 Enrichment Score: 1.55 n = 234 
Term Count % PValue Fold Enrichment 
GO:0043065~positive regulation of apoptosis 14 4 0.027 1.964 
GO:0043068~positive regulation of programmed cell death 14 4 0.028 1.950 
GO:0010942~positive regulation of cell death 14 4 0.029 1.941 
 
Table 18: List of significantly (q < 0.05) differentially expressed genes (cut off ± 0.5 log2 fold change) after 
treatment of DV90 cells with IC50 JQ1 for 24h 
gene symbol log2 fold change 
ACTBL2 -2.999 
AGR3 -2.452 
SPINK6 -2.209 
FER1L6 -2.194 
FGFBP1 -1.921 
GPR110 -1.493 
MUC2 -1.464 
MLKL -1.380 
PSCA -1.332 
CEACAM6 -1.328 
MIR4738 : H3F3A : H3F3B : UNK -1.298 
RASA4 : RASA4CP : LOC102725198 : RASA4B : RP11-
514P8.6 : RP11-514P8.8 -1.244 
INHBA -1.237 
EDAR -1.208 
C1orf143 -1.198 
PDE8B -1.192 
EREG -1.141 
TRIB3 -1.110 
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gene symbol log2 fold change 
NR1D1 -1.084 
MGLL -1.083 
CCL26 -1.080 
DUSP27 -0.993 
KRT17P1 -0.989 
MYC -0.986 
SLC35G6 -0.966 
LIPC -0.961 
PHLDA3 -0.934 
SULT1C2 -0.870 
PDE9A -0.860 
MPST -0.851 
ANO1 -0.840 
GLYCTK -0.825 
RP11-121A14.3 : NEK6 -0.824 
AEN -0.823 
SDCBP2 : FKBP1A-SDCBP2 -0.803 
SCARB1 -0.790 
FAM182B : FAM27C : FAM27B -0.754 
GDF15 -0.738 
FSTL4 -0.734 
LOC389602 : AC021218.2 -0.731 
EPB41L1 -0.723 
RGS14 -0.717 
ANAPC1 : LOC730268 : AC083899.3 -0.706 
POMZP3 -0.678 
PPFIA3 -0.669 
JPH4 -0.668 
PKP1 -0.667 
CAPN8 -0.666 
AIM1L -0.666 
SNORA4 : EIF4A2 : SNORA63 : SNORD2 : SNORA81 : 
MIR1248 -0.666 
ADRA2C -0.650 
NDUFC2-KCTD14 : KCTD14 : NDUFC2 -0.649 
SLC25A45 -0.631 
ABLIM1 -0.630 
RARA : BCOR -0.628 
PLEKHG6 -0.622 
SPINK4 -0.618 
TRIP13 -0.614 
CES2 -0.613 
RP11-9B6.1 -0.608 
FAM136A : LOC100287852 -0.604 
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gene symbol log2 fold change 
SERPINB5 -0.600 
TCTEX1D4 : RP11-269F19.9 -0.599 
RAPGEFL1 -0.596 
ANKMY1 -0.584 
TUBD1 -0.574 
PVRL4 -0.569 
LOC101928102 : RP11-160N1.10 -0.568 
GCNT3 -0.563 
CPN2 -0.563 
TBX15 -0.562 
DCTD -0.560 
NETO1 -0.556 
MIS18BP1 -0.553 
RP11-293M10.1 -0.533 
CD68 : SNORA67 : LOC101928634 : RP11-186B7.4 -0.528 
CAPN2 -0.527 
SH3RF2 -0.521 
DOT1L -0.520 
SLC35G5 : SLC35G4P : SLC35G6 -0.519 
ZBTB7C -0.517 
QRSL1 -0.517 
FLNB -0.514 
PTK6 -0.512 
LBR -0.510 
RASA4 : RASA4B : RASA4CP : LOC102725198 : RASA4DP 
: RP11-514P8.6 : RP11-514P8.8 -0.507 
ANKRD33 -0.503 
CDH17 -0.501 
HNF1B 0.501 
CD2AP 0.502 
CD28 0.503 
PERP 0.503 
ITGA3 0.506 
H3F3A : H3F3AP4 : H3F3B : H3F3AP6 : RP11-349N19.2 0.506 
REEP3 0.506 
IRS2 0.508 
DUSP18 0.512 
DAPK1 0.514 
TFAP2A 0.514 
FBXO8 0.516 
FOXP4 0.516 
KRT19 0.518 
MIDN 0.520 
GATA4 0.521 
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gene symbol log2 fold change 
MKLN1 0.524 
GNAI2 0.530 
ITPKC 0.533 
UBE2H 0.535 
EHF 0.536 
SELL 0.539 
CROCCP2 : CROCC : CROCCP3 0.542 
C6orf203 0.544 
H3F3B : H3F3A : MIR4738 0.547 
GPRC5C 0.553 
ITFG3 0.554 
AHR 0.557 
RHOV 0.558 
FOSB 0.569 
RHPN2 0.569 
IER2 0.571 
HIST4H4 : HIST1H4I : HIST1H4A : HIST1H4D : HIST1H4F 
: HIST1H4K : HIST1H4J : HIST1H4C : HIST1H4H : 
HIST1H4B : HIST1H4E : HIST1H4L : HIST2H4A : 
HIST2H4B 
0.572 
RASA4B : RASA4 0.574 
ABHD11 0.575 
COQ2 0.581 
CREB3L1 0.583 
ERBB3 0.585 
SSH3 0.587 
LRP11 0.587 
S100P 0.592 
CXCL2 0.597 
CAPN5 0.602 
ATP2B4 0.606 
EIF4A2 : SNORA63 : SNORD2 : SNORA4 : SNORA81 : 
MIR1248 0.606 
MAPRE3 0.608 
POU5F1B 0.609 
RHOB 0.610 
C6orf132 0.610 
ARPC5 0.612 
KLF14 0.620 
LOC100130691 : AC074286.1 : NFE2L2 0.624 
VDR 0.627 
ZKSCAN1 0.641 
TNRC18 : TNRC18P3 0.645 
MIR4640 : DDR1 0.648 
PPP1R1B 0.652 
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gene symbol log2 fold change 
FXYD3 0.656 
RFX2 0.661 
WWC1 0.662 
ARHGEF37 0.669 
HOXA13 0.671 
UNC5B 0.679 
RASA4 : RASA4B : RP11-514P8.6 : RP11-514P8.8 0.681 
TNRC18 0.683 
LGALS3 0.689 
MACROD2 0.691 
SH2D3A 0.702 
NR4A2 0.703 
TMEM45B 0.731 
HIST1H2BJ 0.733 
HOXB3 0.733 
TMSB4X 0.743 
LINC00998 : AC073346.2 0.743 
LOC101930595 : RP11-326C3.2 : ATHL1 0.749 
ZFP36 0.755 
JUND 0.758 
ID1 0.772 
DAOA 0.773 
PIK3C2B 0.775 
SIRT4 0.791 
CTH 0.794 
DRD1 0.802 
MIR21 : VMP1 0.816 
OGDH 0.824 
FOXA1 0.832 
PHLDA1 0.837 
DUSP6 0.840 
LY86 0.843 
ITGB4 0.844 
CTNND1 : TMX2 : TMX2-CTNND1 0.847 
TRIB1 0.847 
TJP3 0.863 
JUN 0.868 
OR4N4 : LOC101927079 : LOC727924 : RP11-69H14.6 : 
LOC102723532 0.870 
IL1RAPL1 0.880 
MALL 0.882 
MYH14 0.904 
PPP1R15A 0.914 
UPK2 0.930 
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gene symbol log2 fold change 
ATF3 0.935 
CIRBP 0.948 
HIST1H4B : HIST1H4I : HIST1H4A : HIST1H4D : 
HIST1H4F : HIST1H4K : HIST1H4J : HIST1H4C : 
HIST1H4H : HIST1H4E : HIST1H4L : HIST2H4A : HIST4H4 
: HIST2H4B 
0.973 
CSRNP1 1.017 
IRF1 1.017 
SOX9 1.034 
MAP3K8 1.035 
MLPH 1.069 
HIST1H2BG : HIST1H2BF : HIST1H2BE : HIST1H2BI : 
HIST1H2BC 1.080 
NR4A1 1.087 
NUAK2 1.115 
HIST1H2BF 1.123 
HIST2H4B : HIST2H4A : HIST1H4I : HIST1H4A : 
HIST1H4D : HIST1H4F : HIST1H4K : HIST1H4J : 
HIST1H4C : HIST1H4H : HIST1H4B : HIST1H4E : 
HIST1H4L : HIST4H4 
1.148 
PCDH11Y : PCDH11X 1.170 
OR4N3P : OR4N2 : LOC102723532 : RP11-2F9.2 : OR4N4 : 
LOC101927079 : RP11-69H14.6 : LOC727924 1.193 
ELF3 1.198 
SPIRE2 1.218 
HHLA3 1.271 
GPX2 1.357 
MMP24-AS1 : EDEM2 : RP4-614O4.11 1.382 
HEXIM1 1.385 
ABCC3 1.530 
DHRS2 1.712 
PDK4 1.730 
ARHGDIG 1.862 
CXCL8 : IL8 1.898 
RCAN1 2.041 
HIST1H2BG : HIST1H2BJ 2.166 
HIST1H2BD 2.627 
 
